<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:769.8pt;left:195.7pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">Full Terms &amp; Conditions of access and use can be found at</span></p>
<p style="top:780.8pt;left:154.5pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">https://www.tandfonline.com/action/journalInformation?journalCode=kgmi20</span></p>
<img style="position:absolute;transform:matrix(.6192,0,-0,.6243609,-9.279999,-24.696)" src="data:image/jpeg;base64,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">
<p style="top:44.3pt;left:127.9pt;line-height:15.0pt"><b><span style="font-family:OpenSans,serif;font-size:15.0pt">Gut Microbes</span></b></p>
<p style="top:136.3pt;left:127.9pt;line-height:8.0pt"><b><span style="font-family:OpenSans,serif;font-size:8.0pt">ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/kgmi20</span></b></p>
<img style="position:absolute;transform:matrix(.03047619,0,-0,.030475427,-806.04006,-336.36866)" src="data:image/png;base64,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">
<p style="top:171.8pt;left:97.1pt;line-height:18.0pt"><b><span style="font-family:OpenSans,serif;font-size:18.0pt">Probiotic and commensal gut microbial therapies</span></b></p>
<p style="top:192.8pt;left:97.1pt;line-height:18.0pt"><b><span style="font-family:OpenSans,serif;font-size:18.0pt">in multiple sclerosis and its animal models: a</span></b></p>
<p style="top:213.8pt;left:97.1pt;line-height:18.0pt"><b><span style="font-family:OpenSans,serif;font-size:18.0pt">comprehensive review</span></b></p>
<p style="top:261.0pt;left:97.1pt;line-height:12.0pt"><b><span style="font-family:OpenSans,serif;font-size:12.0pt">Lorrie L. Blais, Theresa L. Montgomery, Eyal Amiel, Paula B. Deming &amp;</span></b></p>
<p style="top:275.0pt;left:97.1pt;line-height:12.0pt"><b><span style="font-family:OpenSans,serif;font-size:12.0pt">Dimitry N. Krementsov</span></b></p>
<p style="top:311.9pt;left:97.1pt;line-height:10.0pt"><b><span style="font-family:OpenSans,serif;font-size:10.0pt">To cite this article:</span></b><span style="font-family:Arial,serif;font-size:10.0pt"> Lorrie L. Blais, Theresa L. Montgomery, Eyal Amiel, Paula B. Deming &amp;</span></p>
<p style="top:324.2pt;left:97.1pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">Dimitry N. Krementsov (2021) Probiotic and commensal gut microbial therapies in multiple</span></p>
<p style="top:336.3pt;left:97.1pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">sclerosis and its animal models: a comprehensive review, Gut Microbes, 13:1, 1943289, DOI:</span></p>
<p style="top:348.3pt;left:97.1pt;line-height:10.0pt"><span style="font-family:Arial,serif;font-size:10.0pt">10.1080/19490976.2021.1943289</span></p>
<p style="top:368.6pt;left:97.1pt;line-height:10.0pt"><b><span style="font-family:OpenSans,serif;font-size:10.0pt">To link to this article: </span></b><span style="font-family:OpenSans,serif;font-size:10.0pt"> https://doi.org/10.1080/19490976.2021.1943289</span></p>
<img style="position:absolute;transform:matrix(.024177779,0,-0,.02417822,-150.61333,65.583377)" src="data:image/png;base64,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">
<p style="top:423.9pt;left:131.8pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">&#xa9; 2021 The Author(s). Published with</span></p>
<p style="top:433.9pt;left:131.8pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">license by Taylor &amp; Francis Group, LLC.</span></p>
<img style="position:absolute;transform:matrix(.0352,0,-0,.03519962,145.49338,219.74604)" src="data:image/png;base64,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">
<p style="top:425.9pt;left:351.4pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">View supplementary material </span></p>
<img style="position:absolute;transform:matrix(.033854169,0,-0,.033853566,387.53205,398.56336)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.0368,0,-0,.03680083,-146.82666,307.36805)" src="data:image/png;base64,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">
<p style="top:466.8pt;left:131.8pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">Published online: 15 Jul 2021.</span></p>
<img style="position:absolute;transform:matrix(.03906667,0,-0,.03906667,146.65338,389.75404)" src="data:image/png;base64,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">
<p style="top:468.8pt;left:351.4pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">Submit your article to this journal </span></p>
<img style="position:absolute;transform:matrix(.033854169,0,-0,.033853566,410.77607,455.7633)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.0448,0,-0,.044800596,-144.42667,458.80873)" src="data:image/png;base64,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">
<p style="top:509.7pt;left:131.8pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">Article views: 2099</span></p>
<img style="position:absolute;transform:matrix(.03502222,0,-0,.035022096,145.44004,337.92597)" src="data:image/png;base64,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">
<p style="top:511.7pt;left:351.4pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">View related articles </span></p>
<img style="position:absolute;transform:matrix(.033854169,0,-0,.033853566,335.92005,512.9633)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.041244445,0,-0,.041244318,-145.49333,406.87275)" src="data:image/png;base64,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">
<p style="top:554.6pt;left:131.8pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">View Crossmark data</span></p>
<img style="position:absolute;transform:matrix(.033854169,0,-0,.033853566,45.447999,570.16348)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAgAAAAFaCAIAAADn53KhAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAPHUlEQVR4nO3dXW7byBKAUe7CgBH/XEpIDOgxG/D+V3UZc8aTOLQt
S9Vdze5zHuZpMHAPi/Xpz/I0AQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAwE7c3t4+Pj4eOMP/XmRfMYArzP9altrMRcQA2J9lbWUvz67c3NxkX1KA
zyyrKntb9ml5IpV9bQHedzwes/dk57KvMMA7stfjELIvMsBfvNlbx+l0yr7UAL+x
/WvKvtoAv8leiWN5fHzMvuAA/8peiWPxiSCgFff399krcTjZ1xzghTcA6su+5gAv
/N5vfdnXHOCFANR3PB6zLzuAl4Ay+CAQ0ATPAOoTAKAVngRUJgBAKzwJqEwAgFb4
HtDKBABoiCcBNQkA0JbsrTgQAQDa8vDwkL0YRyEAQHOWxZS9G4cgAECLNKACAQAa
pQGlCQDJDofD8XhcP/vx+z9p0HKx/vei2nhoQFECQFVPT0+HF/PLNsmefy5X7c+J
aEA5AkBxNzc3HtT3qs4IaUAhAkApz8/P2eNNcafTqc44aUAJAkC819f06Z73A3ZN
AIjku1xGU/kPi2tALAEghtU/rMqTpgGBBIBrrR/syZ5kclR+BrDSgCgCwFWs/sGl
BGDSgCACwIW8zcucF4BJAyIIAJew/VklBmDSgKsJAF9ze3tr+/MqNwCTBlxHAPgC
X9TOG+kBmDTgCgLAuTzw528tBGDSgEsJAGex/dnUSAAmDbiIAPA5n/XkPe0EYNKA
rxMAPpE9ojStqQBMGvBFAsBHPPbnY60FYNKArxAA3pU9nOxAzW8DPZ8GnEkA2ObL
3ThT9qhu04BzCAAb3DycL3ta32WMPyUAvPX09JQ9luxGg+8B/E4DPiYAvJU9k+xG
m28AvKEBHxAA/pA9kOzGsv1vbm6yB/YsGvAeAeA/ft2Xc6xzkj2tX6MBmwSAfzTy
sZ/Dvx5pzzIk2XN6uUcN+MujALDKevj/7du37KMzCg14QwD4pebD/+XR/S7ePKRL
GvA7AeCXOtO2x9eO6Y8GvBIAamx/j/ppigasBGB0Fe4Eq58G+aLDWQAo/d7vw8ND
9hFhQ9Gx3wsBGNrPnz/LzdaSlqenp+wjwoZyY78vAjC0orO11CX7fLCh6NjviwAM
rdxgZZ8MtpWb+T0SgHGVe/U/+2SwrdDA75cAjKtQAG5vb7NPBhtKTPveCcCgTqdT
iXn6/v179slgQ4lp74AADKrQw//sY8GGEqPeBwEYVIkAZJ8JNoTPeU8EYFDhk7SX
vw3CUMLnvDMCMKISk5R9JnirxJx3RgBGFP76z/Pzc/aZ4A+xE94rARhR+BhlHwj+
ED7hvRKAEcXOUPZp4A+x4903ARjO3d1d7AxlHwj+Ezvb3ROA4cS+AXA4HLIPBP8I
HOxBCMBwYgfI2780InawByEAwwn8Q0ge/tOIqJEejQAMJ3B6/K1HWhA40qMRgOEE
PgM4Ho/Zp2F0UcM8JgEYTuD0+Hu/5Aoc5jEJwHACp8c7wCQKnORhCcBwAqcn+yiM
K3CMRyYAwwmcnuyjMKjAGR6cAAwncHqyj8KIAgcYARjL8XiMGh2fAaW+qOllJQBj
Wa531OgIAJVFjS6vBGAsAsBORc0tvxOAsQgAexQ1tLwhAGMRAHYnamL5mwCMRQDY
l6hxZZMAjEUA2JGoWa3v+CL7p/icAIxFANiLqEGt7/VLEttvgACMRQDYhagpre/N
V+Q23gABGIsA0L6oEa1v8wvSW26AAIxFAGhc1HzW98Gfx2i2AQIwFgGgZVHDWd+n
fxypzQYIwFgEgGZFTWZ9Z/5pvAYbIABjEQDaFDWW9X3pD6O21gABGIsA0KComazv
gj+L3VQDBGAsAkBrogayvgu2/6qdBgjAWASApkRNY30Xb/9VIw0QgLEIAO2IGsX6
rtz+qxYaIABjEQAaETWH9YVs/1V6AwRgLAJAC6KGsL7A7b/KbYAAjEUASBc1gfWF
b/9VYgMEYCwCQK6o8auv0PZfZTVAAMYiACSKmr36im7/VUoDBGAsAkCWqMGrr8L2
X9VvgACMRQBIETV19VXb/qvKDRCAsQgA9UWNXH2Vt/+qZgMEYCwCQGVR81ZfyvZf
VWuAAIxFAKgpatjqS9z+qzoNEICxCADVRE1afenbf1WhAQIwFgGgjqgxq6+R7b8q
3QABGIsAUEHUjNXX1PZfFW1Ag+elIAGgtKgBq6/ZbViuAdknoy4BoKio6aqv2e2/
KtSA7GNRlwBQTtRo1df49l+VaED2mahLAChkmYeo0apsF9t/FduAw+GQfSDqEgBK
sP2rCWyAjwANRwAIZ/tXFtWA7HNQnQAQy/ZPcX0DTqdT9iGoTgAIZPsnurIB2T8+
GQSAKLZ/uuUgh8Phgv8D2T84SQSAELZ/I759+3b+tVj/zewfmTwCwPVs/9ac8zxg
uWpe9x+dAHAl279Nd3d388tH+/8++OFF9g9IAwSAa9j+u3B84Q7lLQHgYrY/7JsA
cBnbH3ZPALiA7Q89EAC+yvaHTggAX2L7Qz8EgPPZ/tAVAeBMtj/0RgA4h+0PHRIA
PmX7Q58EgI9d9u2SLbD94RMCwAdsf+iZAPAe2x86JwBssv2hfwLAG8/Pz7Y/DEEA
+J3tDwMRAF7Z/jAWAWBl+8NwBIDJ9ocxCQC2PwxKAAZn+8O4BGBktj8MTQCGZfvD
6ARgTLY/IAAjsv2BXwRgNLY/8A8BGIrtD/xHAMZh+wN/EIBB2P7AWwIwAtsf2CAA
3bP9gW0C0DfbH3iXAHTM9gc+IgC9sv2BTwhAl2x/4HMC0B/bHziLAHTG9gfOJQA9
sf2BLxCAbtj+wNcIQB9sf+DLBKADtj9wCQHYO9sfuJAA7JrtD1xOAPbL9geuIgA7
ZfsD1xKAPbL9gQACsDu2PxBDAPbF9gfCCMCOLNs/6mLVZ/tDcwRgL2z/QA8PD8u4
Hj6z/Dut/eQQSQB2wfYPsfwkF5/i/v4++8eHaALQPts/RMioZx8CQglA42z/KNe/
eb5M+HI5ss8BcQSgZbZ/lKiPTi3/neyjQBwBaJbtHyjqXIacrghAm2z/WIGnyz4K
xBGABtn+4QIPmH0UiCMADfK7vuECz5h9FIgjAK2x/UsIPGb2USCOADTF9i8k8KTZ
R4E4AtCUqGtRWePbfxIA2CQATYm6FjW1v/0nAYBNAtCU3b0EtIvtPwkAbBKApkRd
izr2sv0nAYBNAtCUa76usrIdbf9JAGCTALQm6nIUta/tPwkAbBKA1vz8+TPqihSy
u+0/CQBsEoAGnU6nqIsSbo/bfxIA2CQAbWqzATvd/pMAwCYBaFZrDdjv9p8EADYJ
QMvaacCut/8kALBJABr348ePqAt0sb1v/0kAYJMAtC+3AR1s/0kAYJMA7EJWA/rY
/pMAwCYB2Iv6Dehm+08CAJsEYEdqNqCn7T8JAGwSgH1ZGrD8f466ZO/pbPtPAgCb
BGB3Sjegv+0/CQBsEoA9KteALrf/JACwSQB2qkQDet3+kwDAJgHYr2VfBzag4+0/
CQBsEoBdW7Z2yF+R7Hv7TwIAmwRg765vQPfbfxIA2CQAHbimASNs/0kAYJMA9OGy
Bgyy/ScBgE0C0I2v/kH5cbb/JACwSQB6cn4Dhtr+kwDAJgHozDkNGG37TwIAmwSg
Px9fpgG3/yQAsEkAevX3e8LLBRpz+08CAJsEoGPLxV0zsPzz6ekp+8fJFDXkswDQ
EwFgBFFDPgsAPREARhA15LMA0BMBYARRQz4LAD0RAEYQNeSzANATAWAEUUM+CwA9
EQBGEDXkswDQEwFgBFFDPgsAPREARhA15LMA0BMBYARRQz4LAD0RAEYQNeSzANAT
AWAEUUM+CwA9EQBGEDXkswDQEwFgBFFDPgsAPREARhA15LMA0BMBYARRQz4LAD0R
AEYQNeSzANATAWAEUUM+CwA9EQBGEDXkswDQEwFgBFFDPgsAPREARhA15LMA0BMB
YARRQz4LAD0RAEYQNeSzANATAWAEUUM+CwA9EQBGEDXkswDQEwFgBFFDPgsAPREA
RhA15LMA0JPj8Rh1YxwOh+zTwLaoIZ8FgM64N+he1IR7lENvou6NWQBo0vPzsyGH
be4N+nZ3dxc14Z4B0Juoe2Px7du37NPAW4FvdM0e5dCZwHvj4eEh+zTw1vKwPWrC
PQOgN4G3x/JQK/s08FbUeK+yTwOhAu8NvwpAgwIn3DMAerNsbbcHHYsa71X2aSBU
4EtAi8fHx+wDwX8Cf9d99hyX/gTeHrMnATQm9vHN6XTKPhCEin2INHuOTEvMNnwi
9ia5vb3NPhD8Evj+1uz1H3oV+zTZfUIjYgd79gyALsXeJLNfCKAB4VPt/S36FPu7
8rMnATQgdqRnD//pWOyrpbMnAaQK/2jDLAB0LPxuccOQJfb7n1de/6Fn4TeMe4Ys
JYbZN93SuRK3jTcDqKzEGM+eztK9QneOBlBNoRn2XJb+Fbp5Fvf399mHo3/lBtjv
NjKEcrfQjx8/sg9Hz75//15odD2FZRThHwb9nS8KpZCic+sDzQyk3I00ezBFAUUn
1qv/jKXog6lZAwgV/m0/b3z//j37iFBX0Ttq5W1hrjS/PDwvOqUe/jOi8K8Geu/u
8q4AF1gePZRe/Suv/jOoCnfXyoMszrds5NIvUb7yWiXjenp6qnanrTza4gP/e1Fz
IJ+fn7MPDXkq32+r9XUhMWDx48eP+hO48vAfin/E4lPLD7B2KKVG1JQ+bK+8LAm/
3N3dZd+MUJsv/oR/ZN+MUJUXf+AP2bckVOLFH9iQfWNCDdn3GTQp+8aE4nzuE95V
4q9sQyO88QufaOeDehDIN1PBWep8TRBU4/s+4Qvq/1I+FOLrCOHLvB9AB3zjCFyo
3J9ghQpOp1P2PQR7dn9/n30XwyVsfwjw8+fP7HsZvib7poG+ZN/RcBbf8wNFeEuA
li2r34f9oSC/IkCzsm8OGIOnArTjcDj4jgeozZdGkM7H/CHN6XR6/YOOUM06ctnj
D0zT8/PzckN6QkAd/qILtCh7M9A5qx9adzqdPCEgyjJIx+PRr/XCzmSvDvbNx3ug
E8udPP/73h28sX79+Pqs0V9thCEsT+0fHh6W2/7x8XH9NNGBrs0vH9xcLvT6Ty/s
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA1PF/ZVDGMU9E+YYA
AAAASUVORK5CYII=">
<img style="position:absolute;transform:matrix(.039111116,0,-0,.039111116,146.66669,441.70674)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAlgAAAJYCAIAAAAxBA+LAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAd30lEQVR4nO3d3W7iWBaGYd9PDpE6AxUjDkol5QJy/7cyOLv+ujqp
sAl4re31PPo06rMhYPstCJBpgrs5Lg7z/KXt6cmG3NnTYnkQzw6Hw8vLS/TBBZDS
uXuvV8xD+LXbVtjZ6XSKPugAou33+y9f2pMGq7nD+dH3HBGo5eHh4bV8nvnZr83z
4fn5OfrYBLin3/r3FH7ZtZw7iz5OAe5gnmfxs4v39Pj4GH3MAtzC1687/bPr5qkh
MDa/ArTPb561EBjQ8ah/drN5XgiM5Ofnps1uuqfoQxvgI6/vhQm/XNpm5zVSIK/9
fh9+lbQK8xopkM75wuT7P23NHQ6H6KMe4Id59o4YC9hut4s+9oHyHh8fw6+GVnZ+
WQgE89XYlmDeRApEOJ1OPhphOeY3hcDqXt8aqoKWZd41A6zqePQBCUu36NMCKMMv
BS3n5nmOPjmAAlTQEs9bZoA782F5yzyfowDuy1tjLP+Ox2P0iQJslAraIPPqKHAH
KmjjzIcogFtTQRtqnhECN6WCNtweHh6izxtgK1TQxpwnhcAtqKANOn+tF7gBFbSR
5xkh8DkqaEPPx+qBT1FBG31eGgWup4K2ifkoIXAVFbRtzEujwDVU0DYzIQS6qaBt
aUII9FFB29iEEOiggra9CSFwKRW0TU4IgYuooG11Qgh8TAVtwxNC4ANFKujrRWIF
HmZCCPxNkQoKYTghBDKqU0EhDCeEQDqlKiiE4YQQyKVaBYUwnBACiRSsoBCGE0Ig
i5oVFMJwQgikULaCQhhOCIF4lSsohOGEEAhWvIJCGE4IgUgqKIThhBAIo4JCmIEQ
AjFUUAiTEEIggAr+PiGMJYTA2lTwjwlhLCEEVqWC/50QxhJCYD0q+OaEMJYQAitR
wfcmhLGEEFiDCv5lQhhLCIG7U8G/TwhjCSFwXyr44YQwlhACd6SCl0wIYwkhcC8q
eOGEMJYQAnehgpdPCGMJIXB7Ktg1IYwlhMCNqWDvhDCWEAK3pIJXTAhjCSFwMyp4
3YQwlhACtzFmBQ8ZbrYQxhJC4AYy5KR/hyS3XAhjCSHwWRla0r9DnhsvhLGEEPiU
DCHp3yHV7RfCWEIIXC9DRfp3yPYjCGEsIQSulCEh/Tsk/CmEMJYQAtfI0I/+/VnB
JD+IEMYSQqBbhnj0740KJvlZhDCWEAJ9MpSjf29XMMmPI4SxhBDokCEb/Xu3gkl+
IiGMJYTApTI0o39/q2CSH0oIYwkhcJEMwejfBxVM8nMJYSwhBD6WoRb9+7iCSX40
IYwlhMAHMqSifxdVMMlPJ4SxhBD4mwyd6N+lFUzyAwphLCEE3pUhEv3rqGCSn1EI
Ywkh8LYMhehfXwWT/JhCGEsIgTdkyEP/uiuY5CcVwlhCCPwpQxv6d00Fk/ywQhhL
CIF/yRCG/l1ZwSQ/rxDGEkLglwxV6N/1FUzyIwthLCEEvsuQhP59qoJJfmohjCWE
wCJDD/r32Qom+cGFMJYQAili0L8bVDDJzy6EsYQQqstQgv7dpoJJfnwhjCWEUFqG
DPTvZhVMcg8IYSwhhLoyNKB/t6xgkjtBCGMJIRSVIQD9u3EFk9wPQhhLCKGiDFf/
/t2+gknuCiGMJYRQToZLf//uUsEk94YQxhJCqCXDdb9/96pgkjtECGMJIRSS4aLf
vztWMMl9IoSxhBCqyHDF7999K5jkbhHCWEIIJWS43Pfv7hVMcs8IYSwhhO3LcK3v
3xoVTHLnCGEsIYSNy3Ch799KFUxy/whhLCGELctwle/fehVMchcJYSwhhM3KcInv
36oVTHIvCWEsIYRtynB979/aFUxyRwlhLCGEDcpwce9fQAWT3FdCGEsIYWsyXNn7
F1PBJHeXEMYSQtiUDJf1/oVVMMk9JoSxhBC2I8M1vX+RFUxypwlhLCGEjchwQe9f
cAWT3G9CGEsIYQsyXM37F1/BKcddJ4SxhBCGl+FS3r8UFZxy3HtCGEsIYWwZruP9
y1LBKccdKISxhBAGluEi3r9EFZxy3IdCGEsIYVQZruD9y1XBKcfdKISxhBCGlOHy
3b90FZxy3JNCGEsIYTwZrt39y1jBKcedKYSxhBAGk+HC3b+kFZxy3J9CGEsIYSQZ
rtr9y1vBKcddKoSxhBCGkeGS3b/UFZxy3KtCGEsIYQwZrtf9y17BKccdK4SxhBAG
kOFi3b8BKjjluG+FMJYQQnYZrtT9G6OCU467VwhjCSGkluEy3b9hKjjluIeFMJYQ
Ql4ZrtH9G6mCU447WQhjCSEkleEC3b+n6LutW4b7WQhjVQjhfr8/H2bzfDj/P57/
tfr6/35oNyD8+LeenR/Bw/mhPBwGe8pxjQxX5/6NV8Epx10thLG2F8Ldbnf+kdoV
M8MRbnfa+fg5e3x8vMdRFGzMA3fICk457m0hjLWNEJ5Op3me28kYfkjb+jsfS+d/
AN3qcAo25kE8agWnHHe4EMYaOoSn02N7WpDhSLbYtSPh/E+iW5wWccY8lMd+qTrD
fS6EsUYM4X6/z3DoWtYdRr2qjHlYD/xcsMlwt496yG7FQCF8ff3zEH7E2gh7Gu/6
nOFy3L+xnws2Ge55IYw1RAiPx+OPd3uaXb5xnhpmuBb3b7R/a7wjw50/zJG6UZlD
+PLy8nrzJNCu3wCftchwIe7fRio45bj/hTBWzhC+/hZQ/+xWS3zRznAV3tQd2i/D
QyCEsbKF8Nu3bxkOS9vcUl66xzzWU96Vn5DhURDCWHlC+PrlL+HnuG126S41Ga6/
/dtaBaccD0S6o7OYDCF8eXl5/Syg2X233+9jT7dfMlx8+5f+161XyfBYCGGs8BBm
OAitzr5+TfAFNGMe9Bt8LthkeDiEMFboMXDIcARaqcX/zZMxD/ptPhdsMjwiQhgr
wzFgtubmeXa+dW2zzwWbDA+KEMbKcAyYrbyYv1kx5sm25eeCTYbHRQhjZTgGzFbf
6pf3Mc+07VdwyvHQCGGsDMeA2fpb9QXSMU+zjb8i+lOGR0cIY2U4BswittaznTHP
sRLPBZsMD5AQxspwDJiFbI0/XjjmCVaoglOOx0gIY2U4BsxCNs93vuCPeXZVeUX0
pwwPkxDGynAMmEXNqfXHaj0XbDI8UkIYK8MxYBY159Xvq1jBKceDJYSxMhwDZnG7
wwuBY55U5V4R/SnD4yWEsTIcA2Zxu/X1f8wzquhzwSbDQyaEsTIcA2ZRu/FXj455
OpWu4JTjURPCWBmOAbO43a4CY55LdV8R/SnDAyeEsTIcA2ZRu9kzwjFPpOrPBZsM
j50QxspwDJgFruxZpILfZXj4hDBWhmPALHCfPYXOTyrDf4b+eUX0lwwXQSGMleEY
MAvcp86feT6E/wD981zwXzJcBIUwVoZjwCxw1588Y1bQc8E/ZbgICmGsDMeAWeBK
nTmeC74hw0MphLEyHANmgbvmtDmdTucrV/hN75zngm/LcBEUwlgZjgGzwF132sTf
7s55LviuDBdBIYyV4RgwC1z3OTPg20RV8G8yXASFMFaGY8AscH0nzOEw3BtkvCL6
gQwXQSGMleEYMAtcx9lyOp3Cb27nPBf8WIaLoBDGynAMmAWu42wZ7UVRFbxIhoug
EMbKcAyYBW6rp4pXRC+V4ZEVwlgZjgGzwF1+qsTfVtvqhDBW8RC+fhiMQPHHwEXn
yZhfImPDTAhjJbkYxc0LSJGenuL78vGtHPA9MjbYhDCWEEY/AqWNEcIBv0TGBpsQ
xhLC6EegtAFC+PXrbrQ3i9p4E8JYQhj9CJQ2QAjLnyG2xoQwVvnTXAgjZQ+h3w7a
OhPCWEIY/QiUlj2E5U8PW2lCGKv8mS6EkVKH8OvXXfiNsyITwlhCGP0IlJY6hBlu
nBWZEMYSwuhHoLQMrXn7lj08PITfMqszIYwlhNGPQGl5Q1j+xLCV5xvSwzw+PpY/
34UwUt4Q+uygrTtXohjfvn3zjRkOv1hJQ3g87sNvlpWal0ZDqOCPCWGkpCF0btjq
cyVa236/d6Y7/DLIGEKfmrD15xnhyl7fDVf894K/TwgjZQyhv7hk6+/5+TniBCxq
t/OP3T8mhJEyhjD8BlnBRZx9RangWxPCSOlC6NUSW39eF13Ny8tLhotOvglhpAzH
ZLobZNUmhKvx7ph3JoSRMnTnjxsUfkRauQnhOrze8/6EMFKuEB6Px/BbYwX38vIS
dw5WEf4o554QRsoVQv9gtJDFnYBV+KKojyaEkbKFMP7WWLV5XfTenNcXTAgjZThE
f94UTwdt/fmu7fvyXPCyCWGkRCH0djKLmAvQHfnXreNwCIlC6F+Otv72+33oCbhl
KtgzIYyUKITht8Pqzeui96KCnRPCSFlCeDjE3w6rttPpFHz+bdSYXxf8FPqilBBG
yhJC/360lXc8ejp4F2P+sn/pkBCWlSWEfkFo604F72LE54LzvP9x4wNvhhBGyhLC
8BthlfbkRdF7GPG54M8KTkJYmBBauR0Ong7e3ogV/CM/QlhWihCe/3kefiOsyFTw
HuZ5Dn9ke/f7c8EfP0Xg7RHCSClCOOJZZCNOBe9hzHe6vREeISwrRQjHfFHFhptr
ze2NePL+97lgI4RlpQhh+C2wbe98gTse/xd9rm3QuSjhD27/3k2OEJYlhLb9eY/o
PYz4G433ngv++IkCb5sQRkoRQh8itLvN9eUujsdNPRdshLCsFCEMvwW2xT09Pj5G
n1/bNGIF//5csBHCsoTQtren4/EYfWZt1ogVvDAzQlhWihB6adRusnk++HXgXW24
gpMQFpYihOG3wIbd8gm2c/88BVzB8fi/6If7miPk8h9QCMsSQhtlhx/78nrBevI3
dde0mU/N/4UQliWEbb5wBN414p8LveTdMX8QwrKEsE0I4W3H4zH69OzeFRWchLAw
IWwTQnjD6fQYfW5277oKTkJYmBC2CSH86fHxcbhfDV5dwUkICxPCNiGEf9neN6hd
8CMH3nghjCSEbUIIv7w+EYy/NHTtkxWchLCwDEe7EEIiI/6h7M9XcBLCwoSwTQhh
Ue33gr8TwrKEsE0IYfr27dtwf2j3VhWchLAwIWwTQqrb7XbRp2H3bljBSQgLE8I2
IaS0/X5f+blgI4RlCWGbEFLXw8ND2d8L/k4IyxLCNiGkKK+I/iSEZQlhmxBS0cvL
y3B/DfROFZyEsDAhbBNCyjlXMMP537X7VXASwsIynAhCCAG8O+YPQliWELYJIbVk
OPO7du8KTkJYWIbTQQhhVd4j+iYhLEsI24SQKrw7JuU9I4SRhLBNCCkhwwnftdUq
OAlhYRnOCyGENXhF9O+EsCwhbBNCNk4FPySEZQlhmxCyZSp4CSEsSwjbhJDN8nnB
CwlhWULYJoRs0zzHn+Fdi6rgJISFCWGbELJBXhHtIoRlCWGbELI1ngv232OBP74Q
RhLCNiFkU/xe8ApCWJYQtgkh2+G54HWEsCwhbBNCNmKe5+izqW9JKjgJYWFC2CaE
bIF3x3yGEJYlhG1CyPD8XvCThLAsIWwTQsamgp8nhGUJYZsQMjC/F7wJISxLCNuE
kFF5LngrQliWELYJIUM6HvfR507f0lZwEsLChLBNCBmP94jelhCWJYRtQshgPBe8
OSEsSwjbhJCR+L3gPQhhWULYJoQM43g8Rp8vfRuigpMQFiaEbULIGA6H+DO2a6NU
cBLCwoSwTQgZgOeCdyWEZQlhmxCS3en0GH2a9G2sCk5CWJgQtgkhqT0+Po71YYnh
KjgJYWFC2CaE5OUb1NYhhGUJYZsQktTrE8H4s/TyDVrBSQgLy3CKCSG87XQ6RZ8a
fRu3gpMQFiaEbUJIOn4vuDIhLEsI24SQXL59+zbW18eMXsFJCAsTwjYhJJHdbhd9
RvRtAxWchLAwIWwTQrLY7/eeC4YQwrKEsE0ISeHh4cHvBaMIYVlC2CaExPOKaCwh
LEsI24SQYC8vL6EX4u5trIKTEBYmhG1CSKRzBTOcipdvexWchLCwDGefEFKdd8dk
IIRlCWGbEBImw0l4+bZawUkIC8twDgohdXmPaB5CWJYQtgkhAbw7JhUhLEsI24SQ
tWU49y7f5is4CWFhGU5GIaQcr4gmJIRlCWGbELIeFcxJCMsSwjYhZCUqmJYQliWE
bULIGnxeMDMhLEsI24SQu5vn+JPt8lWr4CSEhQlhmxByX14RzU8IyxLCNiHkjjwX
HIIQliWEbULIvfi94CiEsCwhbBNC7sJzwYEIYVlC2CaE3N48z9EHdseKV3ASwsKE
sE0IuTHvjhmOEJYlhG1CyC35veCIhLAsIWwTQm5GBQclhGUJYZsQcht+LzguISxL
CNuEkBvwXHBoQliWELYJIZ91PO6jD+OOqeB/CWFZQtgmhHzKWBV02X2TEJYlhG1C
yPUOh/iz6PJ5LvgeISxLCNuEkCudTqfoo7drLrjvEsKyhLBNCLnGWBX0XPDvhLAs
IWwTQq4ReunsnUvtB4SwLCFsE0K6DfSF2p4LXkIIyxLCNiGkz/F4jD5oL50KXkgI
yxLCNiGkT/QRe/lcYS8lhGUJYZsQ0iHDaWM3nxCWleGMFkJGMtanBm2QCWEkIWwT
Qi411h8atEEmhJGEsE0IuchYX6tt40wIIwlhmxDysf1+rC8UtYEmhJGEsE0I+ViG
s8U2OiGMlOHUFkIG4D0yds8JYSQhbBNCPpDhVLHtTggjZTi7hZDsBvoeGRtzQhhJ
CNuEkL8Z6su1bcQJYSQhbBNC3uWDg3b/CWEkIWwTQt7l6aDde2fRh3lpQtgmhLzN
J+hthR0OLkGRhLDNUcjbhNBW2D///BN9pJcmhG1CyBtOp1P0kWkl9vz8HH2wlyaE
bULIGzwdtHUWfaRXJ4RtQsgbog9LKzJvGQ0mhG1CyJ98p5qttuiDvTohbBNC/pTh
3LAa84wwWIaTXQhJ59u3b9HHpFXZPO+jj/fqhLBNCPmXeY4/MazIdrtd9PFenRC2
CSH/4ttkbLVFH+wI4fcJIb/4S/S22ubZxSeeELY5FvnFt2zbajudTtHHO0L4fULI
L9FHo9WZ94umIIRtQsh3vlbNVpvv2k5CCNscjnzn/aK2zvzppTyEsE0I+c73i9pa
87poFkLYJoR8550yts6ij3R+EcI2IWRxPB6jD0UrsfORFn2w84sQtgkhC08HbYX5
7GA2QtjmuGQRfRxaiUUf5vxJCNuEkEX0cWjb3z///BN9mPMnIWwTQnyzmq0w7xTN
SAjbhBC/ILT7zgcH0xLCNiHEX5ywO86XyGQmhG2OUXyU3u60Jx+WSE4I24SQDMeh
bW8Hf18iPyH8frBGPxDEiz4IbXvz1pgxCGGbEFZ3OMSfCbahPangQISwTQir85ZR
u9X2+3304UwfIWwTwuqE0D63wzx/mec5+kDmGkL4/SCOfiAI5s8Q2nV7/dSNV0HH
JoRtQlidDxHa3/f66Zqn9r/tP7wddDOEsE0IqwsNoecTEEkIhZCFEEJZQiiELEK/
VkYIIZIQCiELzwihLCEUQhZCCGUJoRCyEEIoSwiFkIUQQllCKIQshBDKEkIhZCGE
UJYQCiELIYSyhFAIWQghlCWEQshCCKEsIRRCFkIIZQmhELIQQihLCIWQhRBCWUIo
hCyEEMoSQiFkIYRQlhAKIQshhLKEUAhZCCGUJYRCyEIIoSwhFEIWQghlCaEQshBC
KEsIhZCFEEJZQiiELIQQyhJCIWQhhFCWEAohCyGEsoRQCFkIIZQlhELIQgihLCEU
QhZCCGUJoRCyEEIoSwiFkIUQQllCKIQshBDKEkIhZCGEUJYQCiELIYSyhFAIWQgh
lCWEQshCCKEsIRRCFkIIZQmhELIQQihLCIWQhRBCWUIohCyEEMoSQiFkIYRQlhAK
IQshhLKEUAhZCCGUJYRCyEIIoSwhFEIWQghlCaEQshBCKEsIhZCFEEJZQiiELIQQ
yhJCIWQhhFCWEAohCyGEsoRQCFkIIZQlhELIQgihLCEUQhZCCGUJoRCyEEIoSwiF
kIUQQllCKIQshBDKEkIhZCGEUJYQCiELIYSyhFAIWQghlCWEQshCCKEsIRRCFkII
ZQmhELIQQihLCIWQhRBCWUIohCyEEMoSQiFkIYRQlhAKIQshhLKEUAhZCCGUJYRC
yEIIoSwhFEIWQghlCaEQshBCKEsIhZCFEEJZQiiELIQQyhJCIWQhhFCWEAohCyGE
soRQCFkIIZQlhELIQgihLCEUQhZCCGUJoRCyEEIoSwiFkIUQQllCKIQshBDKEkIh
ZCGEUJYQCiELIYSyhFAIWQghlCWEQshCCKEsIRRCFkIIZQmhELIQQihLCIWQhRBC
WUK4LPQiaCaEEEkIzcInhBBJCM3CJ4QQSQjNwieEEEkIzcInhBBJCM3CJ4QQSQjN
wieEEEkIzcInhBBJCM3CJ4QQSQjNwieEEEkIzcInhBBJCM3CJ4QQKUkIn8JvhFnc
hBAiJQlh+JXILHBCCJGE0Cx8QgiRUoTQX0Gy2hNCiJQihBluhFnchBAiZWhQihth
FjchhEgZGjQdj/E3wixuQgiRUoRwt9uF3wizuAkhREoRwtfb4aOEVnZCCJHyhDD+
dpgFTQghUoYALbfjcIi/HWZBE0KIlCWErzcl/HpkFjIhhEiJQuhj9VZ1QgiREoXw
8fHRW2as5IQQIiUK4eS9o1Z0QgiRcoVwnufwW2O2+oQQIuUK4eRJoVWcEEKkdCF8
eHgIv0Fm604IIVK6EE4+U2jlJoQQKWMIJy+QWq0JIURKGsKzL1/CL09m60wIIVLe
EO73+/BbZrbKhBAi5Q3h5AVSqzIhhEipQ3h2Op3Cb5/ZnSeEECl7CM+en599Dalt
ekIIkQYI4Y8b6mVS2+qEECINE8Lp++cL5dC2NyGESCOF8Mct1kLb2IQQIo0Xwun1
I4Z+a2gbmhBCpCFD2Ox2u3n2YqltYEIIkQYO4U+vH70//xgHX0ZjY04IIdIWQvi7
cxTneb88SfwexSd1tL8u/gQQQoiV4ToQfR9QWI4/dSKEEEkIKU0IASGkNCEEhJDS
hBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoT
QkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0I
ASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEE
hJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQ
QkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAI
KU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGk
NCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDS
hBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkoT
QkAIKU0IASGkNCEEhJDShBAQQkoTQkAIKU0IASGkNCEEhJDShBAQQkpLEsLoG2Bm
wYu+FlJYjhCaWfVFXwspTAjNLMOir4UUJoRmlmHR10IKE0Izy7DoayGFCaGZZVj0
tZDChNDMMiz6WkhhQmhmGRZ9LaQwITSzDIu+FlKYEJpZhkVfCylMCM0sw6KvhRQ2
z/vwE8DMLPpaSGFfvsSfAGZWfr55nzjHo2eEZha/6GshhR2Px/ATwMws+lpIYc/P
z+EngJmV3yH6Wkht0SeAmZkQEir6BDCz6ptnISSUPxBvZrE7i74QUptPUJhZ7E6n
U/SFkNrOh2D4aWBmlRd9FQS/JjSzuM2zEJLA+UAMPxnMrOb8gpAU9nvfL2NmMYu+
/sEP3jJjZuvP66Ik4kMUZrb+vC5KIrvdLvyUMLNi8zl6kvHqqJmtOU8HSefl5SX8
xDCzMvN0kJSOx0P0uWFmJfb16y76ggfv8K4ZM7v35nmOvtTB+3zjmpnde9HXOfjI
4eAFUjO713zFNmPwDlIzu8dUkJHMs+eFZnbL7ff76AsbdNJCM7vdnqIvaXAVH6gw
s8/v8fEx+mIGn+ADFWb2iR12Ox8ZZHyvn6mQQzPrm88LsjXH49Gf8DWzy/bku2PY
rNdPVvjFoZm9tyffpk0Jh8PBZw3N7PfNsz8oQT37/f7Lq/Az0MyidnY8+oAgvL65
9PVzh09+j2i23bWXgg7nk/38Hzf8LeD/AQDHM/gX34jlAAAAAElFTkSuQmCC">
<p style="top:554.6pt;left:351.4pt;line-height:9.0pt"><span style="font-family:OpenSans,serif;font-size:9.0pt">Citing articles: 3 View citing articles </span></p>
<img style="position:absolute;transform:matrix(.033854169,0,-0,.033853566,417.59205,570.16348)" src="data:image/png;base64,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">


<p style="top:81.9pt;left:51.0pt;line-height:10.0pt"><span style="font-family:MyriadPro,serif;font-size:10.0pt">REVIEW</span></p>
<p style="top:102.9pt;left:51.0pt;line-height:14.0pt"><b><span style="font-family:MyriadPro,serif;font-size:14.0pt;color:#10137d">Probiotic and commensal gut microbial therapies in multiple sclerosis and its </span></b></p>
<p style="top:118.9pt;left:51.0pt;line-height:14.0pt"><b><span style="font-family:MyriadPro,serif;font-size:14.0pt;color:#10137d">animal models: a comprehensive review</span></b></p>
<p style="top:140.7pt;left:51.0pt;line-height:10.5pt"><span style="font-family:MyriadPro,serif;font-size:10.5pt">Lorrie L. Blais, Theresa L. Montgomery</span></p>
<p style="top:140.7pt;left:230.1pt;line-height:10.5pt"><span style="font-family:MyriadPro,serif;font-size:10.5pt">, Eyal Amiel</span></p>
<p style="top:140.7pt;left:292.1pt;line-height:10.5pt"><span style="font-family:MyriadPro,serif;font-size:10.5pt">, Paula B. Deming</span></p>
<p style="top:140.7pt;left:381.1pt;line-height:10.5pt"><span style="font-family:MyriadPro,serif;font-size:10.5pt">, and Dimitry N. Krementsov</span></p>
<p style="top:160.4pt;left:51.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">Department of Biomedical and Health Sciences, University of Vermont, Burlington, VT, USA</span></p>
<p style="top:190.6pt;left:63.0pt;line-height:7.5pt"><b><span style="font-family:MyriadPro,serif;font-size:7.5pt;color:#10137d">ABSTRACT</span></b></p>
<p style="top:199.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">The need for alternative treatments for multiple sclerosis (MS) has triggered copious amounts of </span></p>
<p style="top:209.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">research into microbial therapies focused on manipulating the microbiota&#x2013;gut&#x2013;brain axis. This </span></p>
<p style="top:219.5pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">comprehensive review was intended to present and systematically evaluate the current clinical and </span></p>
<p style="top:229.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">preclinical evidence for various probiotic and commensal gut microbial therapies as treatments for </span></p>
<p style="top:239.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">MS, using the Bradford Hill criteria (BHC) as a multi-parameter assessment rubric. Literature searches </span></p>
<p style="top:249.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">were performed to identify a total of 37 relevant studies (6 human, 31 animal), including 28 </span></p>
<p style="top:259.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">probiotic therapy and 9 commensal therapy studies. In addition to presenting qualitative summa-</span></p>
<p style="top:269.5pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">ries of these findings, therapeutic evidence for each bacterial formulation was assessed using the </span></p>
<p style="top:279.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">BHC to generate summative scores. These scores, which encompassed study quality, replication, </span></p>
<p style="top:289.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">and other considerations, were used to rank the most promising therapies and highlight deficien-</span></p>
<p style="top:299.5pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">cies. Several therapeutic formulations, including VSL#3, </span><i><span style="font-family:MyriadPro,serif;font-size:9.0pt">Lactobacillus paracasei, Bifidobacterium </span></i></p>
<p style="top:309.4pt;left:63.0pt;line-height:9.0pt"><i><span style="font-family:MyriadPro,serif;font-size:9.0pt">animalis, E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:9.0pt">Nissle 1917, and </span><i><span style="font-family:MyriadPro,serif;font-size:9.0pt">Prevotella histicola</span></i><span style="font-family:MyriadPro,serif;font-size:9.0pt">, emerged as the most promising. In contrast, </span></p>
<p style="top:319.5pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">a number of other therapies were hindered by limited evidence of replicable findings and other </span></p>
<p style="top:329.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">criteria, which need to be addressed by future studies in order to harness gut microbial therapies to </span></p>
<p style="top:339.4pt;left:63.0pt;line-height:9.0pt"><span style="font-family:MyriadPro,serif;font-size:9.0pt">ultimately provide cheaper, safer, and more durable treatments for MS.</span></p>
<p style="top:190.6pt;left:453.0pt;line-height:7.5pt"><b><span style="font-family:MyriadPro,serif;font-size:7.5pt;color:#10137d">ARTICLE HISTORY </span></b></p>
<p style="top:199.2pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Received 4 March 2021  </span></p>
<p style="top:208.2pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Revised 18 May 2021  </span></p>
<p style="top:217.3pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Accepted 7 June 2021 </span></p>
<p style="top:233.6pt;left:453.0pt;line-height:7.5pt"><b><span style="font-family:MyriadPro,serif;font-size:7.5pt;color:#10137d">KEYWORDS </span></b></p>
<p style="top:242.3pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Multiple sclerosis; probiotics; </span></p>
<p style="top:251.2pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">commensals; microbiome; </span></p>
<p style="top:260.2pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microbiota&#x2013;gut&#x2013;brain axis; </span></p>
<p style="top:269.2pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">autoimmune disease; </span></p>
<p style="top:278.3pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">comprehensive literature </span></p>
<p style="top:287.2pt;left:453.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">review</span></p>
<p style="top:382.8pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Introduction</span></b></p>
<p style="top:404.2pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Multiple sclerosis</span></i></b></p>
<p style="top:424.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Multiple sclerosis (MS) is a chronic autoimmune </span></p>
<p style="top:438.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">disease of the central nervous system (CNS) char-</span></p>
<p style="top:452.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">acterized by neuroinflammation, myelin sheath </span></p>
<p style="top:466.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">degeneration, axonal loss, and blood&#x2013;brain barrier </span></p>
<p style="top:480.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(BBB) deterioration.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">1</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">2 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Globally, about 2.8 million </span></p>
<p style="top:494.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">people are estimated to live with MS.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">3 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">The disease </span></p>
<p style="top:508.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">typically follows four different clinical courses: </span></p>
<p style="top:522.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinically isolated syndrome (CIS), relapsing- </span></p>
<p style="top:536.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">remitting MS (RRMS), primary progressive MS </span></p>
<p style="top:550.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(PPMS), and secondary progressive MS (SPMS), </span></p>
<p style="top:564.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">with progressive forms being most severe and </span></p>
<p style="top:578.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">refractory to treatment.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">1 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">As MS progresses, most </span></p>
<p style="top:592.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">patients are challenged with chronic pain and fati-</span></p>
<p style="top:606.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">gue, gradual sensorimotor impairments, bowel and </span></p>
<p style="top:620.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bladder dysfunction, cognitive changes, and overall </span></p>
<p style="top:634.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">diminished quality of life.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">1</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">2</span></sup></p>
<p style="top:648.3pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">There are currently 15 FDA-approved disease- </span></p>
<p style="top:662.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">modifying therapies (DMTs) used to decrease the </span></p>
<p style="top:676.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">severity and frequency of MS relapses.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">4&#x2013;6 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">These </span></p>
<p style="top:690.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">DMTs are generally effective at mitigating MS </span></p>
<p style="top:383.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">pathology by suppressing various aspects of the </span></p>
<p style="top:397.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immune system, but they are also expensive,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">2 </span></sup></p>
<p style="top:411.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">often accompanied by an array of side effects,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">5 </span></sup></p>
<p style="top:425.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and demonstrate decreased efficacy over time.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">6&#x2013;9 </span></sup></p>
<p style="top:439.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">As such, improved, alternative MS treatments are </span></p>
<p style="top:453.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">warranted.</span></p>
<p style="top:467.4pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Like most chronic diseases, susceptibility to MS </span></p>
<p style="top:481.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">is driven by both genetic and environmental com-</span></p>
<p style="top:495.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ponents, with the latter including well-documented </span></p>
<p style="top:509.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">risk factors like Epstein&#x2013;Barr virus infection, vita-</span></p>
<p style="top:523.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">min D-insufficiency, and smoking.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">10</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">11 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">An emer-</span></p>
<p style="top:537.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ging putative pseudo-environmental risk factor for </span></p>
<p style="top:551.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">MS and other chronic diseases is an imbalance </span></p>
<p style="top:565.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(dysbiosis) in the gut microbiome, a complex eco-</span></p>
<p style="top:579.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">system of trillions of microorganisms inhabiting </span></p>
<p style="top:593.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">our intestinal tracts. A generalized mechanism pro-</span></p>
<p style="top:607.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">posed is the bidirectional communication between </span></p>
<p style="top:621.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the CNS and gut by way of the so-called micro-</span></p>
<p style="top:635.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">biota-gut-brain axis (MGBA).</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">1</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">12&#x2013;14 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Dysbiosis </span></p>
<p style="top:649.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">within the gut can promote effector T cell pheno-</span></p>
<p style="top:663.3pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">types toward proinflammatory pathways that sub-</span></p>
<p style="top:677.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sequently </span></p>
<p style="top:677.4pt;left:377.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">increase </span></p>
<p style="top:677.4pt;left:441.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">intestinal </span></p>
<p style="top:677.4pt;left:511.3pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">barrier </span></p>
<p style="top:691.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">permeability.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">15&#x2013;20 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">This enables the release of </span></p>
<p style="top:717.7pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#10137d">CONTACT </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Dimitry N. Krementsov </span></p>
<p style="top:717.7pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#00007f">dkrement@uvm.edu </span></p>
<p style="top:717.7pt;left:252.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Department of Biomedical and Health Sciences, University of Vermont, Burlington, VT 05405</span></p>
<p style="top:726.6pt;left:63.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Supplemental data for this article can be accessed on the </span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#00007f">publisher&#x2019;s website</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">.</span></p>
<p style="top:42.0pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES                                              </span></p>
<p style="top:51.0pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">2021, VOL. 13, NO. 1, e1943289 (27 pages) </span></p>
<p style="top:60.0pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">https://doi.org/10.1080/19490976.2021.1943289</span></p>
<img style="position:absolute;transform:matrix(.3202415,0,-0,.3266161,551.6974,82.65063)" src="data:image/png;base64,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">
<p style="top:738.3pt;left:51.0pt;line-height:7.0pt"><span style="font-family:MyriadPro,serif;font-size:7.0pt">&#xa9; 2021 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. </span></p>
<p style="top:746.3pt;left:51.0pt;line-height:7.0pt"><span style="font-family:MyriadPro,serif;font-size:7.0pt">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (</span><span style="font-family:MyriadPro,serif;font-size:7.0pt;color:#00007f">http://creativecommons.org/licenses/by/4.0/</span><span style="font-family:MyriadPro,serif;font-size:7.0pt">), which permits unrestricted use, </span></p>
<p style="top:754.3pt;left:51.0pt;line-height:7.0pt"><span style="font-family:MyriadPro,serif;font-size:7.0pt">distribution, and reproduction in any medium, provided the original work is properly cited.</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbial antigens and intestinal immune cells into </span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">circulation, further promoting systemic, low-level </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">inflammation which may contribute to the wea-</span></p>
<p style="top:92.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">kened BBB tight junctions and enhanced T cell </span></p>
<p style="top:106.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">autoreactivity observed in MS.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">15</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">16</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">18&#x2013;20 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">The direc-</span></p>
<p style="top:120.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tionality of whether MS contributes to, as opposed </span></p>
<p style="top:134.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to results from, this dysbiosis, however, is still </span></p>
<p style="top:148.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">unclear. Nevertheless, multiple studies</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">16</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">18&#x2013;20 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">have </span></p>
<p style="top:162.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">characterized MS gut microbiomes as distinct from </span></p>
<p style="top:176.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">their healthy control-counterparts, generally pos-</span></p>
<p style="top:190.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sessing an elevated relative abundance of micro-</span></p>
<p style="top:204.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">rganisms associated with inflammation that when </span></p>
<p style="top:218.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">transplanted into mice have been shown to exacer-</span></p>
<p style="top:232.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bate an experimental animal model of MS, experi-</span></p>
<p style="top:246.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mental autoimmune encephalomyelitis (EAE).</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">19</span></sup></p>
<p style="top:282.9pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Commensal and probiotic gut bacterial therapies</span></i></b></p>
<p style="top:303.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Given the putative role of gut dysbiosis in promot-</span></p>
<p style="top:317.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ing MS susceptibility, an attractive therapeutic </span></p>
<p style="top:331.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">approach would be to restore balance of the micro-</span></p>
<p style="top:345.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">biome, and/or to take advantage of the intimate </span></p>
<p style="top:359.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cross-talk between the immune system and gut </span></p>
<p style="top:373.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microorganisms to inhibit or skew autoimmune </span></p>
<p style="top:387.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">responses.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">21&#x2013;24 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Hence, gut targeted microbial </span></p>
<p style="top:401.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapies have been gaining traction as alternative </span></p>
<p style="top:415.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">or supplemental treatment options for a variety of </span></p>
<p style="top:429.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">conditions, including MS.</span></p>
<p style="top:443.1pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Gut bacterial commensals are generally benefi-</span></p>
<p style="top:457.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cial organisms naturally comprising the gut </span></p>
<p style="top:471.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbiome </span></p>
<p style="top:471.1pt;left:122.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to </span></p>
<p style="top:471.1pt;left:145.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">maintain </span></p>
<p style="top:471.1pt;left:201.3pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a </span></p>
<p style="top:471.1pt;left:219.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">healthy </span></p>
<p style="top:471.1pt;left:267.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">host </span></p>
<p style="top:485.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">environment.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">22 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Whereas probiotics are defined </span></p>
<p style="top:499.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">by the International Scientific Association for </span></p>
<p style="top:513.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Probiotics and Prebiotics (ISAPP) as &#x201c;live micro-</span></p>
<p style="top:527.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">organisms that, when administered in adequate </span></p>
<p style="top:541.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">amounts, confer a health benefit on the host.&#x201d;</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">25 </span></sup></p>
<p style="top:555.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">For the purposes of this review, these are defined </span></p>
<p style="top:569.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">as live bacteria that can be supplemented into the </span></p>
<p style="top:583.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbiome to elicit beneficial changes in the </span></p>
<p style="top:597.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">commensal microbial community structure, and/ </span></p>
<p style="top:611.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">or exert direct beneficial effects on the host.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">22</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">26</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">27 </span></sup></p>
<p style="top:625.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">It should be noted, however, that the exact dis-</span></p>
<p style="top:639.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tinction between gut bacterial commensals and </span></p>
<p style="top:653.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bacterial probiotics remains arbitrary and far </span></p>
<p style="top:667.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">from uniform across studies, organizations, and </span></p>
<p style="top:681.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">regulatory guidelines. Nevertheless, both com-</span></p>
<p style="top:695.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensals and probiotics have important roles in </span></p>
<p style="top:709.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">digestive and immune health, including nutrient </span></p>
<p style="top:723.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and vitamin synthesis, metabolism of host dietary </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">products, intestinal barrier reinforcement, preven-</span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion of pathogenic microbe colonization, and anti- </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">inflammatory </span></p>
<p style="top:78.7pt;left:446.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immunoregulation.-</span></p>
<p style="top:90.3pt;left:306.0pt;line-height:8.1pt"><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">21</span><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">22</span><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">26</span><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">27</span><span style="font-family:MinionPro,serif;font-size:11.5pt">Consequently, both have the therapeutic </span></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">potential to mitigate MS pathology through mod-</span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ulation of the MGBA. This, in combination with </span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">accessibility and relatively low costs, makes pro-</span></p>
<p style="top:148.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">biotic and commensal therapies attractive alterna-</span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tive MS treatment candidates.</span></p>
<p style="top:198.7pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Alternative MS therapies: where do we stand?</span></i></b></p>
<p style="top:218.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">A number of recent reviews have attempted to </span></p>
<p style="top:232.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">compile the growing body of evidence for gut </span></p>
<p style="top:246.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbiome-targeted therapies, though most of </span></p>
<p style="top:260.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">these are far from comprehensive. </span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">12</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">26&#x2013;34 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">To date, </span></p>
<p style="top:274.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">there have been two published reviews that evaluate </span></p>
<p style="top:288.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the clinical utility of probiotics and explore possible </span></p>
<p style="top:302.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">underlying mechanisms, including one systematic </span></p>
<p style="top:316.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">review of two clinical and five preclinical studies,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">31 </span></sup></p>
<p style="top:330.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and one recent study with a meta-analysis of three </span></p>
<p style="top:344.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical studies and systematic review of 22 precli-</span></p>
<p style="top:358.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">nical studies.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">33 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Though valuable for highlighting </span></p>
<p style="top:372.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic therapeutic efficacy, both of these reviews </span></p>
<p style="top:386.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">are exclusively focused on probiotics without con-</span></p>
<p style="top:400.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sideration of commensal therapy, and neither </span></p>
<p style="top:414.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ranked the current evidence of each specific gut </span></p>
<p style="top:428.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bacterial formulations using a quantitative objec-</span></p>
<p style="top:442.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tive rubric. Addressing the latter is particularly </span></p>
<p style="top:456.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">important, given that it helps to identify stronger </span></p>
<p style="top:470.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and weaker areas within the field, highlight discre-</span></p>
<p style="top:484.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">pancies, and ultimately provide direction for future </span></p>
<p style="top:498.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">research.</span></p>
<p style="top:512.9pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Accordingly, in this comprehensive review, we </span></p>
<p style="top:526.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">attempt to (1) compile the current clinical and pre-</span></p>
<p style="top:540.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical evidence of MS mitigation by probiotic and </span></p>
<p style="top:554.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">commensal therapies; and (2) systematically rank </span></p>
<p style="top:568.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the evidence of each gut-bacterial formulation </span></p>
<p style="top:582.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">using the Bradford Hill criteria (see below). In </span></p>
<p style="top:596.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">doing so, we aim to identify the most promising </span></p>
<p style="top:610.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">emerging therapies, as well as to highlight existing </span></p>
<p style="top:624.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">shortcomings in the field and emphasize specific foci </span></p>
<p style="top:638.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">for future studies.</span></p>
<p style="top:674.5pt;left:306.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Methods</span></b></p>
<p style="top:695.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">This comprehensive review was originally intended </span></p>
<p style="top:709.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">as a systematic review, and therefore registered in </span></p>
<p style="top:723.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the International Prospective Register of Systematic </span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-2</span></p>
<p style="top:27.2pt;left:113.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Reviews (PROSPERO; ID# CRD42020206819) fol-</span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">lowing the initial search, but prior to screening </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">articles.</span></p>
<p style="top:114.6pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Search strategies</span></i></b></p>
<p style="top:134.9pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Searches were conducted by two authors (LB &amp; </span></p>
<p style="top:148.9pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">TM) on August 27, 2020 and January 4, 2021 </span></p>
<p style="top:162.9pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">using four databases: OvidMEDLINE, CINAHL, </span></p>
<p style="top:176.9pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">PubMed, and Web of Science. One paper was iden-</span></p>
<p style="top:190.9pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tified separately by one author (DK) outside of the </span></p>
<p style="top:204.9pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">search strategy.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">35 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Search strategies were tailored to </span></p>
<p style="top:218.8pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">each database using keywords, MeSH and MH </span></p>
<p style="top:232.8pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">headings, truncation, and an English Language fil-</span></p>
<p style="top:246.8pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ter (Supp. File 1A).</span></p>
<p style="top:282.8pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Selection criteria</span></i></b></p>
<p style="top:303.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Studies from all years were included in this review if </span></p>
<p style="top:317.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">they (1) were written or available in English, (2) </span></p>
<p style="top:331.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">investigated the effects of probiotic and/or com-</span></p>
<p style="top:345.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensal therapy on MS or an MS animal model </span></p>
<p style="top:359.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">severity and progression, and (3) utilized an experi-</span></p>
<p style="top:373.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mental/intervention-based study design. Studies </span></p>
<p style="top:387.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were excluded if they did not meet the inclusion </span></p>
<p style="top:401.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">criteria and/or used a non-intervention/experimen-</span></p>
<p style="top:415.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tal study design, including cohorts, cross-sectional </span></p>
<p style="top:429.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies, case&#x2013;control studies, case series, and case </span></p>
<p style="top:443.0pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reports.</span></p>
<p style="top:478.9pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Operational definitions</span></i></b></p>
<p style="top:499.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">As mentioned above, the distinction between bac-</span></p>
<p style="top:513.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">terial probiotics and commensals is not well </span></p>
<p style="top:527.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">defined, particularly as it applies to MS. For the </span></p>
<p style="top:541.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">purposes of this review, a bacterial therapeutic </span></p>
<p style="top:555.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">was considered &#x201c;probiotic&#x201d; when meeting evidence </span></p>
<p style="top:569.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">level 1&#x2013;2 based on World Gastroenterology </span></p>
<p style="top:583.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Organization guidelines from the Oxford Center </span></p>
<p style="top:597.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">for Evidence-Based Medicine, and &#x201c;commensal&#x201d; if </span></p>
<p style="top:611.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">falling at evidence level 3 and below where RCTs </span></p>
<p style="top:625.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">are lacking.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">36 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Study interventions were therefore </span></p>
<p style="top:639.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">classified as &#x201c;probiotic therapy&#x201d; if researchers sup-</span></p>
<p style="top:653.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">plemented with the following putative probiotics: </span></p>
<p style="top:667.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp., </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bifidobacterium </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp., </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Escherichia </span></i></p>
<p style="top:681.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">coli </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917 (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli Nissle 1917), Enterococcus </span></i></p>
<p style="top:695.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">faecium </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. faecium</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">), or </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Streptococcus thermophilus </span></i></p>
<p style="top:709.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">S. thermopohilis</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">); or &#x201c;commensal therapy&#x201d; if </span></p>
<p style="top:723.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">researchers supplemented with any other species </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of commensal bacteria, including </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Prevotella </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp., </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Akkermansia </span></i></p>
<p style="top:64.7pt;left:383.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">spp., </span></p>
<p style="top:64.7pt;left:422.6pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Pediococcus </span></i></p>
<p style="top:64.7pt;left:493.7pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">acidilactici </span></i></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. </span></i></p>
<p style="top:78.7pt;left:341.2pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">acidilactici), </span></i></p>
<p style="top:78.7pt;left:419.1pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Clostridium </span></i></p>
<p style="top:78.7pt;left:495.7pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">butyricum </span></i></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">C. butyricum</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">), and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bacteroides fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">).</span></p>
<p style="top:106.7pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">There were two animal studies that were excep-</span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tions to these classifications, for the following rea-</span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sons. Both studies introduced putative probiotic </span></p>
<p style="top:148.8pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. via stable colonization by </span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a single inoculation rather than continuous treat-</span></p>
<p style="top:176.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ment, which is more representative of commensal </span></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy than a probiotic therapy.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">37</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38</span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Additionally, </span></p>
<p style="top:204.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the bacterial strains used in these two studies are </span></p>
<p style="top:218.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">not strains recognized as probiotics, but are instead </span></p>
<p style="top:232.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">isolates from commensal murine gut microbiota. </span></p>
<p style="top:246.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">These two studies were hence classified as com-</span></p>
<p style="top:260.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensal therapy.</span></p>
<p style="top:301.7pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Data extraction</span></i></b></p>
<p style="top:321.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Following screening studies for relevance against </span></p>
<p style="top:335.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the selection criteria (LB, TM, &amp; DK), data were </span></p>
<p style="top:349.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">extracted from the included studies by two authors </span></p>
<p style="top:363.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(LB &amp; TM) (Supp. File 1). The study metrics </span></p>
<p style="top:377.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">extracted included first author, year of publication, </span></p>
<p style="top:391.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">DOI, location of study, study design, sample, inter-</span></p>
<p style="top:405.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">vention, duration of study, MS model (for animal </span></p>
<p style="top:419.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies), measurements/outcomes, statistical meth-</span></p>
<p style="top:433.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ods, and power (for human studies). The study </span></p>
<p style="top:447.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">measurement/outcomes extracted included clinical </span></p>
<p style="top:461.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">parameters of MS/EAE severity and progression, </span></p>
<p style="top:475.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immune and metabolic indices, microbiome and </span></p>
<p style="top:489.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">metabolome parameters, and mechanistic or corre-</span></p>
<p style="top:503.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">lative findings.</span></p>
<p style="top:539.9pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Evaluating quality and evidence of included studies</span></i></b></p>
<p style="top:555.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Included studies were subject to quality and risk of </span></p>
<p style="top:569.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bias (ROB) assessments using the Cochrane ROB </span></p>
<p style="top:583.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tool</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">39 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">for human studies and SYRCLE tool</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">40 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">for </span></p>
<p style="top:597.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">animal studies. High quality was assigned to studies </span></p>
<p style="top:611.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">with a low ROB, including randomized controlled </span></p>
<p style="top:625.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">trials (RCTs) and animal studies that explicitly sta-</span></p>
<p style="top:639.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ted using randomization and blinding measures. </span></p>
<p style="top:653.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Medium quality was assigned to studies with an </span></p>
<p style="top:667.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">uncertain ROB, including non-RCT human studies </span></p>
<p style="top:681.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and animal studies that did not explicitly state using </span></p>
<p style="top:695.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">randomization and/or blinding measures. Low </span></p>
<p style="top:709.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quality was assigned to studies with a high ROB, </span></p>
<p style="top:723.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">including studies with considerable confounding, </span></p>
<p style="top:27.2pt;left:429.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:506.2pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-3</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">in addition to not explicitly stating the use of ran-</span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">domization or blinding. These quality assessments </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were factored into the summative evaluation of </span></p>
<p style="top:92.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">each bacterial therapy; therefore, no studies were </span></p>
<p style="top:106.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">excluded from analysis on the basis of ROB.</span></p>
<p style="top:120.7pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The overall quality and strength of therapeutic </span></p>
<p style="top:134.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">evidence provided by each bacterial formulation </span></p>
<p style="top:148.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">was assessed using the Bradford Hill criteria </span></p>
<p style="top:162.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(BHC), which includes the following: temporal </span></p>
<p style="top:176.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">relationship, strength of relationship, dose&#x2013; </span></p>
<p style="top:190.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">response relationship, replication of findings, bio-</span></p>
<p style="top:204.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">logical plausibility, cessation of exposure, specificity </span></p>
<p style="top:218.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of association, and coherence between multiple </span></p>
<p style="top:232.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">approaches.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">41</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">42 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">The descriptions and numerical </span></p>
<p style="top:246.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">designations of each BHC can be found in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table </span></p>
<p style="top:260.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">1</span><span style="font-family:MinionPro,serif;font-size:11.5pt">. Sufficient evidence (Yes or No) was determined </span></p>
<p style="top:274.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">for each criterion (except for replication, see below) </span></p>
<p style="top:288.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and assigned a score of 1 for yes, followed by </span></p>
<p style="top:302.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">summation across all criteria to yield a final &#x201c;BH </span></p>
<p style="top:316.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score&#x201d; for each therapy. Replication of findings was </span></p>
<p style="top:330.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the most heavily weighted criterion, and was scored </span></p>
<p style="top:344.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">as follows: 3 = replicated in human and animal </span></p>
<p style="top:358.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies, 2 = replicated by different groups, 1 = repli-</span></p>
<p style="top:372.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cated by the same group, 0 = not replicated, </span></p>
<p style="top:386.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">&#x2212;2 = conflicting findings (not considering lack of </span></p>
<p style="top:400.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">effect as conflicting with positive). The calculations </span></p>
<p style="top:414.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">are detailed in Supplemental File 2 and summarized </span></p>
<p style="top:428.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">.</span></p>
<p style="top:470.1pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Results</span></b></p>
<p style="top:491.5pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">A. Study characteristics</span></i></b></p>
<p style="top:511.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The study characteristics and major findings of the </span></p>
<p style="top:525.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">included studies are summarized in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 1</span><b><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">&#x2013;</span></b><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">3</span><span style="font-family:MinionPro,serif;font-size:11.5pt">. </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">A total of 770 de-duplicated articles were found </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">by the initial search, 55 additional articles were </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">found by the second search, and one article</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">76 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">was </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">found by an author (DK) outside of the search </span></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">strategy. A total of 37 studies</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">35</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">37</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">3843&#x2013;76 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">(6 </span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">human, 31 animal) were included for analysis in </span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">this review based on the stated selection criteria </span></p>
<p style="top:148.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(see Methods) (</span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Figure 1</span><span style="font-family:MinionPro,serif;font-size:11.5pt">; Supp. File 1B). Of these </span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">37 studies, 28 (6 human, 22 animal) investigated the </span></p>
<p style="top:176.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">effects of probiotic therapy and 9 (0 human, 9 </span></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">animal) utilized commensal therapy. Studies were </span></p>
<p style="top:204.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">conducted between 1998 and 2020 in the following </span></p>
<p style="top:218.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">countries: USA, Iran, Japan, England, Netherlands, </span></p>
<p style="top:232.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Spain, Russia, Italy, Sweden, France, China, and </span></p>
<p style="top:246.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Republic of Korea.</span></p>
<p style="top:275.5pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Risk of bias</span></i></b></p>
<p style="top:288.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Overall, 10 studies (4 human, 6 animal) were deemed </span></p>
<p style="top:302.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">&#x201c;high quality&#x201d; based on the low risk of bias deter-</span></p>
<p style="top:316.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mined using the Cochrane ROB and SYRCLE tools </span></p>
<p style="top:330.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(Supp. File 1D and 1 F). Most (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 24) of the studies </span></p>
<p style="top:344.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(0 human, 24 animal) were classified as &#x201c;medium </span></p>
<p style="top:358.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quality&#x201d; due to study design limitations or failure to </span></p>
<p style="top:372.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">disclose randomization and/or blinding efforts. The </span></p>
<p style="top:386.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">remaining studies (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 3) were classified as &#x201c;low </span></p>
<p style="top:400.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quality,&#x201d; including two human studies that had </span></p>
<p style="top:414.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">important </span></p>
<p style="top:414.7pt;left:367.3pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">baseline </span></p>
<p style="top:414.7pt;left:418.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">characteristic </span></p>
<p style="top:414.7pt;left:494.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">differences </span></p>
<p style="top:428.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">between groups, substantial risk of confounding </span></p>
<p style="top:442.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">due to concurrent use of a DMT (glatiramer acetate), </span></p>
<p style="top:456.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and compared the results to healthy controls rather </span></p>
<p style="top:470.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">than untreated MS patient controls</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">46</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">47</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">; and one </span></p>
<p style="top:484.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">animal study that was not powered to perform sta-</span></p>
<p style="top:498.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tistical analysis lacked clarity regarding the control </span></p>
<p style="top:512.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">groups and did not explicitly state the use of rando-</span></p>
<p style="top:526.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mization or blinding measures.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">72</span></sup></p>
<p style="top:555.5pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Study design</span></i></b></p>
<p style="top:568.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Four human studies were structured as double- </span></p>
<p style="top:582.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">blind, placebo-controlled RCTs,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">61</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">63</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and the </span></p>
<p style="top:596.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">remaining </span></p>
<p style="top:596.7pt;left:370.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">two </span></p>
<p style="top:596.7pt;left:404.3pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were </span></p>
<p style="top:596.7pt;left:442.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">prospective </span></p>
<p style="top:596.7pt;left:512.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cohort </span></p>
<p style="top:610.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">46</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">47</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">, </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">The animal models of MS included </span></p>
<p style="top:624.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">EAE (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 27), cuprizone-</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">or gliotoxin-induced </span></p>
<p style="top:638.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">demyelination,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">52 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and Theiler&#x2019;s murine encephalo-</span></p>
<p style="top:652.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">myelitis </span></p>
<p style="top:652.7pt;left:354.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">virus-induced </span></p>
<p style="top:652.7pt;left:431.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">demyelinating </span></p>
<p style="top:652.7pt;left:510.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">disease </span></p>
<p style="top:666.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(TMEV-IDD).</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup></p>
<p style="top:695.5pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Subjects</span></i></b></p>
<p style="top:708.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Human subjects were studied exclusively in the </span></p>
<p style="top:722.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">RRMS stage. Expanded disability status scores</span></p>
<p style="top:560.0pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 1. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Bradford Hill criteria numerical designations and </span></p>
<p style="top:571.0pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">descriptions.</span></p>
<p style="top:593.7pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BHC</span></p>
<p style="top:584.7pt;left:135.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BHC </span></p>
<p style="top:593.7pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">#</span></p>
<p style="top:593.7pt;left:202.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Description</span></p>
<p style="top:605.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Temporal relationship</span></p>
<p style="top:605.5pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1</span></p>
<p style="top:605.5pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Does the exposure precede the outcome?</span></i></p>
<p style="top:614.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Strength of relationship</span></p>
<p style="top:614.6pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2</span></p>
<p style="top:614.6pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Level of evidence, ROB, study quality</span></i></p>
<p style="top:623.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Dose-response </span></p>
<p style="top:632.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">relationship</span></p>
<p style="top:623.6pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">3</span></p>
<p style="top:623.6pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">U-shaped, inverse U-shaped, etc.</span></i></p>
<p style="top:641.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Replication of findings</span></p>
<p style="top:641.5pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></p>
<p style="top:641.5pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Across studies, across research groups, etc.</span></i></p>
<p style="top:650.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Biological plausibility</span></p>
<p style="top:650.6pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5</span></p>
<p style="top:650.6pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Do the findings make biological sense?</span></i></p>
<p style="top:659.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Cessation of exposure</span></p>
<p style="top:659.6pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6</span></p>
<p style="top:659.6pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Do the effects change after </span></i></p>
<p style="top:668.5pt;left:163.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">discontinuation?</span></i></p>
<p style="top:677.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Specificity of </span></p>
<p style="top:686.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">association</span></p>
<p style="top:677.5pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7</span></p>
<p style="top:677.5pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Does the exposure lead to the outcome?</span></i></p>
<p style="top:695.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Coherence between </span></p>
<p style="top:704.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">multiple approaches</span></p>
<p style="top:695.6pt;left:140.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8</span></p>
<p style="top:695.6pt;left:155.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">How well do different lines of </span></i></p>
<p style="top:704.5pt;left:163.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">experimentation or observation support </span></i></p>
<p style="top:713.5pt;left:163.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">one another?</span></i></p>
<p style="top:725.9pt;left:51.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">BHC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, Bradford Hill criteria; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, risk of bias.</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-4</span></p>
<p style="top:27.2pt;left:113.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:59.1pt;left:46.6pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 2. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Human studies of probiotic therapies: summary of study characteristics and major findings.</span></p>
<p style="top:72.7pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:72.7pt;left:89.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:72.7pt;left:117.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:72.7pt;left:172.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Type</span></p>
<p style="top:72.7pt;left:239.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:72.7pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:72.7pt;left:333.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:72.7pt;left:428.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:84.6pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kouchaki </span></p>
<p style="top:93.6pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">60</span></sup></p>
<p style="top:84.6pt;left:88.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:84.6pt;left:108.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">18&#x2013;55 yo </span></p>
<p style="top:93.6pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 30/g</span></p>
<p style="top:84.6pt;left:155.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RRMS EDSS &#x2264; 4.5</span></p>
<p style="top:84.6pt;left:222.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Probiotic capsule, </span></p>
<p style="top:93.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:102.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus, </span></i></p>
<p style="top:111.6pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei, B. bifidum, </span></i></p>
<p style="top:120.6pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. fermentum) </span></i></p>
<p style="top:129.6pt;left:230.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: starch capsule</span></p>
<p style="top:84.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:84.6pt;left:332.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Biweekly </span></p>
<p style="top:93.6pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">for 12 </span></p>
<p style="top:102.6pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wks</span></p>
<p style="top:84.6pt;left:368.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EDSS, BDI, GHQ-28, DASS </span></p>
<p style="top:93.6pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">hs-CRP, MDA; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">plasma NO </span></p>
<p style="top:102.6pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:111.6pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:138.6pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Rahimlou </span></p>
<p style="top:147.6pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">63</span></sup></p>
<p style="top:138.6pt;left:88.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:138.6pt;left:108.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">18&#x2013;50 yo </span></p>
<p style="top:147.6pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 35/g</span></p>
<p style="top:138.6pt;left:155.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RRMS </span></p>
<p style="top:147.6pt;left:163.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EDSS &#x2264; 4.5</span></p>
<p style="top:138.6pt;left:222.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x201c;Protexin&#x201d;</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">a </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">capsule, </span></p>
<p style="top:147.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:156.6pt;left:230.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: maltodextrin </span></p>
<p style="top:165.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">capsule</span></p>
<p style="top:138.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:138.6pt;left:332.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for </span></p>
<p style="top:147.6pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6 mos</span></p>
<p style="top:138.6pt;left:368.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; EDSS; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">BDI, GHQ-28, FSS &amp; MPQ </span></p>
<p style="top:147.6pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-6; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">BDNF; &#x2013; NGF </span></p>
<p style="top:156.6pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:165.6pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:174.6pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Salami </span></p>
<p style="top:183.6pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">64</span></sup></p>
<p style="top:174.6pt;left:88.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:174.6pt;left:108.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">20&#x2013;60 yo </span></p>
<p style="top:183.6pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 24/g</span></p>
<p style="top:174.6pt;left:155.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RRMS </span></p>
<p style="top:183.6pt;left:163.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EDSS &#x2264; 4.5</span></p>
<p style="top:174.6pt;left:222.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Probiotic capsule, </span></p>
<p style="top:183.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:192.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum, </span></i></p>
<p style="top:201.6pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei, L. reuteri, </span></i></p>
<p style="top:210.6pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. fermentum, </span></i></p>
<p style="top:219.6pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. lactis, B. infantis</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">) </span></p>
<p style="top:228.6pt;left:230.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: maltodextrin </span></p>
<p style="top:237.6pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">capsule</span></p>
<p style="top:174.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:174.6pt;left:332.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">16 wks </span></p>
<p style="top:183.6pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(freq. </span></p>
<p style="top:192.6pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">not </span></p>
<p style="top:174.6pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">specified)</span></p>
<p style="top:243.0pt;left:50.6pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:252.1pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EDSS, </span></p>
<p style="top:243.0pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DASS; &#x2013; </span></p>
<p style="top:252.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BDI, GHQ- </span></p>
<p style="top:261.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">28 </span></p>
<p style="top:270.0pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL- </span></p>
<p style="top:279.0pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6, TNF-&#x3b1;, </span></p>
<p style="top:288.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">hs-CRP, </span></p>
<p style="top:297.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MDA, </span></p>
<p style="top:306.0pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8-OHdG; </span></p>
<p style="top:315.0pt;left:116.9pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10, </span></p>
<p style="top:324.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TAC, GSH, </span></p>
<p style="top:333.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">NO </span></p>
<p style="top:342.0pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:351.0pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:360.1pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tamtaji </span></p>
<p style="top:369.1pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">61</span></sup></p>
<p style="top:360.1pt;left:88.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:360.1pt;left:108.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">18&#x2013;55 yo </span></p>
<p style="top:369.1pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 20/g</span></p>
<p style="top:360.1pt;left:155.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RRMS </span></p>
<p style="top:369.1pt;left:163.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EDSS &#x2264; 4.5</span></p>
<p style="top:360.1pt;left:222.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Probiotic capsule, </span></p>
<p style="top:369.1pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:378.0pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus, </span></i></p>
<p style="top:387.0pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei, </span></i></p>
<p style="top:396.1pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. fermentum, </span></i></p>
<p style="top:405.1pt;left:230.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. bifidum</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">) </span></p>
<p style="top:414.0pt;left:230.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: starch capsule</span></p>
<p style="top:360.1pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:360.1pt;left:332.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for </span></p>
<p style="top:369.1pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">12 wks</span></p>
<p style="top:360.1pt;left:368.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD: &#x2013; </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">BMI; no relapses </span></p>
<p style="top:369.1pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-8, TNF-&#x3b1;; &#x2013; IL-1, PPAR-&#x3b3;, LDLR </span></p>
<p style="top:378.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:387.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:423.0pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tankou </span></p>
<p style="top:432.1pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">46</span></sup></p>
<p style="top:423.0pt;left:88.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">High</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt"> n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 7 MS, </span></p>
<p style="top:432.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">taking GA </span></p>
<p style="top:441.1pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 2 MS, </span></p>
<p style="top:450.0pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">untreated </span></p>
<p style="top:459.0pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 13 HC</span></p>
<p style="top:423.0pt;left:155.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RRMS</span></p>
<p style="top:423.0pt;left:222.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: VSL3,</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">b </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">3.6 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">12 </span></sup></p>
<p style="top:432.1pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/d </span></p>
<p style="top:441.1pt;left:230.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">HC</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span></p>
<p style="top:450.0pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">VSL3,</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">b </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">3.6 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">12 </span></sup></p>
<p style="top:459.0pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/d</span></p>
<p style="top:423.0pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:423.0pt;left:332.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for </span></p>
<p style="top:432.1pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 mos</span></p>
<p style="top:423.0pt;left:368.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:432.1pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. IL-10+ Tregs; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. intermediate &amp; </span></p>
<p style="top:441.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">inflammatory monocytes, costimulatory marker </span></p>
<p style="top:450.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD80 on classical monocytes, MFI of HLA-DR on </span></p>
<p style="top:459.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">myeloid-derived DCs, rel freq. of T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">1 &amp; T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells; </span></p>
<p style="top:468.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. IL-10+ Tregs &amp; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. of inflammatory </span></p>
<p style="top:477.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">monocytes following cessation; &#x2013; freq. B cells, NK </span></p>
<p style="top:486.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cells, myeloid or plasmacytoid DCs, na&#xef;ve CD4 or </span></p>
<p style="top:495.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD8 T cells, central memory CD4 or CD8 T cells, </span></p>
<p style="top:504.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">effector memory CD4 T cells </span></p>
<p style="top:513.1pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactobacillus, Streptococcus</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, &amp; </span></p>
<p style="top:522.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bifidobacterium</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, which returned to baseline </span></p>
<p style="top:531.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">following cessation </span></p>
<p style="top:540.1pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:549.1pt;left:50.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tankou </span></p>
<p style="top:558.0pt;left:58.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">47</span></sup></p>
<p style="top:549.1pt;left:88.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">High</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt"> n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 7 MS, </span></p>
<p style="top:558.0pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">taking GA </span></p>
<p style="top:567.0pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 2 MS, </span></p>
<p style="top:576.1pt;left:116.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">untreated </span></p>
<p style="top:585.1pt;left:116.9pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 13 HC</span></p>
<p style="top:549.1pt;left:155.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RRMS </span></p>
<p style="top:558.0pt;left:163.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EDSS = 1.4 &#xb1; 0.9</span></p>
<p style="top:549.1pt;left:222.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: LBS,</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">c </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">3.6 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">12 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/ </span></p>
<p style="top:558.0pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">d </span></p>
<p style="top:567.0pt;left:230.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">HC</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: LBS,</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">c </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">3.6 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">12 </span></sup></p>
<p style="top:576.1pt;left:230.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/d</span></p>
<p style="top:549.1pt;left:300.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:549.1pt;left:332.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for </span></p>
<p style="top:558.0pt;left:340.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 mos</span></p>
<p style="top:549.1pt;left:368.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:558.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. IL-10+ Tregs; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. intermediate &amp; </span></p>
<p style="top:567.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">inflammatory monocytes, costimulatory marker </span></p>
<p style="top:576.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD80 on classical monocytes, MFI of HLA-DR on </span></p>
<p style="top:585.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">myeloid-derived DCs, rel freq. of T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">1 &amp; T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells; </span></p>
<p style="top:594.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. IL-10+ Tregs &amp; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. of inflammatory </span></p>
<p style="top:603.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">monocytes following cessation; &#x2013; freq. B cells, NK </span></p>
<p style="top:612.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cells, myeloid or plasmacytoid DCs, na&#xef;ve CD4 or </span></p>
<p style="top:621.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD8 T cells, central memory CD4 or CD8 T cells, </span></p>
<p style="top:630.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">effector memory CD4 T cells </span></p>
<p style="top:639.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactobacillus, Streptococcus</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, &amp; </span></p>
<p style="top:648.1pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bifidobacterium; </span></i><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Veillonellaceae </span></i></p>
<p style="top:657.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">family &amp; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Collinsela </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">genus; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span></p>
<p style="top:666.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Akkermansia, Blautia, Dorea, B. adolescentis</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">; </span></p>
<p style="top:675.0pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microbiome changes returned to baseline </span></p>
<p style="top:684.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">following cessation &amp; were associated with </span></p>
<p style="top:693.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">changes in stool metabolic profile </span></p>
<p style="top:702.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of MS risk allele HLA.DQA.1, &amp; </span></p>
<p style="top:711.0pt;left:376.2pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">HLA.DPA1, ILGST, MALT1, LGALS3 </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">in monocytes; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:720.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10RA, LILRB2, CYBB</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">; most returned </span></p>
<p style="top:729.1pt;left:376.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">to baseline following cessation.</span></p>
<p style="top:27.2pt;left:429.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:506.2pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-5</span></p>


<p style="top:53.6pt;left:51.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">All findings are reported with respect to control group(s) unless otherwise indicated. </span></p>
<p style="top:60.9pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">a</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Protexin </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. subtilis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 21, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. bifidum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 23, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. breve </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 25, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. infantis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 27, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. longum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 30, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 35, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. rhamnosus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 54, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. helveticus </span></i></p>
<p style="top:71.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 45, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. salivarius </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 57, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. lactis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ssp. lactis PXN 63, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">S. thermophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 66, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 37, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbrueckii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ssp. bulgaricus PXN 39, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 47. </span></p>
<p style="top:78.9pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">b</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">VSL3 </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24732, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24730, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24734, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbruckeii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">bulgaricus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24734, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. longum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24736, </span></p>
<p style="top:89.6pt;left:57.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. infantis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24737, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. breve </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24732, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">S. thermophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24731. </span></p>
<p style="top:96.9pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">c</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">LBS </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= see </span><span style="font-family:MyriadPro,serif;font-size:5.7pt">b</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">VSL3. </span></p>
<p style="top:107.6pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Key</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">decreased; </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">increased; &#x2013; no change or no difference compared to control; NA, not applicable to this study. </span></p>
<p style="top:116.6pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abbreviations</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: ROB, risk of bias; MS, multiple sclerosis; yo, y old; g, group; RRMS, relapsing-remitting multiple sclerosis; GA, glatiramer acetate; HC, healthy </span></p>
<p style="top:125.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">controls; EDSS, Expanded Disability Status Scale; T, treatment group; C, control; CFU, colony forming units; Thera, therapeutic; wks, weeks; mos, months; freq., </span></p>
<p style="top:134.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">frequency; CD, clinical disease; IM, immune/metabolic; MM, microbiome/metabolome; MC, mechanistic/correlative; BDI, Beck Depression Inventory; GHQ-28, </span></p>
<p style="top:143.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">General Health Questionnaire-28; DASS, Depression Anxiety Stress Scales; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; </span></p>
<p style="top:152.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">FSS, Fatigue Severity Scale; MPQ, McGill Pain Questionnaire; IL, interleukin; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; TNF-&#x3b1;, tumor </span></p>
<p style="top:161.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">necrosis factor alpha; 8-OHdG, 8-Oxo-2</span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2b9;</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">-deoxyguanosine; TAC, total antioxidant capacity; GSH, glutathione; BMI, body mass index; HLA-DR, human leukocyte </span></p>
<p style="top:170.6pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">antigen-antigen D related; DC, dendritic cell; rel. abund., relative abundance; NK, natural killer.</span></p>
<p style="top:223.1pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 3. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Animal studies of probiotic therapies: summary of study characteristics and major findings.</span></p>
<p style="top:236.7pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:236.7pt;left:106.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:236.7pt;left:143.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:236.7pt;left:194.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:236.7pt;left:252.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:236.7pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:236.7pt;left:366.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:236.7pt;left:457.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:248.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Maassen </span></p>
<p style="top:257.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">59</span></sup></p>
<p style="top:248.6pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:248.6pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F SJL mice </span></p>
<p style="top:257.6pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;12 wko </span></p>
<p style="top:266.6pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 6/g</span></p>
<p style="top:248.6pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:257.6pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:248.6pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ML1 </span></p>
<p style="top:257.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">393 </span></p>
<p style="top:266.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i></p>
<p style="top:275.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">NCIB 8826 </span></p>
<p style="top:284.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. murinus </span></i></p>
<p style="top:293.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CNRZ </span></p>
<p style="top:302.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">10 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:311.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NaCO</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">3</span></p>
<p style="top:248.6pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:248.6pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Every other day for 5 </span></p>
<p style="top:257.6pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">admins</span></p>
<p style="top:248.6pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CDB (T1), weak </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T2), </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:257.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T4), &#x2013; (T3) </span></p>
<p style="top:266.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:275.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:284.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:320.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Salehipour </span></p>
<p style="top:329.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">50</span></sup></p>
<p style="top:320.6pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:320.6pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:329.6pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;10 wko </span></p>
<p style="top:338.6pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 8/g</span></p>
<p style="top:320.6pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:329.6pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:338.6pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:320.6pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">A7, </span></p>
<p style="top:329.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:338.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i></p>
<p style="top:347.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PTCC 1631,10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:356.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">o.g. </span></p>
<p style="top:365.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1+ T2 </span></p>
<p style="top:374.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: sterile saline</span></p>
<p style="top:320.6pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:320.6pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 22 d</span></p>
<p style="top:320.6pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: delayed EAE onset (T1-T3), T3 </span></p>
<p style="top:329.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">more pronounced; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE CS, CDI, </span></p>
<p style="top:338.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence, infiltration of MNCs, and </span></p>
<p style="top:347.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination (T1-T3), T3 more </span></p>
<p style="top:356.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pronounced </span></p>
<p style="top:365.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">ASP, IFN-&#x3b3;, IL-6, IL-17 (T1-T3) </span></p>
<p style="top:374.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">, T3 more pronounced; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">% CD4 </span></p>
<p style="top:383.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ CD25+ Foxp3+ Tregs, IL-4, IL-10, </span></p>
<p style="top:392.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TGF-&#x3b2; (T1-T3), T3 more </span></p>
<p style="top:401.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pronounced </span></p>
<p style="top:410.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:419.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">GATA3, FoxP3 </span></i></p>
<p style="top:428.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tbet, ROR</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">&#x3b3;t </span></p>
<p style="top:437.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1-T3), T3 more pronounced</span></p>
<p style="top:446.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">He et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">75</span></sup></p>
<p style="top:446.6pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:446.6pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:455.6pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10&#x2013;12 wko </span></p>
<p style="top:464.6pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 37&#x2013;40/g</span></p>
<p style="top:446.6pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:455.6pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:464.6pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:446.6pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri DSM </span></i></p>
<p style="top:455.6pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">17938 </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">100 &#xb5;L of 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup></p>
<p style="top:464.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:473.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 100 &#xb5;L MRS </span></p>
<p style="top:482.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">media + EAE, o.g. </span></p>
<p style="top:491.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: normal control</span></p>
<p style="top:446.6pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:446.6pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 20 d</span></p>
<p style="top:446.6pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CDS, EAE incidence, maximum </span></p>
<p style="top:455.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS, inflammatory cell infiltration </span></p>
<p style="top:464.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD3 + T cells &amp; CD68 </span></p>
<p style="top:473.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ macrophages in spinal cord, % </span></p>
<p style="top:482.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and abs. # of T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">1 and T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells, IL- </span></p>
<p style="top:491.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">17, IFN-&#x3b3;, </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">% MOG</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">35-55</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">-specific </span></p>
<p style="top:500.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">splenocytes </span></p>
<p style="top:509.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: reversed EAE rel. abund. </span></p>
<p style="top:518.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">changes (</span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bacteriodetes, </span></p>
<p style="top:527.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proteobacteria, Deferribacteres); </span></p>
<p style="top:536.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bifidobacterium, Lactobacillus, </span></i></p>
<p style="top:545.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Prevotella</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, &amp; S24-7 = negative </span></p>
<p style="top:554.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">correlation w/ CS </span></p>
<p style="top:563.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:572.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Goudarzvand </span></p>
<p style="top:581.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">52</span></sup></p>
<p style="top:572.6pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:572.6pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M Wistar rats </span></p>
<p style="top:581.6pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;10 wko </span></p>
<p style="top:590.6pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 8/g</span></p>
<p style="top:572.6pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">GID</span></p>
<p style="top:572.6pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i></p>
<p style="top:581.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bifidobacterium </span></i></p>
<p style="top:590.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">B94 </span></p>
<p style="top:599.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 1.5 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/ </span></p>
<p style="top:608.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mL orally </span></p>
<p style="top:617.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: GID only </span></p>
<p style="top:626.6pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: sterile saline, </span></p>
<p style="top:635.6pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">no GID</span></p>
<p style="top:572.6pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:572.6pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 28 d</span></p>
<p style="top:572.6pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; traveled distance, escape </span></p>
<p style="top:581.6pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">latency, or swimming speed </span></p>
<p style="top:590.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:599.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:608.6pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:647.2pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-6</span></p>
<p style="top:27.2pt;left:113.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:49.9pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 3. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:64.0pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:64.0pt;left:106.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:64.0pt;left:143.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:64.0pt;left:194.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:64.0pt;left:252.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:64.0pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:64.0pt;left:366.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:64.0pt;left:457.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:76.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Consonni </span></p>
<p style="top:85.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:76.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:76.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F Lewis rats </span></p>
<p style="top:85.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6&#x2013;8 wko </span></p>
<p style="top:94.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 6&#x2013;9/g </span></p>
<p style="top:103.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(</span><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1-T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">), </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 18/ </span></p>
<p style="top:112.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">g (</span><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5-T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">)</span></p>
<p style="top:76.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gpMBP- </span></p>
<p style="top:85.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:94.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:76.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. crispatus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LMG </span></p>
<p style="top:85.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">-23257 </span></p>
<p style="top:94.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. rhamnosus </span></i></p>
<p style="top:103.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 53103 </span></p>
<p style="top:112.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i></p>
<p style="top:121.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. lactis BB12 </span></p>
<p style="top:130.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i></p>
<p style="top:139.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. LMG </span></p>
<p style="top:148.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">S-28195 </span></p>
<p style="top:157.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1+ T2 </span></p>
<p style="top:166.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T3+ T4 </span></p>
<p style="top:175.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/ </span></p>
<p style="top:184.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">300 &#xb5;L orally </span></p>
<p style="top:193.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: vehicle</span></p>
<p style="top:76.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:85.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:76.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">15 doses over 3 wks (5 </span></p>
<p style="top:85.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">doses pre-EAE)</span></p>
<p style="top:76.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE incidence &amp; median score </span></p>
<p style="top:85.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">at peak (T1-T6); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">myelin loss, </span></p>
<p style="top:94.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">astrocytosis, &amp; spinal cord immune </span></p>
<p style="top:103.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cell infiltration (T5/T6); delayed EAE </span></p>
<p style="top:112.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">onset (T1,T2, T5, T6); dose-response </span></p>
<p style="top:121.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">relationship observed with T5/T6 </span></p>
<p style="top:130.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">proliferative response to </span></p>
<p style="top:139.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MBP, IFN-&#x3b3;, TNF-&#x3b1;, IL-17 (T5/T6); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:148.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TGF-&#x3b2;, IL-16 (T5/T6) </span></p>
<p style="top:157.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:166.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:202.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Baken et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">73</span></sup></p>
<p style="top:202.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:202.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M Lewis rats </span></p>
<p style="top:211.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6&#x2013;8 wko </span></p>
<p style="top:220.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 8/g</span></p>
<p style="top:202.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gpSCH- </span></p>
<p style="top:211.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:220.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:202.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">strain </span></p>
<p style="top:211.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota, 1 mL of </span></p>
<p style="top:220.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/mL </span></p>
<p style="top:229.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 1 mL saline/ </span></p>
<p style="top:238.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">peptone</span></p>
<p style="top:202.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:211.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:202.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 35 d (starting </span></p>
<p style="top:211.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8 d pre-EAE)</span></p>
<p style="top:202.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">body weight; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:211.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence, duration, CDS, &amp; CDI; </span></p>
<p style="top:220.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">earlier EAE onset </span></p>
<p style="top:229.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:238.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:247.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:256.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Gharehkhani </span></p>
<p style="top:265.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Digehsara </span></p>
<p style="top:274.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">71</span></sup></p>
<p style="top:256.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:256.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:265.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;10 wko</span></p>
<p style="top:256.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Cuprizone (4 </span></p>
<p style="top:265.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wks)</span></p>
<p style="top:256.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wks, </span></p>
<p style="top:265.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cuprizone 4 wks </span></p>
<p style="top:274.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Cuprizone 4 </span></p>
<p style="top:283.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wks, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wks </span></p>
<p style="top:292.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Cuprizone 4 </span></p>
<p style="top:301.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wks, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wks </span></p>
<p style="top:310.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">w/ Vitamin D3 (20 </span></p>
<p style="top:319.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IU/d) </span></p>
<p style="top:328.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wks, </span></p>
<p style="top:337.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/mL </span></p>
<p style="top:346.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Cuprizone 4 </span></p>
<p style="top:355.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wks, 0.2% w/w </span></p>
<p style="top:364.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">All admin orally </span></p>
<p style="top:373.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: normal control</span></p>
<p style="top:256.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:265.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:256.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: more normal &amp; significant Y-maze </span></p>
<p style="top:265.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">alternation behavior (T1-T3) </span></p>
<p style="top:274.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17 (T1-T3), T3 more </span></p>
<p style="top:283.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pronounced; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">TGF-&#x3b2; (T1-T3) </span></p>
<p style="top:292.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:301.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IDO </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">gene &amp; </span></p>
<p style="top:310.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">miR-155 (T1-T3, C2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression </span></p>
<p style="top:319.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">of miR-25 (C2), trending in T1-T3</span></p>
<p style="top:382.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kobayashi </span></p>
<p style="top:391.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">68</span></sup></p>
<p style="top:382.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:382.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M &amp; F Lewis rats </span></p>
<p style="top:391.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7 wko &amp; 2 wko </span></p>
<p style="top:400.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 8/g</span></p>
<p style="top:382.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gpSCH- or </span></p>
<p style="top:391.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gpMBP- </span></p>
<p style="top:400.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:409.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:382.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">strain </span></p>
<p style="top:391.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota in M rats (7 </span></p>
<p style="top:400.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wko), 1&#x2013;2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:409.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:418.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">strain </span></p>
<p style="top:427.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota in F rats (7 </span></p>
<p style="top:436.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wko), 1&#x2013;2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:445.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:454.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">strain </span></p>
<p style="top:463.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota in M &amp; </span></p>
<p style="top:472.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F rats (2 wko), 9.2&#x2013; </span></p>
<p style="top:481.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10.1 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:490.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. breve </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">strain </span></p>
<p style="top:499.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Yakult in M &amp; F rats </span></p>
<p style="top:508.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(2 wko), 5.0&#x2013; </span></p>
<p style="top:517.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6.9 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:526.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 0.5 mL saline/ </span></p>
<p style="top:535.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">peptone</span></p>
<p style="top:382.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:391.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:382.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily </span></p>
<p style="top:391.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1-T2: 35 d (starting </span></p>
<p style="top:400.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7 d pre-EAE) </span></p>
<p style="top:409.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3-T4: 63 d (starting </span></p>
<p style="top:418.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5 wks pre-EAE)</span></p>
<p style="top:382.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">mortality in T1-T4 except T4 </span></p>
<p style="top:391.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">males (</span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191;</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">); &#x2013; EAE onset, peak, </span></p>
<p style="top:400.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mean CDS, infiltration of MNCs </span></p>
<p style="top:409.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM: &#x2013; </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MBP IgG </span></p>
<p style="top:418.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:427.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:544.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kobayashi </span></p>
<p style="top:553.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">74</span></sup></p>
<p style="top:544.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:544.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F SJL &amp; C57BL6 </span></p>
<p style="top:553.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:562.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7 wko </span></p>
<p style="top:571.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 15/g</span></p>
<p style="top:544.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:553.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE (SJL) </span></p>
<p style="top:562.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; MOG- </span></p>
<p style="top:571.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:580.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:589.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(C57BL6)</span></p>
<p style="top:544.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">YIT 9029, </span></p>
<p style="top:553.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">0.6&#x2013;1.2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:562.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">o.g. </span></p>
<p style="top:571.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 0.2 mL saline/ </span></p>
<p style="top:580.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">peptone</span></p>
<p style="top:544.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:553.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:544.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 50 (SJL) or 29 </span></p>
<p style="top:553.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(C57BL6) d (both </span></p>
<p style="top:562.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">starting 1 wk pre- </span></p>
<p style="top:571.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE)</span></p>
<p style="top:544.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE CS on ds 12, 29, &amp; 30 </span></p>
<p style="top:553.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(SJL); &#x2013; EAE onset, peak score, MNC </span></p>
<p style="top:562.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">infiltration, white matter </span></p>
<p style="top:571.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination, or neutrophil </span></p>
<p style="top:580.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">infiltration (SJL &amp; C57BL6) </span></p>
<p style="top:589.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">% CD8 + T cells in spleen </span></p>
<p style="top:598.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(SJL), </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10, % Tregs in spleen, </span></p>
<p style="top:607.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17, IFN-&#x3b3; (SJL) </span></p>
<p style="top:616.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:625.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:637.1pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:429.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:506.2pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-7</span></p>


<p style="top:49.9pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 3. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:64.0pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:64.0pt;left:106.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:64.0pt;left:143.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:64.0pt;left:194.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:64.0pt;left:252.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:64.0pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:64.0pt;left:366.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:64.0pt;left:457.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:76.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lavasani </span></p>
<p style="top:85.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">48</span></sup></p>
<p style="top:76.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:76.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 (WT &amp; </span></p>
<p style="top:85.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10-/-) mice </span></p>
<p style="top:94.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;10 wko </span></p>
<p style="top:103.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 3&#x2013;18/g</span></p>
<p style="top:76.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:85.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:94.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:76.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i></p>
<p style="top:85.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 13434 </span></p>
<p style="top:94.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:103.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM </span></p>
<p style="top:112.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">15312 </span></p>
<p style="top:121.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:130.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM </span></p>
<p style="top:139.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">15313 </span></p>
<p style="top:148.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:157.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PCC </span></p>
<p style="top:166.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">101 </span></p>
<p style="top:175.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:184.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbrueckii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. </span></p>
<p style="top:193.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">bulgaricus DSM </span></p>
<p style="top:202.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">20081 </span></p>
<p style="top:211.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 5 mL of 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:220.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU orally until </span></p>
<p style="top:229.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE, then 200 &#xb5;L of </span></p>
<p style="top:238.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:247.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T1 </span></p>
<p style="top:256.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T7</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera Lacto- </span></p>
<p style="top:265.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mix (T1-T3) </span></p>
<p style="top:274.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T8</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: HK T7 </span></p>
<p style="top:283.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T9</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T7 in IL-10-/- </span></p>
<p style="top:292.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:301.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 200 &#xb5;L of 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:310.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:319.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: saline</span></p>
<p style="top:76.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:85.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:76.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 37 d (starting </span></p>
<p style="top:85.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">12 d pre-EAE) or </span></p>
<p style="top:94.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">every other day for </span></p>
<p style="top:103.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">20 d (starting 2 wks </span></p>
<p style="top:112.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">post-EAE onset)</span></p>
<p style="top:76.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; EAE progression (T1-T5,T8); </span></p>
<p style="top:85.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">delayed EAE onset and </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS (T1- </span></p>
<p style="top:94.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3, T7); therapeutic effects of </span></p>
<p style="top:103.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lacto-mix absent in T9 </span></p>
<p style="top:112.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">T cell proliferation (T1-T3) </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:121.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells (T1,T3),, </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IFN-&#x3b3;, </span></p>
<p style="top:130.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TNF-&#x3b1; (T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-4, IL-10, TGF-&#x3b2; </span></p>
<p style="top:139.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CNS inflammation, CD4 + T </span></p>
<p style="top:148.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cell infiltration, IFN-&#x3b3;, TNF-&#x3b1;, IL-17, </span></p>
<p style="top:157.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and IL-17-producing CD4 + T cells </span></p>
<p style="top:166.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T7); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10, IL-10-producing </span></p>
<p style="top:175.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells, Tregs, Foxp3+ cells in </span></p>
<p style="top:184.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">brain, mLN, spleen (T7) </span></p>
<p style="top:193.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:202.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: EAE suppressed in recipient </span></p>
<p style="top:211.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice (mLN cells from T7) &amp; </span></p>
<p style="top:220.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">depletion of CD4+ CD25 + T cells </span></p>
<p style="top:229.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">from mLN cells reverses </span></p>
<p style="top:238.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">suppression</span></p>
<p style="top:328.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sanchez </span></p>
<p style="top:337.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">49</span></sup></p>
<p style="top:328.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:328.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M &amp; F C57BL6 (WT, </span></p>
<p style="top:337.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD45.1, CD45.2, </span></p>
<p style="top:346.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">GF, TLR-2-/-, &amp; </span></p>
<p style="top:355.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TLR-9-/-) mice </span></p>
<p style="top:364.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; SJL mice </span></p>
<p style="top:373.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">9&#x2013;10 wko </span></p>
<p style="top:382.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">&#x2265; 10/g</span></p>
<p style="top:328.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:337.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:346.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:355.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(C57BL6) </span></p>
<p style="top:364.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; PLP- </span></p>
<p style="top:373.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:382.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE (SJL)</span></p>
<p style="top:328.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i></p>
<p style="top:337.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 27092 in </span></p>
<p style="top:346.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice </span></p>
<p style="top:355.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph HK T1 in </span></p>
<p style="top:364.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice </span></p>
<p style="top:373.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:382.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM </span></p>
<p style="top:391.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2649 in C57BL6 </span></p>
<p style="top:400.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:409.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:418.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC </span></p>
<p style="top:427.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">11582 in C57BL6 </span></p>
<p style="top:436.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:445.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:454.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC </span></p>
<p style="top:463.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">334 in C57BL6 mice </span></p>
<p style="top:472.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:481.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM </span></p>
<p style="top:490.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5622 in C57BL6 </span></p>
<p style="top:499.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:508.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T7</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T2 in CD45.1 </span></p>
<p style="top:517.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 donor mice </span></p>
<p style="top:526.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">AT into CD45.2 </span></p>
<p style="top:535.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice </span></p>
<p style="top:544.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T8</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T2 in TLR-2-/- </span></p>
<p style="top:553.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice </span></p>
<p style="top:562.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T9</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T2 in TLR-9-/- </span></p>
<p style="top:571.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice </span></p>
<p style="top:580.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T10</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T2 in WT </span></p>
<p style="top:589.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice GMT </span></p>
<p style="top:598.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">into GF C57BL6 </span></p>
<p style="top:607.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:616.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T11</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T2 in </span></p>
<p style="top:625.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">SJL mice </span></p>
<p style="top:634.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:643.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS, MRS </span></p>
<p style="top:652.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">medium, or T1- </span></p>
<p style="top:661.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">conditioned </span></p>
<p style="top:670.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">medium</span></p>
<p style="top:328.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:337.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:328.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 34&#x2013;39 d </span></p>
<p style="top:337.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 2 wks pre- </span></p>
<p style="top:346.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE) or daily for 39 d </span></p>
<p style="top:355.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 21 dpi) </span></p>
<p style="top:364.5pt;left:352.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T10</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: daily for 28 d </span></p>
<p style="top:373.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 70 d pre- </span></p>
<p style="top:382.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE) and GMT at </span></p>
<p style="top:391.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">42 d pre-EAE</span></p>
<p style="top:328.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE CS (T1-T6); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:337.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence (T1-T6); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:346.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination, infiltrating </span></p>
<p style="top:355.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">macrophages &amp; lymphocytes in </span></p>
<p style="top:364.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">brain &amp; spinal cord, and severity of </span></p>
<p style="top:373.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsequent relapses (T1-T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:382.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE CS w/ T1-conditioned media; &#x2013; </span></p>
<p style="top:391.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BBB &amp; BSCB permeability (T2) </span></p>
<p style="top:400.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM: &#x2013; </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">prop. CD4+ IFN-&#x3b3; + T cells, </span></p>
<p style="top:409.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4+ IL-17A+ T cells, or Tregs in </span></p>
<p style="top:418.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CNS (T1-T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CCL3, CCL4, CXCL5, </span></p>
<p style="top:427.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CXCL13 (T2) </span></p>
<p style="top:436.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE incidence (T10); &#x2013; EAE </span></p>
<p style="top:445.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS (T10) </span></p>
<p style="top:454.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: EAE suppression and </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:463.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination eliminated in </span></p>
<p style="top:472.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TLR2-/- mice; &#x2013; EAE incidence or </span></p>
<p style="top:481.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">severity in AT recipient mice of T2</span></p>
<p style="top:682.1pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-8</span></p>
<p style="top:27.2pt;left:113.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:49.9pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 3. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:64.0pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:64.0pt;left:106.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:64.0pt;left:143.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:64.0pt;left:194.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:64.0pt;left:252.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:64.0pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:64.0pt;left:366.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:64.0pt;left:457.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:76.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Yamashita </span></p>
<p style="top:85.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">67</span></sup></p>
<p style="top:76.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:76.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F SJL mice </span></p>
<p style="top:85.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5 wko </span></p>
<p style="top:94.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 10/g</span></p>
<p style="top:76.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:85.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:76.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: HK </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. helveticus </span></i></p>
<p style="top:85.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">SBT2171, 1 mg i.p. </span></p>
<p style="top:94.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 1 mg PBS i.p. </span></p>
<p style="top:103.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS, no EAE </span></p>
<p style="top:112.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(n = 3)</span></p>
<p style="top:76.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:85.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:76.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">3&#xd7;/wk for 3 wks (pre- </span></p>
<p style="top:85.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE), daily for 42 dpi</span></p>
<p style="top:76.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE incidence, CS, </span></p>
<p style="top:85.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">enlargement of inguinal LNs, </span></p>
<p style="top:94.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">infiltrating MNCs </span></p>
<p style="top:103.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt"># T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17, T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">1, &amp; CD4 + T cells </span></p>
<p style="top:112.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">in spinal cord, IL-17; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-6, TGF-&#x3b2;, </span></p>
<p style="top:121.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Foxp3+, IFN-&#x3b3; in inguinal LNs; &#x2013; IL- </span></p>
<p style="top:130.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10 in inguinal LNs, &#x2013; Ccl20 in spinal </span></p>
<p style="top:139.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cord, CCR2, CCR4, &amp; CCR6 on T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 </span></p>
<p style="top:148.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cells in dLNs </span></p>
<p style="top:157.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:166.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:175.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Libbey et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">54</span></sup></p>
<p style="top:175.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:175.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M C57BL6 mice </span></p>
<p style="top:184.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wko </span></p>
<p style="top:193.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 15/g</span></p>
<p style="top:175.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:184.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:193.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:175.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: r</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Nissle </span></p>
<p style="top:184.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1917, 1.31 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:193.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. single </span></p>
<p style="top:202.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gavage day </span></p>
<p style="top:211.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: r</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Nissle </span></p>
<p style="top:220.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1917, 1.19 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:229.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU + 1.25 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:238.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. double </span></p>
<p style="top:247.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gavage </span></p>
<p style="top:256.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 70 &#xb5;L PBS </span></p>
<p style="top:265.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: r</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Nissle </span></p>
<p style="top:274.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1917, no EAE</span></p>
<p style="top:175.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:175.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1&#x2013;2 admins 3 or 7 d </span></p>
<p style="top:184.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pre-EAE </span></p>
<p style="top:193.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Follow for 35&#x2013;36 dpi</span></p>
<p style="top:175.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">survival &amp; &#x2013; CS, onset, </span></p>
<p style="top:184.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence, CDS, maximal score, </span></p>
<p style="top:193.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">meningitis, demyelination, PVC </span></p>
<p style="top:202.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS, weight loss, PVC in T2; </span></p>
<p style="top:211.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">survival (T2); &#x2013; EAE onset, </span></p>
<p style="top:220.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence, CDS, maximal score, </span></p>
<p style="top:229.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">meningitis, demyelination (T2) </span></p>
<p style="top:238.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">microglia, Tregs, IFN-&#x3b3;, IL-27 </span></p>
<p style="top:247.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CNS-derived cells, </span></p>
<p style="top:256.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microglia, CD8 + T cells, CD4 + T </span></p>
<p style="top:265.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cells, T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">1 cells, Tregs in brain (T2); </span></p>
<p style="top:274.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells (T2) </span></p>
<p style="top:283.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:292.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:301.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Secher et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">55</span></sup></p>
<p style="top:301.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:301.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M C57BL6 mice </span></p>
<p style="top:310.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;12 wko </span></p>
<p style="top:319.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 30&#x2013;40/g</span></p>
<p style="top:301.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:310.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:319.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:301.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Nissle 1917 </span></p>
<p style="top:310.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: archetypal K12 </span></p>
<p style="top:319.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MG1655 </span></p>
<p style="top:328.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:337.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS</span></p>
<p style="top:301.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:310.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:301.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 37 d (starting </span></p>
<p style="top:310.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7 d pre-EAE)</span></p>
<p style="top:301.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE CS, mortality, incidence, </span></p>
<p style="top:310.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CDS, maximal score; &#x2013; onset; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:319.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">colon &amp; ileum permeability </span></p>
<p style="top:328.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">total CD4+ and MOG- </span></p>
<p style="top:337.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">specific CD4 + T cells in spinal cord, </span></p>
<p style="top:346.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IFN-&#x3b3;, GM-CSF, IL-17, TNF-&#x3b1;, IL-6; </span></p>
<p style="top:355.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">total CD4+ and MOG-specific </span></p>
<p style="top:364.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells in LNs, IL-10, CD4 </span></p>
<p style="top:373.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ Foxp3+ cells from draining LNs </span></p>
<p style="top:382.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:391.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of Reg3g, </span></p>
<p style="top:400.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Reg3b, Claudin-8, ZO-1</span></p>
<p style="top:409.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Mestre et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">43</span></sup></p>
<p style="top:409.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:409.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F SJL mice </span></p>
<p style="top:418.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5&#x2013;8 wko </span></p>
<p style="top:427.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 5&#x2013;10/g</span></p>
<p style="top:409.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TMEV-IDD</span></p>
<p style="top:409.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: TMEV-IDD w/ </span></p>
<p style="top:418.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Vivomixx</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">b </span></sup></p>
<p style="top:427.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">100 &#xb5;L of 3 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup></p>
<p style="top:436.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:445.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Sham w/ </span></p>
<p style="top:454.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Vivomixx</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">b </span></sup></p>
<p style="top:463.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: TMEV-IDD w/ </span></p>
<p style="top:472.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">vehicle </span></p>
<p style="top:481.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Sham w/ </span></p>
<p style="top:490.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">vehicle</span></p>
<p style="top:409.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:409.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">3&#xd7;/wk for 15 d (70&#x2013;85 </span></p>
<p style="top:418.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">dpi)</span></p>
<p style="top:409.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">horizontal &amp; vertical activity, </span></p>
<p style="top:418.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">latency to fall </span></p>
<p style="top:427.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells, B cells, % </span></p>
<p style="top:436.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Foxp3+ CD39+ and Foxp3-CD39 </span></p>
<p style="top:445.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ T cells in spleen, IL-1B, IL-6; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:454.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bregs, IL-10; &#x2013; TNF-&#x3b1;; microglia </span></p>
<p style="top:463.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">exhibited anti-inflammatory </span></p>
<p style="top:472.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">activation or </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">proinflammatory </span></p>
<p style="top:481.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">activity </span></p>
<p style="top:490.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Anaerostipes, </span></i></p>
<p style="top:499.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Dorea, Oscillospira, </span></i></p>
<p style="top:508.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Enterobacteraceae, Ruminococcus, </span></i></p>
<p style="top:517.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bilophila</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span></p>
<p style="top:526.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bacteroides, Odoribacter, </span></i></p>
<p style="top:535.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactobacillus, Sutterella</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">acetate </span></p>
<p style="top:544.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; butyrate in plasma </span></p>
<p style="top:553.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:565.1pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:429.7pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:506.2pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-9</span></p>


<p style="top:49.9pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 3. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:64.0pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:64.0pt;left:106.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:64.0pt;left:143.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:64.0pt;left:194.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:64.0pt;left:252.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:64.0pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:64.0pt;left:366.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:64.0pt;left:457.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:76.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Calvo-Barreiro </span></p>
<p style="top:85.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">44</span></sup></p>
<p style="top:76.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:76.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 OlaHsd </span></p>
<p style="top:85.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:94.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8 wko </span></p>
<p style="top:103.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 17&#x2013;20/g</span></p>
<p style="top:76.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:85.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:94.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:76.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Lactibiane iki</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">c</span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span></p>
<p style="top:85.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1.6 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:94.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">once daily </span></p>
<p style="top:103.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1 twice daily </span></p>
<p style="top:112.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span></p>
<p style="top:121.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Vivomixx</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">b, </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">9 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:130.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. once daily </span></p>
<p style="top:139.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T3 twice daily </span></p>
<p style="top:148.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">/</span><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: water o.g. </span></p>
<p style="top:157.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">once or twice daily </span></p>
<p style="top:166.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: untreated EAE </span></p>
<p style="top:175.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: normal control</span></p>
<p style="top:76.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:76.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1&#x2013;2&#xd7; daily for 18&#x2013;22 d </span></p>
<p style="top:85.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(13&#x2013;16 or 12&#x2013;15 </span></p>
<p style="top:94.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">dpi)</span></p>
<p style="top:76.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS w/ T1/T2 but not T3/T4 </span></p>
<p style="top:85.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(dose-response observed); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">% </span></p>
<p style="top:94.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination, T cell inflammatory </span></p>
<p style="top:103.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">infiltrate density, &amp; axonal damage </span></p>
<p style="top:112.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1-T4); &#x2013; intestinal permeability or </span></p>
<p style="top:121.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microglia or astrocyte reactivity; </span></p>
<p style="top:130.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">improved motor coordination </span></p>
<p style="top:139.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">ASP w/ T1/T2 but not T3/T4, </span></p>
<p style="top:148.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">% peripheral plasma cells (T1/T2); </span></p>
<p style="top:157.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tregs (T1/T2) </span></p>
<p style="top:166.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; alpha or beta diversity; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:175.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lachnoclostridium </span></i></p>
<p style="top:184.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bifidobacterium </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1/T2), </span></p>
<p style="top:193.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Streptococcus (</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3/T4); </span></p>
<p style="top:202.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Atopobiacaeae </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Bifidobacterium </span></i></p>
<p style="top:211.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">assoc. with </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">accumulated EAE </span></p>
<p style="top:220.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">scores </span></p>
<p style="top:229.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 4x</span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of Th17 txn </span></p>
<p style="top:238.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">factor ROR&#x3b3;t in spinal cord T1/T2</span></p>
<p style="top:247.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kwon et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">69</span></sup></p>
<p style="top:247.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:247.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice </span></p>
<p style="top:256.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6&#x2013;8 wko </span></p>
<p style="top:265.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 10/g</span></p>
<p style="top:247.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:256.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:265.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:247.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph IRT5</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">d </span></sup></p>
<p style="top:256.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera IRT5</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">d </span></sup></p>
<p style="top:265.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Each 5 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o. </span></p>
<p style="top:274.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">g. </span></p>
<p style="top:283.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS</span></p>
<p style="top:247.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:256.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:247.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 3 wks (pre- </span></p>
<p style="top:256.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE) or 16 d </span></p>
<p style="top:265.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 12 dpi)</span></p>
<p style="top:247.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE incidence, CS, </span></p>
<p style="top:256.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">lymphocytes, Gr1+ and CD11b+ </span></p>
<p style="top:265.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">monocytes, and CD4 + T cells in </span></p>
<p style="top:274.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">spinal cord (T1); delayed EAE onset </span></p>
<p style="top:283.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE CS (T2) </span></p>
<p style="top:292.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">ASP, IFN-&#x3b3;, TNF-&#x3b1;, IL-17; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:301.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-4, IL-10, CD4+ Foxp3+ Tregs </span></p>
<p style="top:310.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">from spinal cord </span></p>
<p style="top:319.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:328.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:337.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">McMurran </span></p>
<p style="top:346.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">45</span></sup></p>
<p style="top:337.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:337.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:346.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">13 mo </span></p>
<p style="top:355.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 3&#x2013;5/g</span></p>
<p style="top:337.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Cuprizone (5 </span></p>
<p style="top:346.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">wks)</span></p>
<p style="top:337.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: VSL#3</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">e</span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 1.35 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:346.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:355.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: autoclaved </span></p>
<p style="top:364.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">water</span></p>
<p style="top:337.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:346.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:337.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 7 wks </span></p>
<p style="top:346.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 4 wks pre- </span></p>
<p style="top:355.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">lysolecithin </span></p>
<p style="top:364.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">injection)</span></p>
<p style="top:337.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; remyelination </span></p>
<p style="top:346.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">SCFAs in feces &amp; serum, </span></p>
<p style="top:355.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">inflammatory response at 5 dpi, </span></p>
<p style="top:364.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">density of CD68+ activated </span></p>
<p style="top:373.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microglia &amp; infiltrating </span></p>
<p style="top:382.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">macrophages, # of ODCs at 5 dpi; &#x2013; </span></p>
<p style="top:391.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ODC response at 14 dpi, </span></p>
<p style="top:400.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">inflammatory response at 14 dpi </span></p>
<p style="top:409.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:418.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:427.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ezendam </span></p>
<p style="top:436.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">51</span></sup></p>
<p style="top:427.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:427.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M &amp; F Lewis rats </span></p>
<p style="top:436.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 wko </span></p>
<p style="top:445.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">n = 4&#x2013;8/g</span></p>
<p style="top:427.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gpMBP- </span></p>
<p style="top:436.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:445.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:427.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">w/ EAE, </span></p>
<p style="top:436.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">200 &#xb5;L of 1 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup></p>
<p style="top:445.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:454.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">w/ </span></p>
<p style="top:463.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">no EAE </span></p>
<p style="top:472.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 200 &#xb5;L saline </span></p>
<p style="top:481.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">w/ EAE </span></p>
<p style="top:490.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 200 &#xb5;L saline </span></p>
<p style="top:499.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">w/ no EAE</span></p>
<p style="top:427.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:436.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:427.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for ~60 d </span></p>
<p style="top:436.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 5 wks pre- </span></p>
<p style="top:445.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE)</span></p>
<p style="top:427.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">weight gain for M; shorter EAE </span></p>
<p style="top:436.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">duration for M; &#x2013; EAE onset, </span></p>
<p style="top:445.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">duration, or CDI for F; &#x2013; EAE onset </span></p>
<p style="top:454.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">or CDI for M </span></p>
<p style="top:463.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:472.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:481.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:508.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ezendam &amp; </span></p>
<p style="top:517.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">van </span></p>
<p style="top:526.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Loveren</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">72</span></sup></p>
<p style="top:508.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">High M &amp; F Lewis rats </span></p>
<p style="top:517.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 wko </span></p>
<p style="top:526.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 4&#x2013;8/g</span></p>
<p style="top:508.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">gpMBP- </span></p>
<p style="top:517.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:526.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:508.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T; </span></b><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">strain </span></p>
<p style="top:517.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota, 500 &#xb5;L of </span></p>
<p style="top:526.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1&#x2013;2 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g. </span></p>
<p style="top:535.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 500 &#xb5;L saline/ </span></p>
<p style="top:544.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">peptone</span></p>
<p style="top:508.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:517.5pt;left:319.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:508.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for ~9 wks </span></p>
<p style="top:517.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 5 wks pre- </span></p>
<p style="top:526.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE)</span></p>
<p style="top:508.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; EAE onset, CS, CDI for M &amp; F; </span></p>
<p style="top:517.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">slightly longer duration for F; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:526.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE incidence </span></p>
<p style="top:535.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:544.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:553.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:562.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Johanson </span></p>
<p style="top:571.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">76</span></sup></p>
<p style="top:562.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:562.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:571.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8 wko </span></p>
<p style="top:580.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">n = 10/g</span></p>
<p style="top:562.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG- </span></p>
<p style="top:571.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:580.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:562.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 2327 </span></p>
<p style="top:571.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ad libitum </span></p>
<p style="top:580.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: MRS broth</span></p>
<p style="top:562.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:562.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 20 d</span></p>
<p style="top:562.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">average CS, &#x2013; weight loss </span></p>
<p style="top:571.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:580.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactobacillus 16S V3-V4 </span></p>
<p style="top:589.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">amplicon abundance </span></p>
<p style="top:598.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:607.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abdurasulova </span></p>
<p style="top:616.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">66</span></sup></p>
<p style="top:607.5pt;left:105.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:607.5pt;left:126.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F Wistar rats </span></p>
<p style="top:616.5pt;left:134.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">3 mo </span></p>
<p style="top:625.5pt;left:134.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 26&#x2013;35/g</span></p>
<p style="top:607.5pt;left:189.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">homologous </span></p>
<p style="top:616.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">SCH- </span></p>
<p style="top:625.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:634.5pt;left:197.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:607.5pt;left:237.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. faecium </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LMG </span></p>
<p style="top:616.5pt;left:245.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">-27496 L3 probe, </span></p>
<p style="top:625.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">0.5 mL o.g. </span></p>
<p style="top:634.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Glatiramer </span></p>
<p style="top:643.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">acetate, 0.2 mL s.c. </span></p>
<p style="top:652.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: saline, 0.5 mL o. </span></p>
<p style="top:661.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">g. </span></p>
<p style="top:670.5pt;left:245.1pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: saline, 0.2 mL s. </span></p>
<p style="top:679.5pt;left:245.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">c.</span></p>
<p style="top:607.5pt;left:311.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:607.5pt;left:344.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 15 d (starting </span></p>
<p style="top:616.5pt;left:352.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2 dpi)</span></p>
<p style="top:607.5pt;left:422.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">prevalence, CDS, CS, mortality </span></p>
<p style="top:616.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1/T2); delayed onset and shorter </span></p>
<p style="top:625.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">duration (T1/T2); T1 outperformed </span></p>
<p style="top:634.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2 in prevalence, duration, and CDS </span></p>
<p style="top:643.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4+ CD25+ Foxp3+ Tregs </span></p>
<p style="top:652.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">during peak and recovery phases, </span></p>
<p style="top:661.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells during peak; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 </span></p>
<p style="top:670.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ Tcells during inductive, CD4 </span></p>
<p style="top:679.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ CD25+ Foxp3- Tregs during peak, </span></p>
<p style="top:688.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD8 + T cells during peak &amp; </span></p>
<p style="top:697.5pt;left:430.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">recovery </span></p>
<p style="top:706.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:715.5pt;left:430.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-10</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:624.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(EDSS) were all &#x2264;4.5 as a maximum for inclusion. </span></p>
<p style="top:638.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Male and female participants ranged from 18 to </span></p>
<p style="top:652.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">60 y old. Animal subjects included both male and </span></p>
<p style="top:666.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">female rats (Lewis and Wistar) and mice (C57BL/6, </span></p>
<p style="top:680.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">SJL, and PWD/PhJ) ranging in age from 2 weeks to </span></p>
<p style="top:694.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">13 months, with a mean of 7&#x2013;8 weeks old. Various </span></p>
<p style="top:708.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">genetically modified C57BL/6 mice were used, </span></p>
<p style="top:624.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">including HLA-DR3.DQ8 transgenic</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">57</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:638.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">IL-10-,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">TLR-2-,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and TLR-9-</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">deficient strains.</span></p>
<p style="top:668.3pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Interventions</span></i></b></p>
<p style="top:681.5pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Probiotic therapy involved individual strains and </span></p>
<p style="top:695.5pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">various </span></p>
<p style="top:695.5pt;left:353.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">combinations </span></p>
<p style="top:695.5pt;left:431.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(including </span></p>
<p style="top:695.5pt;left:492.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Lacto-mix, </span></p>
<p style="top:709.5pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactibiane iki, IRT5, Protexin, VSL3/VSL#3/</span></p>
<p style="top:354.9pt;left:221.8pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Titles &amp; abstracts screened</span></b></p>
<p style="top:364.5pt;left:257.6pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 825</span></p>
<p style="top:267.4pt;left:178.0pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">OvidMEDLINE</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 484 </span></p>
<p style="top:277.1pt;left:178.0pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">CINAHL</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 63</span></p>
<p style="top:286.7pt;left:178.0pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">PubMed</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 538</span></p>
<p style="top:296.4pt;left:178.0pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">Web of Science</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 406</span></p>
<p style="top:306.2pt;left:204.9pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 1491</span></b></p>
<p style="top:267.0pt;left:281.9pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">OvidMEDLINE</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 522</span></p>
<p style="top:276.7pt;left:281.9pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">CINAHL</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 64</span></p>
<p style="top:286.3pt;left:281.9pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">PubMed</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 578</span></p>
<p style="top:296.0pt;left:281.9pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">Web of Science</span></i><span style="font-family:Times New Roman,serif;font-size:8.4pt">: 423</span></p>
<p style="top:305.8pt;left:308.8pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 1587</span></b></p>
<p style="top:254.0pt;left:196.4pt;line-height:7.0pt"><b><span style="font-family:Times New Roman,serif;font-size:7.0pt">August 27, 2020</span></b></p>
<p style="top:254.0pt;left:300.2pt;line-height:7.0pt"><b><span style="font-family:Times New Roman,serif;font-size:7.0pt">January 4, 2021</span></b></p>
<p style="top:400.3pt;left:224.3pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Full-text articles screened</span></b></p>
<p style="top:409.8pt;left:259.7pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 98</span></p>
<p style="top:466.9pt;left:220.9pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Studies included for review</span></b></p>
<p style="top:476.4pt;left:259.0pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 37</span></p>
<p style="top:486.1pt;left:233.3pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">(6 human, 31 animal)</span></i></p>
<p style="top:527.4pt;left:146.6pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Probiotic Therapy</span></b></p>
<p style="top:536.9pt;left:168.9pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 28</span></p>
<p style="top:546.8pt;left:143.2pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">(6 human, 22 animal)</span></i></p>
<p style="top:527.4pt;left:328.8pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Commensal Therapy</span></b></p>
<p style="top:536.9pt;left:357.8pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 9</span></p>
<p style="top:546.8pt;left:332.1pt;line-height:8.4pt"><i><span style="font-family:Times New Roman,serif;font-size:8.4pt">(0 human, 9 animal)</span></i></p>
<p style="top:335.8pt;left:364.0pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Duplicates removed</span></b></p>
<p style="top:345.3pt;left:384.6pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 2253</span></p>
<p style="top:419.2pt;left:383.2pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Excluded</span></b></p>
<p style="top:428.7pt;left:389.3pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 61</span></p>
<p style="top:438.3pt;left:351.2pt;line-height:7.0pt"><i><span style="font-family:Times New Roman,serif;font-size:7.0pt">Irrelevant (n=6), Non-intervention </span></i></p>
<p style="top:446.3pt;left:348.7pt;line-height:7.0pt"><i><span style="font-family:Times New Roman,serif;font-size:7.0pt">study (n=3), Used organism product </span></i></p>
<p style="top:454.4pt;left:348.8pt;line-height:7.0pt"><i><span style="font-family:Times New Roman,serif;font-size:7.0pt">or recombinant strain (n=6), No MS </span></i></p>
<p style="top:462.4pt;left:356.8pt;line-height:7.0pt"><i><span style="font-family:Times New Roman,serif;font-size:7.0pt">model (n=1), helminth therapy </span></i></p>
<p style="top:470.4pt;left:390.1pt;line-height:7.0pt"><i><span style="font-family:Times New Roman,serif;font-size:7.0pt">(n=45)</span></i></p>
<p style="top:376.7pt;left:382.8pt;line-height:8.4pt"><b><span style="font-family:Times New Roman,serif;font-size:8.4pt">Excluded</span></b></p>
<p style="top:386.2pt;left:386.7pt;line-height:8.4pt"><span style="font-family:Times New Roman,serif;font-size:8.4pt">n = 728</span></p>
<p style="top:569.6pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Figure 1. </span></b><b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Search strategies, selection criteria, and inclusion of articles</span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">. Articles from four separate databases were identified and </span></p>
<p style="top:580.6pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">screened for inclusion. Note that helminth therapy studies were included in the search strategy but manually removed during the </span></p>
<p style="top:591.6pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">eligibility stage of the second search.</span></p>
<p style="top:50.1pt;left:51.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">All findings are reported with respect to control group(s) unless otherwise indicated. </span></p>
<p style="top:57.4pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">b</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Vivomixx </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24734, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24730, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24735, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbrueckii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">bulgaricus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24734, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. longum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24736, </span></p>
<p style="top:68.0pt;left:57.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. infantis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24737, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. breve </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24732, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">S. thermophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24731. </span></p>
<p style="top:75.4pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">c</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactibiane iki </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. lactis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LA 304, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LA 201, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. salivarius </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LA 302. </span></p>
<p style="top:84.4pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">d</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">IRT5 </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei, L. acidophilus, L. reuteri, B. bifidum, S. thermophilus. </span></i></p>
<p style="top:93.4pt;left:51.0pt;line-height:5.7pt"><b><span style="font-family:MyriadPro,serif;font-size:5.7pt">e</span></b><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">VSL#3 </span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">= see </span><span style="font-family:MyriadPro,serif;font-size:5.7pt">b</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Vivomixx. </span></p>
<p style="top:104.0pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Key</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">decreased; </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">increased; &#x2013; no change or no difference compared to control; NA, not applicable to this study. </span></p>
<p style="top:113.1pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abbreviations</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: ROB, risk of bias; MS, multiple sclerosis; UN, uncertain; M, male; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">F</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, female; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">wk/wks/wko</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, week/weeks/weeks old; mo/mos, month/months; g, </span></p>
<p style="top:122.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">group; WT, wild-type; IL, interleukin; GF, germ-free; TLR, toll-like receptor; EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte </span></p>
<p style="top:131.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">glycoprotein; PLP, proteolipid protein; MBP, myelin basic protein; gp, guinea pig; SCH, spinal cord homogenate; GID, gliotoxin-induced demyelination; TMEV- </span></p>
<p style="top:140.0pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IDD, Theiler&#x2019;s murine encephalomyelitis virus-induced demyelinating disease; CFU, colony-forming units; T, treatment group; C, control; o.g., oral gavage; IU, </span></p>
<p style="top:149.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">international units; w/w, weight/weight; HK, heat-killed; -/-, deficient; AT, adoptive transfer; GMT, gut microbiome transfer; i.p., intraperitoneally; PBS, </span></p>
<p style="top:158.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">phosphate-buffered saline; Proph, prophylactic; Thera, therapeutic; admins, administrations; dpi, days post immunization; CD, clinical disease; IM, immune/ </span></p>
<p style="top:167.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">metabolic; MM, microbiome/metabolome; MC, mechanistic/correlative; CDB, clinical disease burden; CS, clinical score; CDI, clinical disease index; MNC, </span></p>
<p style="top:176.0pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mononuclear cell; IgG, immunoglobulin G; ASP, antigen-specific proliferation; IFN-&#x3b3;, interferon gamma; TGF-&#x3b2;, transforming growth factor beta; CDS, </span></p>
<p style="top:185.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cumulative disease score; rel. abund., relative abundance; TNF-&#x3b1;, tumor necrosis factor alpha; CNS, central nervous system; LN, lymph node; BBB, blood&#x2013; </span></p>
<p style="top:194.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">brain barrier; BSCB, blood spinal cord barrier; PVC, perivascular cuffing; GM-CSF, granulocyte monocyte colony-stimulating factor; txn, transcription; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">SCFA</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span></p>
<p style="top:203.1pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">short-chain fatty acid; ODC, oligodendrocyte; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">abs</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">., absolute</span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-11</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Vivomixx/LBS) of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus spp</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">. including </span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. casei, L. paracasei, L. plantarum, L. reuteri, </span></i></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. delbrueckii </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">subsp. bulgaricus, </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. crispatus, </span></i></p>
<p style="top:92.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. rhamnosus, L. murinus, L. brevis, L. helveticus, </span></i></p>
<p style="top:106.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. lactis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">subsp. lactis, </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. fermentum, L. acidophilus</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, </span></p>
<p style="top:120.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. salivarius</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, Bifidobactererium ssp. including </span></p>
<p style="top:134.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis, B</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">. B94, </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. breve, B. longum, B. bifidum, </span></i></p>
<p style="top:148.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. infantis, B. lactis, B. subtilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">as well as </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i></p>
<p style="top:162.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917, </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. faecium</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">S. thermophilus</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">. All </span></p>
<p style="top:176.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">four human RCT studies utilized probiotic combi-</span></p>
<p style="top:190.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">nations at 2 &#xd7; 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">9 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">CFU/mL ranging from 12 weeks </span></p>
<p style="top:204.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to 6 months duration, while the prospective cohorts </span></p>
<p style="top:218.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">used 3.6 &#xd7; 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">12 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">CFU/d for 2 months. The animal </span></p>
<p style="top:232.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies administered a mean of 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">9 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">CFU/mL (range </span></p>
<p style="top:246.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">8</span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">&#x2013;10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">10 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">CFU/mL) for 2&#x2013;7 weeks duration. </span></p>
<p style="top:260.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Probiotics were administered prophylactically,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">54</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">59</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">, </span></sup></p>
<p style="top:274.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapeutically,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">46</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">47</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">52</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">61</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">63</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">66</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">75</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">76 </span></sup></p>
<p style="top:274.7pt;left:277.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">or </span></p>
<p style="top:288.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">both.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">51</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">72</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup></p>
<p style="top:302.7pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">There were no human studies using commensal </span></p>
<p style="top:316.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy identified. Animal studies used </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Prevotella </span></i></p>
<p style="top:330.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">histicola </span></i></p>
<p style="top:330.7pt;left:145.3pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. </span></i></p>
<p style="top:330.7pt;left:214.8pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">histicola</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">),</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">57</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58 </span></sup></p>
<p style="top:344.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. acidilactici</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">70</span></sup><i><span style="font-family:MinionPro,serif;font-size:11.5pt">C. butyricum,</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65</span></sup><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Akkermansia muci-</span></i></p>
<p style="top:358.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">niphila </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">A. muciniphila</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">),</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">35 </span></sup><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. reuteri</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">37</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">, </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">(by stable </span></p>
<p style="top:372.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">colonization), </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Allobaculum,</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">at </span></p>
<p style="top:386.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a dosage ranging 5 &#xd7; 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">6 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">to 1 &#xd7; 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">10 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">CFU/mL for </span></p>
<p style="top:400.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">one administration or 2&#x2013;5 weeks. Commensals </span></p>
<p style="top:414.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were </span></p>
<p style="top:414.7pt;left:92.2pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">administered </span></p>
<p style="top:414.7pt;left:172.3pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">prophylactically,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">37</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65 </span></sup></p>
<p style="top:428.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapeutically,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">35 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">or both.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">57</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">70</span></sup></p>
<p style="top:457.9pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Measurements and outcomes</span></i></b></p>
<p style="top:471.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The most common measurements for clinical para-</span></p>
<p style="top:485.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">meters for human studies included EDSS, mental </span></p>
<p style="top:499.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">health and quality of life assessments (Beck </span></p>
<p style="top:513.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Depression Inventory (BDI), General Health </span></p>
<p style="top:527.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Questionnaire-28 (GHQ-28), Depression Anxiety </span></p>
<p style="top:541.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Stress Scale (DASS), Fatigue Severity Scale (FSS), </span></p>
<p style="top:555.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">McGill Pain Questionnaire (MPQ)). Notably, none </span></p>
<p style="top:569.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of the human studies assessed MRI lesions. For </span></p>
<p style="top:583.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">animal studies, clinical signs of motor disability </span></p>
<p style="top:597.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and associated quantitative variables (EAE inci-</span></p>
<p style="top:611.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">dence, onset, duration, and clinical scores; motor </span></p>
<p style="top:625.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">function, coordination, and activity for other MS </span></p>
<p style="top:639.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">models), histopathology (demyelination, CNS infil-</span></p>
<p style="top:653.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tration), BBB and intestinal permeability, and </span></p>
<p style="top:667.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">weight loss. Cytokine analysis, oxidative stress/anti-</span></p>
<p style="top:681.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">oxidant markers, and immunophenotyping were </span></p>
<p style="top:695.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the most commonly measured immune/metabolic </span></p>
<p style="top:709.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">indices. Microbiome and metabolome assessments </span></p>
<p style="top:723.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were primarily measured using fecal microbiome </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">analysis, and fecal/serum short-chain fatty acid </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(SCFA) production. Gene expression and adoptive </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">transfer </span></p>
<p style="top:78.7pt;left:358.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">experiments </span></p>
<p style="top:78.7pt;left:431.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">comprised </span></p>
<p style="top:78.7pt;left:496.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">additional </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mechanistic and correlative findings.</span></p>
<p style="top:131.8pt;left:306.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">B. Probiotic therapy</span></b></p>
<p style="top:153.2pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Major trends</span></i></b></p>
<p style="top:173.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The major findings of each probiotic therapy study </span></p>
<p style="top:187.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">included can be found in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Tables 2 and 3 </span><span style="font-family:MinionPro,serif;font-size:11.5pt">for human </span></p>
<p style="top:201.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and animal studies, respectively. A qualitative sum-</span></p>
<p style="top:215.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mary of these studies is provided below, followed </span></p>
<p style="top:229.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">by a semi-quantiative ranked evaluation using BH </span></p>
<p style="top:243.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">criteria.</span></p>
<p style="top:275.9pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Clinical studies</span></i></b></p>
<p style="top:289.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Four of the human probiotic therapy studies </span></p>
<p style="top:303.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">included were double-blind, placebo-controlled </span></p>
<p style="top:317.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">RCTs, and thus all were classified as &#x201c;high quality&#x201d; </span></p>
<p style="top:331.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">61</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">63</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Probiotic therapy produced mod-</span></p>
<p style="top:345.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">est decreases in EDSS that, while sometimes statis-</span></p>
<p style="top:359.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tically significant, were not found to be clinically </span></p>
<p style="top:373.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">significant based on the authors&#x2019; designation of an </span></p>
<p style="top:387.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">EDSS change of &#x2265;1.0 point for levels less than 5.5 or </span></p>
<p style="top:401.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">&#x2265;0.5 point for levels greater than 5.5.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">The </span></p>
<p style="top:415.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">impact on EDSS seemed more pronounced in the </span></p>
<p style="top:429.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">shorter, 12 week study, suggesting that the observed </span></p>
<p style="top:443.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">benefits may only be transient.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Probiotic therapy </span></p>
<p style="top:457.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">did, however, lead to marked improvements in </span></p>
<p style="top:471.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quality of life as measured through the BDI, </span></p>
<p style="top:485.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">GHQ-28, </span></p>
<p style="top:485.1pt;left:374.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">DASS, </span></p>
<p style="top:485.1pt;left:430.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">FSS, </span></p>
<p style="top:485.1pt;left:474.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:485.1pt;left:517.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">MPQ </span></p>
<p style="top:499.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">assessments.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">63</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">The proinflammatory cytokines </span></p>
<p style="top:513.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">that were measured (IL-6, IL-8, and TNF&#x3b1;) were </span></p>
<p style="top:527.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">consistently reduced in the probiotic treatment </span></p>
<p style="top:541.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">groups, as were several oxidative stress markers </span></p>
<p style="top:555.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(hs-CRP, MDA).</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">61</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">63</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Anti-inflammatory cyto-</span></p>
<p style="top:569.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">kines and antioxidants were measured, showing </span></p>
<p style="top:583.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">elevated IL-10 and plasma nitric oxide.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">60</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">64</span></sup></p>
<p style="top:597.1pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Two additional prospective cohort studies used </span></p>
<p style="top:611.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy with the probiotic mixture VSL#3.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">46</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">47 </span></sup></p>
<p style="top:625.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">While neither study focused on clinical outcome, </span></p>
<p style="top:639.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">both found that VSL#3 elicited changes in the </span></p>
<p style="top:653.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">peripheral immune response consistent with an </span></p>
<p style="top:667.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immune regulatory state, including phenotypic </span></p>
<p style="top:681.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">changes in monocytes and dendritic cells and </span></p>
<p style="top:695.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">decreased expression of the MS risk allele HLA- </span></p>
<p style="top:709.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">DQA1. Additionally, these studies found an </span></p>
<p style="top:723.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">increased relative abundance of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus, </span></i></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-12</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bifidobacterium</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, Streptococcus spp. in stool, </span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">which is consistent with the species that were </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">administered in probiotic form in the VSL#3 for-</span></p>
<p style="top:92.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mulation. Further, one study found an increased </span></p>
<p style="top:106.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">relative </span></p>
<p style="top:106.7pt;left:105.2pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">abundance </span></p>
<p style="top:106.7pt;left:176.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of </span></p>
<p style="top:106.7pt;left:205.4pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Collinsela </span></i></p>
<p style="top:106.7pt;left:270.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:120.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Veillonellaceae </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">family members that are typically </span></p>
<p style="top:134.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">depleted in MS gut microbiomes, as well as </span></p>
<p style="top:148.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a decreased relative abundance of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Akkermansia, </span></i></p>
<p style="top:162.7pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Blautia</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Dorea </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">genera, which are typically </span></p>
<p style="top:176.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">enriched.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">46 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Notably, these differences display an </span></p>
<p style="top:190.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">inverse relationship in MS patient cohort gut </span></p>
<p style="top:204.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbiomes, suggesting that VSL#3 may restore </span></p>
<p style="top:218.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the MS-dysbiotic state.</span></p>
<p style="top:247.9pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Preclinical studies</span></i></b></p>
<p style="top:261.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The majority (26 out of 30) of animal studies used </span></p>
<p style="top:275.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the EAE model. This is an important consideration, </span></p>
<p style="top:289.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">since it is a model driven by an autoimmune </span></p>
<p style="top:303.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">response, thus immunomodulation is the most </span></p>
<p style="top:317.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">likely mode of action for any effects on clinical </span></p>
<p style="top:331.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">disease. More studies investigated the effects of </span></p>
<p style="top:345.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48&#x2013;50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">52</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">59</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">67</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">68</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71&#x2013;76 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and probio-</span></p>
<p style="top:359.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tic </span></p>
<p style="top:359.1pt;left:79.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">combinations</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43&#x2013;45</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69 </span></sup></p>
<p style="top:359.1pt;left:221.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">rather </span></p>
<p style="top:359.1pt;left:267.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">than </span></p>
<p style="top:373.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bifidobacterium </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">51&#x2013;53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">68 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle </span></p>
<p style="top:387.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">1917,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">54</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55 </span></sup></p>
<p style="top:387.1pt;left:105.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and just a single study utilized </span></p>
<p style="top:401.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. faecium</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">66</span></sup></p>
<p style="top:415.1pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Proportionally, </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. tended to out-</span></p>
<p style="top:429.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">perform </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bifidobacterium </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. in reducing EAE inci-</span></p>
<p style="top:443.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">dence, </span></p>
<p style="top:443.1pt;left:99.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">onset, </span></p>
<p style="top:443.1pt;left:146.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical </span></p>
<p style="top:443.1pt;left:199.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score, </span></p>
<p style="top:443.1pt;left:245.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">duration, </span></p>
<p style="top:457.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">demyelination, immune cell infiltration, and </span></p>
<p style="top:471.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">motor activity. Positive clinical outcomes were </span></p>
<p style="top:485.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">observed in about 64% of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. studies </span></p>
<p style="top:499.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 14), 25% of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bifidobacterium </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. studies </span></p>
<p style="top:513.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 4), 100% of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917 studies </span></p>
<p style="top:527.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 2), and about 81% of probiotic combination </span></p>
<p style="top:541.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 11), while </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. faecium </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">was shown to be at </span></p>
<p style="top:555.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">least as effective as the standard MS DMT glatir-</span></p>
<p style="top:569.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">amer acetate.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">66 </span></sup></p>
<p style="top:569.1pt;left:140.5pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. casei </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">Shirota,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">68</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">72</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">73 </span></sup></p>
<p style="top:569.1pt;left:270.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:583.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50&#x2013;53 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">were the least clinically successful </span></p>
<p style="top:597.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapies among the studies investigated, while </span></p>
<p style="top:611.1pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. paracasei</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. plantarum</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i></p>
<p style="top:625.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">54</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">appeared the most successful. </span></p>
<p style="top:639.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Notably, despite disparate outcomes, VSL#3</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:653.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Vivomixx</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">contain the same probiotic formula-</span></p>
<p style="top:667.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion, although importantly each study used </span></p>
<p style="top:681.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a different model: cuprizone-induced demyelina-</span></p>
<p style="top:695.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion/remyelination vs. TMEV-IDD vs. EAE, respec-</span></p>
<p style="top:709.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tively, with the former (cuprizone) lacking a strong </span></p>
<p style="top:723.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immune-mediated </span></p>
<p style="top:723.1pt;left:153.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">component. </span></p>
<p style="top:723.1pt;left:225.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Furthermore, </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. paracasei</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and the combinations of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. crispatus </span></i></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. rhamnosus</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">subsp. lactis </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">strains</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">were able to elicit clinical benefits whether </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">administered live or heat-killed</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">, </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">while Lacto-mix</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48 </span></sup></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">was only effective when live probiotic organisms </span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were used. Five studies demonstrated a dose&#x2013; </span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">response relationship,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">54 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and three studies </span></p>
<p style="top:148.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">provided evidence for the combinatorial effects of </span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotics.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Only ~32% of the animal studies </span></p>
<p style="top:176.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 22) reported primarily no effect or exacerba-</span></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion of clinical disease.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">51</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">59</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">68</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">72&#x2013;75 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">It should also be </span></p>
<p style="top:204.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">noted that only four of the studies were classified as </span></p>
<p style="top:218.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">high quality, all of which reported positive results </span></p>
<p style="top:232.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">with probiotics.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup></p>
<p style="top:246.7pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The majority of studies reported favorable sec-</span></p>
<p style="top:260.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ondary immunological findings, with elevated levels </span></p>
<p style="top:274.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of anti-inflammatory cytokines (IL-10, IL-4, TGF- </span></p>
<p style="top:288.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">&#x3b2;)</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">59</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">74 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and CD4+ CD25+ FoxP3 </span></p>
<p style="top:302.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">+ Tregs</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">54</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">74 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and reduced levels of proin-</span></p>
<p style="top:316.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">flammatory cytokines (IL-17, IL-1, IL-6, TNF-&#x3b1;, </span></p>
<p style="top:330.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">IFN-&#x3b3;),</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">67</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">75 </span></sup></p>
<p style="top:330.7pt;left:441.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">chemokines </span></p>
<p style="top:330.7pt;left:510.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(CCL3, </span></p>
<p style="top:344.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">CCL4, CXCL5, CXCL13),</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and T</span><span style="font-family:MinionPro,serif;font-size:8.1pt">H</span><span style="font-family:MinionPro,serif;font-size:11.5pt">1 and T</span><span style="font-family:MinionPro,serif;font-size:8.1pt">H</span><span style="font-family:MinionPro,serif;font-size:11.5pt">17 </span></p>
<p style="top:358.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cells.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">54</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">67</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">74</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">75 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Multiple </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. and </span></p>
<p style="top:372.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic combinations also demonstrated decreased </span></p>
<p style="top:386.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">antigen-specific </span></p>
<p style="top:386.7pt;left:389.2pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">T </span></p>
<p style="top:386.7pt;left:408.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cell </span></p>
<p style="top:386.7pt;left:435.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">proliferation.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">69 </span></sup></p>
<p style="top:400.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Putatively beneficial microbiome changes included </span></p>
<p style="top:414.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">an increased relative abundance of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Firmicutes, </span></i></p>
<p style="top:428.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bacteriodetes, Proteobacteria </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">phyla and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Sutterella, </span></i></p>
<p style="top:442.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bifidobacterium, Streptococcus, Lactobacillus</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span></p>
<p style="top:456.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Prevotella </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">75 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Two studies measured SCFA </span></p>
<p style="top:470.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">production and found increased levels in both serum </span></p>
<p style="top:484.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and feces.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">43</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Four studies reported increased </span></p>
<p style="top:498.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">expression of T</span><span style="font-family:MinionPro,serif;font-size:8.1pt">H</span><span style="font-family:MinionPro,serif;font-size:11.5pt">2 and Treg regulators (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">GATA3, </span></i></p>
<p style="top:512.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Foxp3</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">),</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">miR-25,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">antimicrobial peptides (Reg3g, </span></p>
<p style="top:526.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Reg3b),</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and tight junction proteins (Claudin-8, </span></p>
<p style="top:540.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ZO-I);</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and decreased expression of T</span><span style="font-family:MinionPro,serif;font-size:8.1pt">H</span><span style="font-family:MinionPro,serif;font-size:11.5pt">1 and T</span><span style="font-family:MinionPro,serif;font-size:8.1pt">H </span></p>
<p style="top:554.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">17 regulators (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Tbet, ROR&#x3b3;t)</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">44</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">50 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">miR-155,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and the </span></p>
<p style="top:568.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">IDO </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">gene,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">71 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">a potential marker of MS/EAE relapses. </span></p>
<p style="top:582.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Furthermore, Lavasani et al. performed an adoptive </span></p>
<p style="top:596.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">transfer experiment of CD4+ CD25 + T cells from </span></p>
<p style="top:610.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mesenteric lymph nodes of the probiotic Lacto-mix </span></p>
<p style="top:624.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">group and found that the recipient mice had sup-</span></p>
<p style="top:638.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">pressed EAE symptoms and elevated IL-10 levels.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48 </span></sup></p>
<p style="top:652.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">These effects, however, were eliminated when tested </span></p>
<p style="top:666.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">in IL-10-deficient mice.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Notably, Sanchez et al. also </span></p>
<p style="top:680.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">included an adoptive transfer experiment of splenic </span></p>
<p style="top:694.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and mesenteric lymph node leukocytes of heat-killed </span></p>
<p style="top:708.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. paracasei</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">&#x2013;treated donor mice into recipient mice </span></p>
<p style="top:722.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and found no such effects.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Additional mechanistic </span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-13</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">findings included decreased intestinal barrier </span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">permeability</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">55 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and oligodendrocyte differentiation </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">enhancement.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">45</span></sup></p>
<p style="top:115.1pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">BHC scores and rankings</span></i></b></p>
<p style="top:135.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The BH score calculations and findings for probio-</span></p>
<p style="top:149.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tic therapy are detailed in Supplemental File 2, and </span></p>
<p style="top:163.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">summarized in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">. Given the large number of </span></p>
<p style="top:177.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies and treatments, we do not discuss each </span></p>
<p style="top:191.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">individually, but instead highlight and contrast </span></p>
<p style="top:205.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">some of the key findings below.</span></p>
<p style="top:219.3pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">One probiotic treatment approach emerged as </span></p>
<p style="top:233.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the most strongly supported (BH score = 9), </span></p>
<p style="top:247.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">namely the VSL#3 multi-species formulation, </span></p>
<p style="top:261.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">which was assessed in two human and three </span></p>
<p style="top:275.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">animal studies. Two out of three animal studies </span></p>
<p style="top:289.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reported significant clinical improvement in the </span></p>
<p style="top:303.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">EAE model. The third study used the cuprizone </span></p>
<p style="top:317.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">demyelination model and reported a lack of </span></p>
<p style="top:331.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical improvement, but some favorable histo-</span></p>
<p style="top:345.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">logic changes. The human studies did not mea-</span></p>
<p style="top:359.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sure </span></p>
<p style="top:359.2pt;left:88.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical </span></p>
<p style="top:359.2pt;left:140.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">parameters, </span></p>
<p style="top:359.2pt;left:213.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">but </span></p>
<p style="top:359.2pt;left:247.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reported </span></p>
<p style="top:373.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immunological </span></p>
<p style="top:373.2pt;left:134.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:373.2pt;left:164.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbiological </span></p>
<p style="top:373.2pt;left:250.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">changes </span></p>
<p style="top:387.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">that would be consistent with favorable immune </span></p>
<p style="top:401.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">modulation. Hence, this particular approach </span></p>
<p style="top:415.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">satisfied seven out of eight BH criteria (BHC </span></p>
<p style="top:429.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">#1, 3&#x2013;8), with high evidence for replication </span></p>
<p style="top:443.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">). In contrast, another combination </span></p>
<p style="top:457.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">treatment </span></p>
<p style="top:457.3pt;left:119.2pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:457.3pt;left:154.3pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">acidophilus, </span></i></p>
<p style="top:457.3pt;left:232.2pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:457.3pt;left:263.1pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">casei, </span></i></p>
<p style="top:471.3pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. fermentum</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. bifidum</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">) was used in two </span></p>
<p style="top:485.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">high-quality human RCTs, but lacked supporting </span></p>
<p style="top:499.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mechanistic and/or animal model studies (BH </span></p>
<p style="top:513.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score = 5; </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">). Additional promising pro-</span></p>
<p style="top:527.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">biotic treatments with high BH scores included </span></p>
<p style="top:541.2pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis, L. paracasei</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917, </span></p>
<p style="top:555.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">each </span></p>
<p style="top:555.2pt;left:85.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">receiving </span></p>
<p style="top:555.2pt;left:141.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a </span></p>
<p style="top:555.2pt;left:159.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">BH </span></p>
<p style="top:555.2pt;left:188.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score </span></p>
<p style="top:555.2pt;left:226.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of </span></p>
<p style="top:555.2pt;left:248.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">7; </span></p>
<p style="top:555.2pt;left:270.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:569.2pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:569.2pt;left:73.1pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">plantarum</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, </span></p>
<p style="top:569.2pt;left:138.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Lacto-mix, </span></p>
<p style="top:569.2pt;left:203.1pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:569.2pt;left:225.3pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">crispatus </span></i></p>
<p style="top:569.2pt;left:279.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">&amp; </span></p>
<p style="top:583.2pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. rhamnosus</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and the </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">combination </span></p>
<p style="top:597.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy, all of which received a BH score of 6.</span></p>
<p style="top:611.2pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The majority of the remaining microbial treat-</span></p>
<p style="top:625.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ments were characterized by low BH scores, </span></p>
<p style="top:639.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">resulting from a paucity of studies, lack of </span></p>
<p style="top:653.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mechanistic evidence, and/or presence of conflict-</span></p>
<p style="top:667.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ing evidence. The latter is exemplified by </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. casei </span></i></p>
<p style="top:681.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(BH score = 1), which was examined in six ani-</span></p>
<p style="top:695.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mal studies, but showed evidence of disease </span></p>
<p style="top:709.3pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">exacerbation or lack of effect in four of those </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies, resulting in a deduction of 2 points for </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">BHC #4. We note that this interpretation is con-</span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">founded by the fact that different strains/isolates </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were used across these different studies, highlight-</span></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ing the need for careful standardization and </span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">interpretation.</span></p>
<p style="top:170.5pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">BHC deficiencies</span></i></b></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Using the Bradford Hill criteria, several therapies </span></p>
<p style="top:204.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">had considerable evidence for strength of relation-</span></p>
<p style="top:218.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ship, dose&#x2013;response relationship, biological plau-</span></p>
<p style="top:232.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sibility, and coherence. Future studies should </span></p>
<p style="top:246.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">focus on strengthening these areas further by </span></p>
<p style="top:260.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">investigating dosing effects, establishing more </span></p>
<p style="top:274.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">direct evidence of MGBA involvement with more </span></p>
<p style="top:288.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic organisms and combinations, addres-</span></p>
<p style="top:302.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sing alternative explanations, and repeating inter-</span></p>
<p style="top:316.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ventions in various contexts. Additionally, more </span></p>
<p style="top:330.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">evidence is needed to fulfill the remaining </span></p>
<p style="top:344.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Bradford Hill criteria categories (BHC #s 1, 4, 6, </span></p>
<p style="top:358.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and 7), including more before-and-after analyses, </span></p>
<p style="top:372.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">using a standardized protocol to facilitate compar-</span></p>
<p style="top:386.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">isons across studies and research groups, and </span></p>
<p style="top:400.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">investigating </span></p>
<p style="top:400.7pt;left:381.8pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cessation </span></p>
<p style="top:400.7pt;left:440.2pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">effects </span></p>
<p style="top:400.7pt;left:484.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table </span></p>
<p style="top:400.7pt;left:530.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">6</span><span style="font-family:MinionPro,serif;font-size:11.5pt">). </span></p>
<p style="top:414.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Strengthening the specificity of association by </span></p>
<p style="top:428.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">comparing the effects of live versus heat-killed </span></p>
<p style="top:442.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">organisms and their soluble products, and the </span></p>
<p style="top:456.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">inclusion of more mechanistic experiments is </span></p>
<p style="top:470.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">also recommended. Future studies and reviews </span></p>
<p style="top:484.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">should also consider the taxonomic reclassifica-</span></p>
<p style="top:498.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp. when referring to those </span></p>
<p style="top:512.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic organisms.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">77</span></sup></p>
<p style="top:526.7pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Lastly, to move toward translational application, </span></p>
<p style="top:540.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">wherein probiotics are stringently defined as confer-</span></p>
<p style="top:554.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ring a known benefit to human health, disease- </span></p>
<p style="top:568.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">specific usage should be assessed in well-powered </span></p>
<p style="top:582.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">RCTs to provide clinically relevant guidance. </span></p>
<p style="top:596.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Notably, a defined benefit to MS patient health </span></p>
<p style="top:610.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">should not be limited to clinical outcome, but also </span></p>
<p style="top:624.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">include secondary parameters such as quality of life, </span></p>
<p style="top:638.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">since it is plausible that probiotic therapy may </span></p>
<p style="top:652.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">improve the well-known GI-associated MS sympto-</span></p>
<p style="top:666.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">matology (e.g. constipation) rather than affecting </span></p>
<p style="top:680.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">overall disease progression directly; and mental </span></p>
<p style="top:694.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">health, since depression has been identified as </span></p>
<p style="top:708.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a risk factor for RRMS disability and relapses.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">78</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">79</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">80</span></sup></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-14</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:50.8pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">C. Commensal therapy</span></b></p>
<p style="top:72.2pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Major trends</span></i></b></p>
<p style="top:92.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The major findings for each of the commensal </span></p>
<p style="top:106.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy animal studies included in this review can </span></p>
<p style="top:120.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">be found in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 4</span><span style="font-family:MinionPro,serif;font-size:11.5pt">. A qualitative summary of these </span></p>
<p style="top:134.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies is provided below, followed by a semi- </span></p>
<p style="top:148.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quantiative ranked evaluation using BH criteria.</span></p>
<p style="top:162.4pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">No human studies were identified for commen-</span></p>
<p style="top:176.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sal therapy in this review, so the below trends are </span></p>
<p style="top:190.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">limited to preclinical findings. All but two </span></p>
<p style="top:204.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. reuteri</span></i><sup><i><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">37</span></i></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Allobaculum</span></i><sup><i><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38</span></i></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">) of the commen-</span></p>
<p style="top:218.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sal organisms studied among the nine studies were </span></p>
<p style="top:232.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">shown to delay EAE onset and decrease clinical </span></p>
<p style="top:246.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">scores, incidence, inflammatory CNS infiltration, </span></p>
<p style="top:260.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and demyelination. </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">was one of two </span></p>
<p style="top:274.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">commensals represented in more than one study </span></p>
<p style="top:288.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and exhibited positive outcomes in each.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56&#x2013;58 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">One </span></p>
<p style="top:302.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">study also reported reduced astrocytosis and micro-</span></p>
<p style="top:316.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">glial activation in the brain and spinal cord of </span></p>
<p style="top:330.4pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">-treated mice,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">while a sister study </span></p>
<p style="top:344.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">found that </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">helped to strengthen the </span></p>
<p style="top:358.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">MGBA by decreasing BBB permeability and restor-</span></p>
<p style="top:372.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ing gut permeability.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Similar to probiotic therapy, </span></p>
<p style="top:386.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reduced proinflammatory and increased anti- </span></p>
<p style="top:400.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">inflammatory immune responses were observed in </span></p>
<p style="top:414.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">each of the commensal studies. Specifically, studies </span></p>
<p style="top:428.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">found decreased IL-17- and IFN-&#x3b3;-producing </span></p>
<p style="top:442.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">CD4 + T cells,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">T</span><span style="font-family:MinionPro,serif;font-size:8.1pt">H</span><span style="font-family:MinionPro,serif;font-size:11.5pt">17 cells,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and IL-17,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">70 </span></sup></p>
<p style="top:456.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">IFN-&#x3b3;,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">70 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">IL-23,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and IL-12</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">70 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">cytokines; and </span></p>
<p style="top:470.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">increased IL-10,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">70 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">TGF-&#x3b2;,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and Tregs.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56&#x2013;58</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65 </span></sup></p>
<p style="top:484.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">These results were consistent across all three </span></p>
<p style="top:498.4pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">treatments.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">57</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58 </span></sup><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. reuteri </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">was also </span></p>
<p style="top:512.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">represented in multiple studies and was shown to </span></p>
<p style="top:526.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">exacerbate EAE in both, either when administered </span></p>
<p style="top:540.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">alone (in the context of a normal microbiome)</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">37 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">or </span></p>
<p style="top:554.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">in combination with </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Allobaculum </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(in a dual- </span></p>
<p style="top:568.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">colonization gnotobiotic model).</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">38</span></sup></p>
<p style="top:582.4pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">For studies that analyzed the microbiome, com-</span></p>
<p style="top:596.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensal therapy groups had a general microbiome </span></p>
<p style="top:610.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">shift toward pre-EAE states following treatment, </span></p>
<p style="top:624.5pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">including an increased relative abundance of </span></p>
<p style="top:638.5pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Bacteriodetes, Firmicutes, Prevotella </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp., and </span></p>
<p style="top:652.5pt;left:51.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">Lactobacillus </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">spp.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">57</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Mechanistically, the adop-</span></p>
<p style="top:666.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tive transfer of splenocytes from </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">-treated </span></p>
<p style="top:680.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mice led to decreased EAE incidence in recipient </span></p>
<p style="top:694.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mice.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Similarly, the adoptive transfer of FoxP3 </span></p>
<p style="top:708.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">+ cells from wild-type </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">-treated mice, </span></p>
<p style="top:722.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">resulted in decreased EAE clinical scores and </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">increased levels of IL-10 in recipient mice.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">These </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">findings were not observed in the recipient mice </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">receiving cells from polysaccharide A (PSA)- </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">deficient </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">-treated mice, suggesting that </span></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">PSA is requisite for EAE protection. Separately, </span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">treatment with </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">C. butyricum </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">was reported to sup-</span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">press phosphorylation of p38 MAPK and JNK sig-</span></p>
<p style="top:148.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">naling pathways &#x2013; which are typically elevated in </span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">EAE &#x2013; in the spinal cords of mice.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">65 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">One commen-</span></p>
<p style="top:176.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sal was also found to be at least as effective as two </span></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">different DMTs (glatiramer acetate</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">57 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and IFN&#x3b2;</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">58</span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">).</span></p>
<p style="top:226.7pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">BHC scores and rankings</span></i></b></p>
<p style="top:246.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The BH score calculations and findings for com-</span></p>
<p style="top:260.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensal therapy are detailed in Supplemental File 2, </span></p>
<p style="top:274.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and summarized in </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">.</span></p>
<p style="top:288.9pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Treatment with </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">had fairly strong </span></p>
<p style="top:302.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">evidence (BH score = 7), but fell short across several </span></p>
<p style="top:316.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">BH categories (BHC #s 4 and 6), as it lacked human </span></p>
<p style="top:330.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies and replication by independent groups </span></p>
<p style="top:344.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">(</span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">). Another promising treatment with </span></p>
<p style="top:358.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a high BH score was </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(BH score = 5), </span></p>
<p style="top:372.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">which scored points in BHC # 1, 2, 5, 7, and 8 </span></p>
<p style="top:386.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">owing to an adoptive transfer experiment, but </span></p>
<p style="top:400.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">lacked replication and evidence of dose-response </span></p>
<p style="top:414.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and cessation effects. The remaining treatments </span></p>
<p style="top:428.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">were characterized by low BH scores (ranging 1&#x2013; </span></p>
<p style="top:442.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">4) comprised of points in BHC # 1, 2, 3, and/or 5, </span></p>
<p style="top:456.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">once again resulting from a paucity of studies, lack </span></p>
<p style="top:470.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of mechanistic evidence, and/or presence of con-</span></p>
<p style="top:484.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">flicting evidence, as observed with </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. reuteri </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(BH </span></p>
<p style="top:498.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score = 1), which was found to exacerbate the dis-</span></p>
<p style="top:512.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ease in three of the five studies, leading to a 2-point </span></p>
<p style="top:526.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">deduction for BHC #4. As noted with </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. casei </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">for </span></p>
<p style="top:540.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic therapy, this interpretation is confounded </span></p>
<p style="top:554.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">by the use of different strains/isolates and modes of </span></p>
<p style="top:568.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">treatment (stable commensal colonization vs. daily </span></p>
<p style="top:582.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">gavage) across studies and would benefit from care-</span></p>
<p style="top:596.9pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ful standardization (</span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 5</span><span style="font-family:MinionPro,serif;font-size:11.5pt">).</span></p>
<p style="top:632.9pt;left:306.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">BHC deficiencies</span></i></b></p>
<p style="top:653.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Using the Bradford Hill criteria, commensal therapy </span></p>
<p style="top:667.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">had strong evidence for temporal relationship, spe-</span></p>
<p style="top:681.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cificity of association, and biological plausibility, but </span></p>
<p style="top:695.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">was lacking in the remaining categories (BHC #s 2&#x2013; </span></p>
<p style="top:709.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">4, 6, and 8; </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Table 6</span><span style="font-family:MinionPro,serif;font-size:11.5pt">). Additional studies replicating </span></p>
<p style="top:723.1pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">current findings and testing more commensal</span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-15</span></p>


<p style="top:51.0pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 4. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Animal studies of commensal therapies: summary of study characteristics and major findings.</span></p>
<p style="top:64.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:64.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:64.6pt;left:134.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:64.6pt;left:181.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:64.6pt;left:252.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:64.6pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:64.6pt;left:370.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:64.6pt;left:454.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:76.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Montgomery </span></p>
<p style="top:85.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">37</span></sup></p>
<p style="top:76.5pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low M &amp; F C57BL6 </span></p>
<p style="top:85.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; PWD mice </span></p>
<p style="top:94.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wko</span></p>
<p style="top:76.5pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2&#xd7; MOG- </span></p>
<p style="top:85.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:94.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:76.5pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">isolated from PWD </span></p>
<p style="top:85.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cecal contents (100 &#xb5;L of </span></p>
<p style="top:94.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU o.g.) w/ 100 &#xb5;L </span></p>
<p style="top:103.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cryopreserved C57BL6 cecal </span></p>
<p style="top:112.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microbiota </span></p>
<p style="top:121.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 200 &#xb5;L cryopreserved </span></p>
<p style="top:130.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 cecal microbiota</span></p>
<p style="top:76.5pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:76.5pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">4 wks (one initial </span></p>
<p style="top:85.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">admin)</span></p>
<p style="top:76.5pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CDS &amp; freq. of infiltrating </span></p>
<p style="top:85.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells in spinal cord; &#x2013; freq. of </span></p>
<p style="top:94.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">infiltrating CD8 + T cells in spinal </span></p>
<p style="top:103.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cord </span></p>
<p style="top:112.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">freq. of GM-CSF- and IFN-&#x3b3;- </span></p>
<p style="top:121.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">producing CD4+ &amp; CD8 + T cells </span></p>
<p style="top:130.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:139.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:148.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Chen et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">65</span></sup></p>
<p style="top:148.5pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:148.5pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:157.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">3&#x2013;4 wko </span></p>
<p style="top:166.5pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 8/g</span></p>
<p style="top:148.5pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">2&#xd7; MOG- </span></p>
<p style="top:157.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:166.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:148.5pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">C. butyricum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">GDBIO1501, </span></p>
<p style="top:157.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5 &#xd7; 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">6 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/mL o.g. </span></p>
<p style="top:166.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: norfloxacin, 5 mg/kg o. </span></p>
<p style="top:175.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">g. </span></p>
<p style="top:184.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS w/ EAE </span></p>
<p style="top:193.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: normal control</span></p>
<p style="top:148.5pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:148.5pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 3 wks </span></p>
<p style="top:157.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pre-EAE</span></p>
<p style="top:148.5pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">daily CS, lymphocyte infiltration, </span></p>
<p style="top:157.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelinating plaques in lumbar </span></p>
<p style="top:166.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">spinal cord </span></p>
<p style="top:175.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells in CNS, LN, colon, </span></p>
<p style="top:184.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">spleen, &amp; small intestine, IFN-&#x3b3;- </span></p>
<p style="top:193.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">producing CD4 + T cells in spleen; &#x2013; </span></p>
<p style="top:202.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17A+IFN-&#x3b3;+ CD4 + T cells; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:211.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">differentiation of Tregs </span></p>
<p style="top:220.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt"># of OTUs, abundance, </span></p>
<p style="top:229.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">diversity, and rel. abund. of </span></p>
<p style="top:238.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Prevotella</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, Bacteriodetes; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. </span></p>
<p style="top:247.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">abund. of Firmicutes, </span></p>
<p style="top:256.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Desulfovibroneceae, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ruminococcus </span></i></p>
<p style="top:265.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">phosphorylation of p38 </span></p>
<p style="top:274.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MAPK, ERK1/2, and JNK in lumbar </span></p>
<p style="top:283.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">spinal cord</span></p>
<p style="top:292.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Mangalam </span></p>
<p style="top:301.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">56</span></sup></p>
<p style="top:292.5pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:292.5pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M &amp; F HLA- </span></p>
<p style="top:301.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DR3.DQ8 </span></p>
<p style="top:310.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">transgenic </span></p>
<p style="top:319.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:328.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;12 wko </span></p>
<p style="top:337.5pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 5&#x2013;11/g</span></p>
<p style="top:292.5pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:301.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:292.5pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. histicola</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup></p>
<p style="top:301.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/mL o.g. </span></p>
<p style="top:310.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span></p>
<p style="top:319.5pt;left:232.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. melaninogenica</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/ </span></p>
<p style="top:328.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mL o.g. </span></p>
<p style="top:337.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">C. sputigena</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup></p>
<p style="top:346.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/mL o.g. </span></p>
<p style="top:355.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">All isolated from </span></p>
<p style="top:364.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">duodenum of celiac disease </span></p>
<p style="top:373.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">patients </span></p>
<p style="top:382.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph mouse-specific </span></p>
<p style="top:391.5pt;left:232.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU/mL o.g. </span></p>
<p style="top:400.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1 w/ Abx-depleted </span></p>
<p style="top:409.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">flora </span></p>
<p style="top:418.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T1 </span></p>
<p style="top:427.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T7</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: HK T6 </span></p>
<p style="top:436.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T8</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T6 cell-free supernatant </span></p>
<p style="top:445.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T9</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T6 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">7 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:454.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T10</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T6 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">9 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:463.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: medium</span></p>
<p style="top:292.5pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:301.5pt;left:332.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:292.5pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Every other day </span></p>
<p style="top:301.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">for 2 wks </span></p>
<p style="top:310.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 7 d </span></p>
<p style="top:319.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pre-EAE or 7 </span></p>
<p style="top:328.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">dpi) </span></p>
<p style="top:337.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abx depletion </span></p>
<p style="top:346.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">for 3 wks </span></p>
<p style="top:355.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">AT at 5 dpi</span></p>
<p style="top:292.5pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE incidence, CDS, regions of </span></p>
<p style="top:301.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">brain &amp; spinal cord inflammation and </span></p>
<p style="top:310.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination, BBB permeability, </span></p>
<p style="top:319.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CNS cellular infiltration (T1); earlier </span></p>
<p style="top:328.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">onset (T1); T1 restored gut </span></p>
<p style="top:337.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">permeability </span></p>
<p style="top:346.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-23, IL-12, IFN-&#x3b3;, IL-17, </span></p>
<p style="top:355.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells, IFN-&#x3b3;- and IL-17- </span></p>
<p style="top:364.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">expressing CD4 + T cells (T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL- </span></p>
<p style="top:373.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10, TGF-&#x3b2;, CD4+ CD25+ Foxp3 </span></p>
<p style="top:382.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ Tregs (T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10 (T2) </span></p>
<p style="top:391.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Prevotella, </span></i></p>
<p style="top:400.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactobacillus, Sutterella </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1), </span></p>
<p style="top:409.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">resembling pre-EAE states </span></p>
<p style="top:418.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Milder EAE (T5); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:427.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence (T7/T8); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:436.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">suppression (T6 vs T9/T10); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:445.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence in AT recipient mice of T1</span></p>
<p style="top:472.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shahi et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">57</span></sup></p>
<p style="top:472.5pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:472.5pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M &amp; F HLA- </span></p>
<p style="top:481.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DR3.DQ8 </span></p>
<p style="top:490.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">double </span></p>
<p style="top:499.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">transgenic </span></p>
<p style="top:508.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice &amp; </span></p>
<p style="top:517.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 </span></p>
<p style="top:526.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:535.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;12 wko </span></p>
<p style="top:544.5pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">&#x2265; 7/g</span></p>
<p style="top:472.5pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:481.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE (HLA) </span></p>
<p style="top:490.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and MOG- </span></p>
<p style="top:499.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:508.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:517.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(C57BL6)</span></p>
<p style="top:472.5pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. histicola</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:481.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">o.g. in HLA mice </span></p>
<p style="top:490.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph Copaxone, 2 mg </span></p>
<p style="top:499.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">s.c. in HLA mice </span></p>
<p style="top:508.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1+ T2 </span></p>
<p style="top:517.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1 in C57BL6 mice </span></p>
<p style="top:526.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T2 in C57BL6 mice </span></p>
<p style="top:535.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T3 in C57BL6 mice </span></p>
<p style="top:544.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T7</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T1 </span></p>
<p style="top:553.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T8</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T2 </span></p>
<p style="top:562.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T9</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T3 </span></p>
<p style="top:571.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS or TSB media</span></p>
<p style="top:472.5pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:481.5pt;left:332.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:472.5pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Every other day </span></p>
<p style="top:481.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">for 2 wks </span></p>
<p style="top:490.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 7 d </span></p>
<p style="top:499.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pre-EAE or 7 </span></p>
<p style="top:508.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">dpi) </span></p>
<p style="top:517.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3, T6, T9 = T1 </span></p>
<p style="top:526.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; T2 on </span></p>
<p style="top:535.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">alternating </span></p>
<p style="top:544.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">days</span></p>
<p style="top:472.5pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">average daily scores &amp; CDS (T2, </span></p>
<p style="top:481.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3,T4-T6,T7-T9); delayed EAE onset </span></p>
<p style="top:490.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T9); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">inflammation, </span></p>
<p style="top:499.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination (T1-T3); effects of T3/ </span></p>
<p style="top:508.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6/T9 not more pronounced </span></p>
<p style="top:517.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17+ CD4+ &amp; IFN-&#x3b3;+ CD4 + T </span></p>
<p style="top:526.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cells in brain &amp; spinal cord (T1,T3); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:535.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4+ Foxp3+ Tregs in splenocytes </span></p>
<p style="top:544.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and GALT (T1,T3); &#x2013; IL-10-producing </span></p>
<p style="top:553.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells (T1-T3) </span></p>
<p style="top:562.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">rel. abund. </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactobacillus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1, </span></p>
<p style="top:571.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C), </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T2,T3) </span></p>
<p style="top:580.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:589.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shahi et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">58</span></sup></p>
<p style="top:589.5pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:589.5pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">M &amp; F HLA- </span></p>
<p style="top:598.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DR3.DQ8 </span></p>
<p style="top:607.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">double </span></p>
<p style="top:616.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">transgenic </span></p>
<p style="top:625.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:634.5pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8&#x2013;12 wko </span></p>
<p style="top:643.5pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">&#x2265; 12/g</span></p>
<p style="top:589.5pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:598.5pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:589.5pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. histicola</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">8 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU </span></p>
<p style="top:598.5pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">o.g </span></p>
<p style="top:607.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph IFN&#x3b2;, 10,000 IU </span></p>
<p style="top:616.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Proph T1+ T2 </span></p>
<p style="top:625.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T1 </span></p>
<p style="top:634.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T5</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T2 </span></p>
<p style="top:643.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Thera T3 </span></p>
<p style="top:652.5pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: TSB media</span></p>
<p style="top:589.5pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:598.5pt;left:332.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:589.5pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Every other day </span></p>
<p style="top:598.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">for 2 wks pre- </span></p>
<p style="top:607.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE (7 doses) </span></p>
<p style="top:616.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">or starting 7 </span></p>
<p style="top:625.5pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">dpi (7 doses)</span></p>
<p style="top:589.5pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">average daily score &amp; CDS (T4- </span></p>
<p style="top:598.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">T6), inflammatory cellular infiltration </span></p>
<p style="top:607.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">into brain &amp; spinal cord (T4,T6), </span></p>
<p style="top:616.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">spinal cord tissue and meningeal/ </span></p>
<p style="top:625.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">stratum regions of brain (T4-T6); no </span></p>
<p style="top:634.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">additive effects for T6 vs T4/T5 </span></p>
<p style="top:643.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Iba-1+ microglia &amp; GFAP+ </span></p>
<p style="top:652.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">astrocytes in brain &amp; spinal cord </span></p>
<p style="top:661.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">white matter, CD4+ IL-17+ &amp; CD4 </span></p>
<p style="top:670.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ IFN-&#x3b3; + T cells (T1-T3); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 </span></p>
<p style="top:679.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ Foxp3+ Tregs, IL-10-producing </span></p>
<p style="top:688.5pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD4 + T cells (T1,T3) </span></p>
<p style="top:697.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:706.5pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:718.1pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-16</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:51.0pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 4. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:65.1pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:65.1pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:65.1pt;left:134.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sample</span></p>
<p style="top:65.1pt;left:181.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MS Model</span></p>
<p style="top:65.1pt;left:252.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Intervention</span></p>
<p style="top:65.1pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Timeline</span></p>
<p style="top:65.1pt;left:370.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Duration</span></p>
<p style="top:65.1pt;left:454.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Major Findings</span></p>
<p style="top:77.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Takata et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">70</span></sup><sup><span style="font-family:MyriadPro,serif;font-size:8.0pt"> </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:77.6pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:86.6pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">&amp; SJL mice </span></p>
<p style="top:95.6pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6 wko </span></p>
<p style="top:104.6pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 17/g</span></p>
<p style="top:77.6pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG-induced </span></p>
<p style="top:86.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE </span></p>
<p style="top:95.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(C57BL6) </span></p>
<p style="top:104.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and PLP- </span></p>
<p style="top:113.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">induced </span></p>
<p style="top:122.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE (SJL)</span></p>
<p style="top:77.6pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: HK </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. acidilactici </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">R037 in </span></p>
<p style="top:86.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C57BL6 mice, 20 mg/mL o. </span></p>
<p style="top:95.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">g. </span></p>
<p style="top:104.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: HK </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. acidilactici </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">R037 in </span></p>
<p style="top:113.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">water in SJL mice, 0.8 mg/ </span></p>
<p style="top:122.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mL orally </span></p>
<p style="top:131.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS, o.g. </span></p>
<p style="top:140.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: PBS in water, orally</span></p>
<p style="top:77.6pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:86.6pt;left:332.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:77.6pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 36 d </span></p>
<p style="top:86.6pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 2 wks </span></p>
<p style="top:95.6pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">pre-EAE)</span></p>
<p style="top:77.6pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS (T1,T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">infiltrating MNCs </span></p>
<p style="top:86.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1); delayed EAE onset (T2) </span></p>
<p style="top:95.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17 &amp; IFN-&#x3b3; in splenocytes &amp; </span></p>
<p style="top:104.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">draining LNs; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10 &amp; CD4+ IL- </span></p>
<p style="top:113.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">10 + T cells in mesenteric LNs and </span></p>
<p style="top:122.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">splenocytes </span></p>
<p style="top:131.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:140.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:149.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Miyauchi </span></p>
<p style="top:158.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">38</span></sup></p>
<p style="top:149.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low F GF C57BL6 </span></p>
<p style="top:158.6pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">mice </span></p>
<p style="top:167.6pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5&#x2013;7 wko </span></p>
<p style="top:176.6pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 5&#x2013;10/g</span></p>
<p style="top:149.6pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG-induced </span></p>
<p style="top:158.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:149.6pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: OTU0001 (</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, 100% </span></p>
<p style="top:158.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">16S rRNA match to strains </span></p>
<p style="top:167.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">H4 &amp; LMG 18238) </span></p>
<p style="top:176.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: OTU0002 (</span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Allobaculum</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">) </span></p>
<p style="top:185.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Both isolated from small </span></p>
<p style="top:194.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">intestine of specific PF mice </span></p>
<p style="top:203.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and o.g. at 5&#x2013;7 wko for </span></p>
<p style="top:212.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">stable colonization. </span></p>
<p style="top:221.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T3</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T1 + T2 co-colonized </span></p>
<p style="top:230.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T4</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: T3 with </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">urvA</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">-deficient </span></p>
<p style="top:239.6pt;left:232.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri </span></i></p>
<p style="top:248.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: na&#xef;ve GF</span></p>
<p style="top:149.6pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:149.6pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">One admin at 5&#x2013; </span></p>
<p style="top:158.6pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7 wko</span></p>
<p style="top:149.6pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS (T2,T3); &#x2013; CS (T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS, EAE </span></p>
<p style="top:158.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">incidence (T4); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">demyelination, </span></p>
<p style="top:167.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">spinal cord infiltration, EAE incidence </span></p>
<p style="top:176.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T3) </span></p>
<p style="top:185.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17A, T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells in lamina </span></p>
<p style="top:194.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">propria of small intestine &amp; </span></p>
<p style="top:203.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">splenocytes (T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tregs in small </span></p>
<p style="top:212.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">intestine (T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells (T3); &#x2013; IL- </span></p>
<p style="top:221.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">17A, T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells, Tregs in small </span></p>
<p style="top:230.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">intestine (T2/T3); &#x2013; T</span><span style="font-family:MyriadPro,serif;font-size:5.7pt">H</span><span style="font-family:MyriadPro,serif;font-size:8.0pt">17 cells in </span></p>
<p style="top:239.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">small intestine (T1/T4) </span></p>
<p style="top:248.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: &#x2013; rel. abund. in small intestine </span></p>
<p style="top:257.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T2/T3); &#x2013; rel. abund. in small </span></p>
<p style="top:266.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">intestine (T1/T4) </span></p>
<p style="top:275.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">expression of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Saa1, Saa2, </span></i></p>
<p style="top:284.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Il23a, Il12b, Csf2, Il23r </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">in small </span></p>
<p style="top:293.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">intestine (T2); &#x2013; expression of </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Saa1, </span></i></p>
<p style="top:302.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Saa2, Il23a </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">in small intestine (T2/T3)</span></p>
<p style="top:311.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ochoa- </span></p>
<p style="top:320.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Reparaz </span></p>
<p style="top:329.6pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">62</span></sup></p>
<p style="top:311.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:311.6pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F SJL mice </span></p>
<p style="top:320.6pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6 wko </span></p>
<p style="top:329.6pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 6&#x2013;8/g</span></p>
<p style="top:311.6pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PLP-induced </span></p>
<p style="top:320.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:311.6pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 1 wk Abx, recolonize w/ </span></p>
<p style="top:320.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">WT </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. fragilis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">NCTC 9343 </span></p>
<p style="top:329.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 1 wk Abx, recolonize w/ </span></p>
<p style="top:338.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PSA-deficient </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. fragilis </span></i></p>
<p style="top:347.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Both at 10</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt">10 </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">CFU in 200 &#xb5;L </span></p>
<p style="top:356.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">sterile PBS o.g. </span></p>
<p style="top:365.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: 1 wk Abx only </span></p>
<p style="top:374.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: sham (no Abx, receive </span></p>
<p style="top:383.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PBS)</span></p>
<p style="top:311.6pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:311.6pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">30 d (one initial </span></p>
<p style="top:320.6pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">admin)</span></p>
<p style="top:311.6pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS, CDS (T1,C1); delayed EAE </span></p>
<p style="top:320.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">onset (T1,C1); &#x2013; EAE incidence </span></p>
<p style="top:329.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tbet (C1), IFN-&#x3b3; (C1), ROR&#x3b3;t </span></p>
<p style="top:338.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1,C1), IL-17 (T1,C1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">GATA-3 (T1, </span></p>
<p style="top:347.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">C1), IL-10 (T1,C1), SMAD-3 (T1), IL-13 </span></p>
<p style="top:356.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(C1), freq. Foxp3+ CD25+ CD4 + T </span></p>
<p style="top:365.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cells in cervical LNs (C1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-17, </span></p>
<p style="top:374.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROR&#x3b3;t, Tbet and </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">GATA-3, IL-10, IL- </span></p>
<p style="top:383.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">13 (T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">conversion of CD103 </span></p>
<p style="top:392.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">+ DCs to Foxp3+ Tregs (T2) </span></p>
<p style="top:401.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: # of detectable bacteria after </span></p>
<p style="top:410.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abx restored (T1,T2) (colonization </span></p>
<p style="top:419.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">confirmed) </span></p>
<p style="top:428.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: Depletion of CD25 + T cells </span></p>
<p style="top:437.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">eliminated protective effects (C1,T1); </span></p>
<p style="top:446.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS &amp; </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-10 in AT recipient mice </span></p>
<p style="top:455.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1 only)</span></p>
<p style="top:464.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Liu et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">35</span></sup></p>
<p style="top:464.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:464.6pt;left:122.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">F C57BL6 mice </span></p>
<p style="top:473.6pt;left:130.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6&#x2013;8 wko </span></p>
<p style="top:482.6pt;left:130.5pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">n </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">= 23&#x2013;28/g</span></p>
<p style="top:464.6pt;left:175.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG-induced </span></p>
<p style="top:473.6pt;left:183.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">EAE</span></p>
<p style="top:464.6pt;left:224.4pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T1</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Akkermansia muciniphila </span></i></p>
<p style="top:473.6pt;left:232.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC BAA-835 </span></p>
<p style="top:482.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">T2</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">K-12 Strain #7296 </span></p>
<p style="top:491.6pt;left:232.5pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">C</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: medium</span></p>
<p style="top:464.6pt;left:324.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:464.6pt;left:356.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Daily for 7 d </span></p>
<p style="top:473.6pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(starting 11 </span></p>
<p style="top:482.6pt;left:364.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">dpi)</span></p>
<p style="top:464.6pt;left:417.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">CD</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">CS, demyelination, axonal loss </span></p>
<p style="top:473.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(T1) </span></p>
<p style="top:482.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">IM: </span></i><i><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2191; </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MOG-specific Foxp3+ Tregs </span></p>
<p style="top:491.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">and total Tregs in spleen (T1); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2191; </span></p>
<p style="top:500.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Foxp3+ Tregs from DCs (T1); &#x2013; direct </span></p>
<p style="top:509.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Foxp3+ Treg induction (T1 vs T2); </span><span style="font-family:SimSun,serif;font-size:8.0pt">&#x2193; </span></p>
<p style="top:518.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IL-6, IL-1b expression in DCs (T1), &#x2013; </span></p>
<p style="top:527.6pt;left:425.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TGF-&#x3b2; expression (T1/T2) </span></p>
<p style="top:536.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MM</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA </span></p>
<p style="top:545.6pt;left:425.1pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">MC</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">: NA</span></p>
<p style="top:557.9pt;left:51.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">All findings are reported with respect to control group(s) unless otherwise indicated. </span></p>
<p style="top:566.9pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Key</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2193; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">decreased; </span><span style="font-family:Times New Roman,serif;font-size:8.0pt">&#x2191; </span><span style="font-family:MyriadPro,serif;font-size:8.0pt">increased; &#x2013; no change or no difference compared to control; NA, not applicable to this study. </span></p>
<p style="top:575.9pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abbreviations</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: ROB, risk of bias; MS, multiple sclerosis; UN, uncertain; M, male; F, female; wk/wks/wko, week/weeks/weeks old; g, group; EAE, experimental </span></p>
<p style="top:585.0pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; PLP, proteolipid protein; T, treatment group; C, control; CFU, colony-forming </span></p>
<p style="top:593.9pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">units; o.g., oral gavage; PBS, phosphate-buffered saline; s.c., subcutaneous; Abx, antibiotics; HK, heat-killed; IFN&#x3b2;, interferon beta; IU, international unit; OTU, </span></p>
<p style="top:602.9pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">operational taxonomic unit; PF, pathogen-free; GF, germ-free; WT, wild-type; PSA, polysaccharide A; Thera, therapeutic; Proph, prophylactic; admin; </span></p>
<p style="top:611.9pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">administration; dpi, days post immunization; CD, clinical disease; IM, immune/metabolic; MM, microbiome/metabolome; MC, mechanistic/correlative; CDS, </span></p>
<p style="top:621.0pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">cumulative disease score; freq., frequency; GM-CSF, granulocyte monocyte colony-stimulating factor; IFN-&#x3b3;, interferon gamma; CS, clinical score; CNS, central </span></p>
<p style="top:629.9pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">nervous system; LN, lymph node; IL, interleukin; rel. abund., relative abundance; BBB, blood&#x2013;brain barrier; AT, adoptive transfer; GALT, gut-associated </span></p>
<p style="top:638.9pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">lymphoid tissue; DC, dendritic cell; TGF-&#x3b2;, transforming growth factor beta; MNC, mononuclear cell.</span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-17</span></p>


<p style="top:51.0pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 5. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Bradford Hill criteria evaluation of probiotic and commensal therapies.</span></p>
<p style="top:73.6pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Therapy</span></p>
<p style="top:73.6pt;left:155.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:73.6pt;left:195.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study Type</span></p>
<p style="top:73.6pt;left:239.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:73.6pt;left:337.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Strain Used</span></p>
<p style="top:73.6pt;left:460.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Treatment Effect</span></p>
<p style="top:64.6pt;left:526.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BH </span></p>
<p style="top:73.6pt;left:522.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Score</span></p>
<p style="top:85.5pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">VSL#3/ </span></p>
<p style="top:94.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Vivomixx/ </span></p>
<p style="top:103.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">LBS</span></p>
<p style="top:85.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Mestre et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">43</span></sup></p>
<p style="top:85.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal </span></p>
<p style="top:94.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">TMEV-IDD </span></p>
<p style="top:103.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:85.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:85.5pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24734, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24730, </span></p>
<p style="top:94.5pt;left:267.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24735, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbrueckii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ssp. bulgaricus DSM </span></p>
<p style="top:103.5pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">24734, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. longum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24736, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. infantis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24737, </span></p>
<p style="top:112.5pt;left:267.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. breve </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24732, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">S. thermophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 24731</span></p>
<p style="top:85.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:85.5pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">9</span></b></p>
<p style="top:112.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Calvo-Barreiro </span></p>
<p style="top:121.5pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">44</span></sup></p>
<p style="top:112.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:121.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:112.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:112.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:130.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">McMurran </span></p>
<p style="top:139.5pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">45</span></sup></p>
<p style="top:130.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal </span></p>
<p style="top:139.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Cuprizone </span></p>
<p style="top:148.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:157.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:130.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:130.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:166.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tankou et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">46</span></sup><sup><span style="font-family:MyriadPro,serif;font-size:8.0pt"> </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">Human </span></p>
<p style="top:166.5pt;left:465.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Prospective </span></p>
<p style="top:175.5pt;left:465.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Cohort</span></p>
<p style="top:181.0pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">High</span></p>
<p style="top:181.0pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved </span></p>
<p style="top:186.4pt;left:59.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(immunologically)</span></p>
<p style="top:190.0pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tankou et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">47</span></sup><sup><span style="font-family:MyriadPro,serif;font-size:8.0pt"> </span></sup><span style="font-family:MyriadPro,serif;font-size:8.0pt">Human </span></p>
<p style="top:190.0pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Prospective Cohort</span></p>
<p style="top:190.0pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">High</span></p>
<p style="top:195.4pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved </span></p>
<p style="top:204.4pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(immunologically &amp; </span></p>
<p style="top:213.5pt;left:63.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">microbiologically)</span></p>
<p style="top:222.4pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei</span></i></p>
<p style="top:222.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lavasani </span></p>
<p style="top:231.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">48</span></sup></p>
<p style="top:222.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:231.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:240.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:222.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:222.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 13434, PCC 101</span></p>
<p style="top:222.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:222.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">7</span></b></p>
<p style="top:249.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Sanchez </span></p>
<p style="top:258.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">49</span></sup></p>
<p style="top:249.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:258.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:267.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:249.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:249.5pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 27092 (live &amp; heat-killed), ATCC 11582, DSM 2649, DSM </span></p>
<p style="top:258.4pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">5622, ATCC 334</span></p>
<p style="top:249.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:276.4pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis</span></i></p>
<p style="top:276.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Salehipour </span></p>
<p style="top:285.5pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">50</span></sup></p>
<p style="top:276.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:285.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:276.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:276.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">PTCC 1631</span></p>
<p style="top:276.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:276.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">7</span></b></p>
<p style="top:294.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ezendam </span></p>
<p style="top:303.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">51</span></sup></p>
<p style="top:294.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:303.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:312.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:294.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:294.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Not specified</span></p>
<p style="top:294.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:321.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Goudarzvand </span></p>
<p style="top:330.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">52</span></sup></p>
<p style="top:321.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal GID </span></p>
<p style="top:330.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:321.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:321.5pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Susbp. lactis B94</span></p>
<p style="top:321.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:339.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Consonni </span></p>
<p style="top:348.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:339.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:348.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:357.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:339.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:339.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Subsp. lactis BB12</span></p>
<p style="top:339.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly improved</span></p>
<p style="top:366.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Consonni </span></p>
<p style="top:375.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:366.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:375.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:384.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:366.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:366.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Subsp. lactis LMG S-28195</span></p>
<p style="top:366.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly improved</span></p>
<p style="top:393.5pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. coli</span></i></p>
<p style="top:393.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Libbey et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">54</span></sup></p>
<p style="top:393.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:402.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:393.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:393.5pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Nissle 1917 recombinant strain for ampicillin resistance </span></p>
<p style="top:402.4pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(pGEN-MCS)</span></p>
<p style="top:393.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:393.5pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">7</span></b></p>
<p style="top:411.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Secher et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">55</span></sup></p>
<p style="top:411.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:420.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:429.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:411.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:411.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Nissle 1917</span></p>
<p style="top:411.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:438.4pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. histicola</span></i></p>
<p style="top:438.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Mangalam </span></p>
<p style="top:447.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">56</span></sup></p>
<p style="top:438.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:447.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:456.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:438.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:438.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Isolated from duodenum of celiac disease patients</span></p>
<p style="top:438.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:438.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">7</span></b></p>
<p style="top:465.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shahi et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">57</span></sup></p>
<p style="top:465.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:474.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:483.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:465.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:465.5pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Isolated from duodenum of celiac disease patients</span></p>
<p style="top:465.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:492.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shahi et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">58</span></sup></p>
<p style="top:492.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:501.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:510.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:492.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:492.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Isolated from duodenum of celiac disease patients</span></p>
<p style="top:492.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:519.4pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum</span></i></p>
<p style="top:519.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lavasani </span></p>
<p style="top:528.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">48</span></sup></p>
<p style="top:519.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:528.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:537.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:519.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:519.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 15312, DSM 15313</span></p>
<p style="top:519.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:519.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">6</span></b></p>
<p style="top:546.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Salehipour </span></p>
<p style="top:555.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">50</span></sup></p>
<p style="top:546.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:555.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:546.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:546.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">A7</span></p>
<p style="top:546.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:564.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Goudarzvand </span></p>
<p style="top:573.5pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">52</span></sup></p>
<p style="top:564.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal GID </span></p>
<p style="top:573.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:564.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:564.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Not specified</span></p>
<p style="top:564.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:582.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Maassen </span></p>
<p style="top:591.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">59</span></sup></p>
<p style="top:582.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:591.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:582.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:582.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">NCIB 8826, 14917</span></p>
<p style="top:582.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:600.4pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lacto-mix</span></p>
<p style="top:600.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lavasani </span></p>
<p style="top:609.5pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">48</span></sup></p>
<p style="top:600.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:609.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:618.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:600.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:600.4pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 15312, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 15313, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. paracasei </span></i></p>
<p style="top:609.5pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 13434</span></p>
<p style="top:600.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:600.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">6</span></b></p>
<p style="top:627.4pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. crispatus &amp; L. rhamnosus</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt"> Consonni </span></p>
<p style="top:636.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:627.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:636.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:645.5pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:627.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:627.4pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. crispatus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LMG </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">-23257 &amp; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. rhamnosus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 53103</span></p>
<p style="top:627.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:627.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">6</span></b></p>
<p style="top:654.4pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis &amp; B. animalis</span></i></p>
<p style="top:654.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Consonni </span></p>
<p style="top:663.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:654.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:663.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:672.4pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:654.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:654.4pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. lactis BB12 &amp; </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. lactis LMG </span></p>
<p style="top:663.4pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">S-28195</span></p>
<p style="top:654.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:654.4pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">6</span></b></p>
<p style="top:681.5pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus, L. casei, </span></i></p>
<p style="top:690.4pt;left:63.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. fermentum, &amp; </span></i></p>
<p style="top:699.4pt;left:63.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. bifidum</span></i></p>
<p style="top:681.5pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kouchaki </span></p>
<p style="top:690.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">60</span></sup></p>
<p style="top:681.5pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Human RCT</span></p>
<p style="top:681.5pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:681.5pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Not specified</span></p>
<p style="top:681.5pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:681.5pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">5</span></b></p>
<p style="top:699.4pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Tamtaji </span></p>
<p style="top:708.4pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">61</span></sup></p>
<p style="top:699.4pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Human RCT</span></p>
<p style="top:699.4pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:699.4pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Not specified</span></p>
<p style="top:699.4pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly improved </span></p>
<p style="top:720.1pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-18</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:51.0pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 5. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:74.1pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Therapy</span></p>
<p style="top:74.1pt;left:155.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:74.1pt;left:195.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study Type</span></p>
<p style="top:74.1pt;left:239.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:74.1pt;left:337.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Strain Used</span></p>
<p style="top:74.1pt;left:460.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Treatment Effect</span></p>
<p style="top:65.1pt;left:526.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BH </span></p>
<p style="top:74.1pt;left:522.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Score</span></p>
<p style="top:83.1pt;left:59.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(immunologically)</span></p>
<p style="top:92.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. fragilis</span></i></p>
<p style="top:92.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ochoa- </span></p>
<p style="top:101.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Reparaz </span></p>
<p style="top:110.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">62</span></sup></p>
<p style="top:92.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:101.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:92.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:92.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">NCTC 9343</span></p>
<p style="top:92.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:92.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">5</span></b></p>
<p style="top:119.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. crispatus</span></i></p>
<p style="top:119.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Consonni </span></p>
<p style="top:128.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:119.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:128.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:137.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:119.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:119.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">LMG </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">-23257</span></p>
<p style="top:119.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:119.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:146.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. rhamnosus</span></i></p>
<p style="top:146.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Consonni </span></p>
<p style="top:155.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">53</span></sup></p>
<p style="top:146.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:155.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:164.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:146.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:146.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 53103</span></p>
<p style="top:146.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:146.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:173.1pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lactibiane iki</span></p>
<p style="top:173.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Calvo-Barreiro </span></p>
<p style="top:182.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">44</span></sup></p>
<p style="top:173.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:182.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:173.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:173.1pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. lactis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LA 304, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LA 201, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. salivarius </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">LA 302</span></p>
<p style="top:173.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:173.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:191.1pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Protexin</span></p>
<p style="top:191.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Rahimlou </span></p>
<p style="top:200.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">63</span></sup></p>
<p style="top:191.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Human </span></p>
<p style="top:200.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">RCT</span></p>
<p style="top:191.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:191.1pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. subtilis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 21, B. bifidum PXN 23, B. breve PXN 25, </span></p>
<p style="top:200.1pt;left:267.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. infantis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 27, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. longum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 30, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 35, </span></p>
<p style="top:209.1pt;left:267.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. rhamnosus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 54, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. helveticus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 45, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. salivarius </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN </span></p>
<p style="top:218.1pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">57, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. lactis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ssp. lactis PXN 63, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">S. thermophilus </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 66, </span></p>
<p style="top:227.1pt;left:267.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 37, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbrueckii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">ssp. bulgaricus PXN 39, </span></p>
<p style="top:236.1pt;left:267.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PXN 47</span></p>
<p style="top:191.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly improved</span></p>
<p style="top:191.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:245.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum, L. casei, </span></i></p>
<p style="top:254.1pt;left:63.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri, L. fermentum, </span></i></p>
<p style="top:263.1pt;left:63.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. infantis, &amp; B. lactis</span></i></p>
<p style="top:245.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Salami et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">64</span></sup></p>
<p style="top:245.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Human RCT</span></p>
<p style="top:245.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:245.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Not specified</span></p>
<p style="top:245.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:245.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:272.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum &amp; B. animalis</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt"> Salehipour </span></p>
<p style="top:281.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">50</span></sup></p>
<p style="top:272.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:281.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:272.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:272.1pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. plantarum </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">A7, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. animalis </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">PTCC 1631</span></p>
<p style="top:272.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:272.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:290.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">C. butyricum</span></i></p>
<p style="top:290.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Chen et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">65</span></sup></p>
<p style="top:290.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:299.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:290.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:290.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">GDBIO1501</span></p>
<p style="top:290.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:290.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:308.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">Allobaculum</span></i></p>
<p style="top:308.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Miyauchi </span></p>
<p style="top:317.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">38</span></sup></p>
<p style="top:308.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:317.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:308.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:308.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Isolated from content of small intestines of specific PF mice</span></p>
<p style="top:308.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly worsened</span></p>
<p style="top:308.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">4</span></b></p>
<p style="top:326.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. murinus</span></i></p>
<p style="top:326.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Maassen </span></p>
<p style="top:335.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">59</span></sup></p>
<p style="top:326.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:335.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:326.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:326.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">CNRZ</span></p>
<p style="top:326.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:326.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">3</span></b></p>
<p style="top:344.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">E. faecium</span></i></p>
<p style="top:344.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abdurasulova </span></p>
<p style="top:353.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">66</span></sup></p>
<p style="top:344.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:353.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:344.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:344.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">LMG </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">-27496</span></p>
<p style="top:344.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:344.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">3</span></b></p>
<p style="top:362.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. helveticus</span></i></p>
<p style="top:362.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Yamashita </span></p>
<p style="top:371.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">67</span></sup></p>
<p style="top:362.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:371.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:380.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:362.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:362.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">SBT2171</span></p>
<p style="top:362.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:362.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">2</span></b></p>
<p style="top:389.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. breve</span></i></p>
<p style="top:389.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kobayashi </span></p>
<p style="top:398.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">68</span></sup></p>
<p style="top:389.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:398.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:407.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:389.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:389.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Yakult</span></p>
<p style="top:389.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly improved </span></p>
<p style="top:398.1pt;left:465.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(F) Worsened </span></p>
<p style="top:407.1pt;left:465.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">(M)</span></p>
<p style="top:389.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">2</span></b></p>
<p style="top:416.1pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">IRT5</span></p>
<p style="top:416.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kwon et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">69</span></sup></p>
<p style="top:416.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:425.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:434.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:416.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:416.1pt;left:259.4pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. acidophilus</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">B. bifidum</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">, </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">S. thermophilus</span></i></p>
<p style="top:416.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:416.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">2</span></b></p>
<p style="top:443.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">P. acidilactici</span></i></p>
<p style="top:443.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Takata et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">70</span></sup></p>
<p style="top:443.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:452.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:461.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:443.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:443.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">R037</span></p>
<p style="top:443.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:443.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">2</span></b></p>
<p style="top:470.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">A. muciniphila</span></i></p>
<p style="top:470.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Liu et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">35</span></sup></p>
<p style="top:470.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:479.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:470.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:470.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC BAA-835</span></p>
<p style="top:470.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:470.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">2</span></b></p>
<p style="top:488.1pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. casei</span></i></p>
<p style="top:488.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Maassen </span></p>
<p style="top:497.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">59</span></sup></p>
<p style="top:488.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:497.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:488.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:488.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">393</span></p>
<p style="top:488.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly improved</span></p>
<p style="top:488.1pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">1</span></b></p>
<p style="top:506.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Gharehkhani </span></p>
<p style="top:515.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Digehsara </span></p>
<p style="top:524.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">71</span></sup></p>
<p style="top:506.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal </span></p>
<p style="top:515.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Cuprizone </span></p>
<p style="top:524.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:533.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:506.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:506.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Not specified</span></p>
<p style="top:506.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:542.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Ezendam &amp; </span></p>
<p style="top:551.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">van </span></p>
<p style="top:560.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Loveren</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">72</span></sup></p>
<p style="top:542.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:551.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:560.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:542.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">High Shirota</span></p>
<p style="top:542.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly worsened</span></p>
<p style="top:569.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Baken et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">73</span></sup></p>
<p style="top:569.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:578.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:587.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:569.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:569.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota</span></p>
<p style="top:569.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Worsened</span></p>
<p style="top:596.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kobayashi </span></p>
<p style="top:605.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">68</span></sup></p>
<p style="top:596.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:605.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:614.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:596.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:596.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Shirota</span></p>
<p style="top:596.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:623.1pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Kobayashi </span></p>
<p style="top:632.1pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">74</span></sup></p>
<p style="top:623.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:632.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:641.1pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:623.1pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:623.1pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">YIT 9029</span></p>
<p style="top:623.1pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:652.7pt;left:501.2pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">(</span><i><span style="font-family:MyriadPro,serif;font-size:9.5pt">Continued</span></i><span style="font-family:MyriadPro,serif;font-size:9.5pt">)</span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-19</span></p>


<p style="top:412.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">organisms and combinations should be the main </span></p>
<p style="top:426.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">focus of future studies, since there were few com-</span></p>
<p style="top:440.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensal therapy studies overall and only </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i></p>
<p style="top:454.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. reuteri </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">were used in more than one study. </span></p>
<p style="top:468.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Future studies should also focus on confirming colo-</span></p>
<p style="top:482.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">nization of the commensal organisms in the gut to </span></p>
<p style="top:496.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reduce confounding and strengthen the specificity of </span></p>
<p style="top:510.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">association (BHC #7). Testing the effects of live </span></p>
<p style="top:524.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">versus heat-killed organisms and their products </span></p>
<p style="top:538.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">should also be prioritized, as these findings may </span></p>
<p style="top:552.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">contribute to the elucidating the underlying thera-</span></p>
<p style="top:566.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">peutic mechanisms. For instance, subsequent studies </span></p>
<p style="top:580.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">by the same research group utilized only </span></p>
<p style="top:594.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">PSA symbiosis factor rather than </span></p>
<p style="top:608.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">administering live, wild-type </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">and found </span></p>
<p style="top:622.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">similar reductions in EAE severity, as well as protec-</span></p>
<p style="top:636.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion against EAE demyelination and inflammatory </span></p>
<p style="top:650.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">responses, providing a key molecular mechanism in </span></p>
<p style="top:664.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">support of the action of the live bacterium.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">81&#x2013;84</span></sup></p>
<p style="top:678.1pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Other recommendations reflect those of probio-</span></p>
<p style="top:692.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tic therapy, namely controlling for alternative </span></p>
<p style="top:706.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">explanations, </span></p>
<p style="top:706.2pt;left:124.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">supporting </span></p>
<p style="top:706.2pt;left:187.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">immunological </span></p>
<p style="top:706.2pt;left:270.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:720.2pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">microbiological </span></p>
<p style="top:720.2pt;left:140.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">findings </span></p>
<p style="top:720.2pt;left:194.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">with </span></p>
<p style="top:720.2pt;left:232.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mechanistic </span></p>
<p style="top:266.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">experiments, and adding standardization to pro-</span></p>
<p style="top:280.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mote study design consistency and ease of compar-</span></p>
<p style="top:294.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ison across studies.</span></p>
<p style="top:335.8pt;left:306.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Discussion</span></b></p>
<p style="top:356.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">The purpose of this comprehensive review was </span></p>
<p style="top:370.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to compile, summarize, and systematically rank </span></p>
<p style="top:384.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the current evidence for probiotic and com-</span></p>
<p style="top:398.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mensal therapeutic efficacy in MS and its pre-</span></p>
<p style="top:412.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical models in an effort to identify weaker </span></p>
<p style="top:426.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">areas that should be addressed in future studies. </span></p>
<p style="top:440.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">A total of 37 studies were evaluated, including </span></p>
<p style="top:454.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">28 for probiotic therapy and 9 for commensal </span></p>
<p style="top:468.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy. The probiotic formulations VSL#3 (BH </span></p>
<p style="top:482.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score = 9), </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis, L. paracasei</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i></p>
<p style="top:496.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917 (BH scores = 7) ranked highest due </span></p>
<p style="top:510.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to their fulfillment of at least six of the eight </span></p>
<p style="top:524.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Bradford Hill criteria. For commensal therapy &#x2013; </span></p>
<p style="top:538.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">which suffered from a complete absence of clin-</span></p>
<p style="top:552.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ical studies &#x2013; the highest rankings went to </span></p>
<p style="top:566.4pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(BH score = 7) and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">(BH </span></p>
<p style="top:580.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">score = 5).</span></p>
<p style="top:594.4pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Animal studies demonstrated generally higher </span></p>
<p style="top:608.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">efficacy for reducing disease severity and progres-</span></p>
<p style="top:622.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sion with probiotic therapy than did the human </span></p>
<p style="top:636.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies, which is not unexpected, given the known </span></p>
<p style="top:650.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">shortcomings of the animal models, and the </span></p>
<p style="top:664.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">expected difficulties in translating basic science </span></p>
<p style="top:678.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">findings into therapy. The disconnect between </span></p>
<p style="top:692.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">human and animal studies could also be due to </span></p>
<p style="top:706.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the difference and extent of the clinical markers </span></p>
<p style="top:720.4pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">measured, as clinical studies only measured MS </span></p>
<p style="top:51.0pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 5. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">(Continued).</span></p>
<p style="top:74.1pt;left:55.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Therapy</span></p>
<p style="top:74.1pt;left:155.3pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study</span></p>
<p style="top:74.1pt;left:195.2pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Study Type</span></p>
<p style="top:74.1pt;left:239.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ROB</span></p>
<p style="top:74.1pt;left:337.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Strain Used</span></p>
<p style="top:74.1pt;left:460.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Treatment Effect</span></p>
<p style="top:65.1pt;left:526.1pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">BH </span></p>
<p style="top:74.1pt;left:522.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Score</span></p>
<p style="top:86.6pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri</span></i></p>
<p style="top:86.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">He et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">75</span></sup></p>
<p style="top:86.6pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:95.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:86.6pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:86.6pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 17938</span></p>
<p style="top:86.6pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:86.6pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">1</span></b></p>
<p style="top:104.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Johanson </span></p>
<p style="top:113.6pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">76</span></sup></p>
<p style="top:104.6pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:113.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:104.6pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:104.6pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ATCC 2327</span></p>
<p style="top:104.6pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Improved</span></p>
<p style="top:122.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Maassen </span></p>
<p style="top:131.6pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">59</span></sup></p>
<p style="top:122.6pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:131.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:122.6pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:122.6pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">ML1</span></p>
<p style="top:122.6pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Worsened</span></p>
<p style="top:140.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Miyauchi </span></p>
<p style="top:149.6pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">38</span></sup></p>
<p style="top:140.6pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:149.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:140.6pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:140.6pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Isolated from content of small intestines of specific PF mice </span></p>
<p style="top:149.6pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">100% 16S rRNA match to strains H4 &amp; LMG 18238 Also </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">uvrA</span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">- </span></p>
<p style="top:158.6pt;left:267.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">deficient </span><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. reuteri</span></i></p>
<p style="top:140.6pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Slightly worsened</span></p>
<p style="top:167.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Montgomery </span></p>
<p style="top:176.6pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">37</span></sup></p>
<p style="top:167.6pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:176.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph</span></p>
<p style="top:167.6pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Low</span></p>
<p style="top:167.6pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Isolated from PWD cecal contents</span></p>
<p style="top:167.6pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Worsened</span></p>
<p style="top:185.6pt;left:55.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">L. delbrueckii </span></i><span style="font-family:MyriadPro,serif;font-size:8.0pt">subsp. </span></p>
<p style="top:194.6pt;left:63.0pt;line-height:8.0pt"><i><span style="font-family:MyriadPro,serif;font-size:8.0pt">bulgaricus</span></i></p>
<p style="top:185.6pt;left:141.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Lavasani </span></p>
<p style="top:194.6pt;left:149.8pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">et al.</span><sup><span style="font-family:MyriadPro,serif;font-size:5.7pt;color:#00007f">48</span></sup></p>
<p style="top:185.6pt;left:192.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Animal EAE </span></p>
<p style="top:194.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Proph &amp; </span></p>
<p style="top:203.6pt;left:200.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Thera</span></p>
<p style="top:185.6pt;left:238.7pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">UN</span></p>
<p style="top:185.6pt;left:259.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">DSM 20081</span></p>
<p style="top:185.6pt;left:457.5pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">No change</span></p>
<p style="top:185.6pt;left:522.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">1</span></b></p>
<p style="top:215.9pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abbreviations</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: ROB, risk of bias; BH, Bradford Hill; EAE, experimental autoimmune encephalomyelitis; Proph, prophylactic; Thera, therapeutic; RCT, randomized </span></p>
<p style="top:225.0pt;left:57.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">controlled trial; GID, gliotoxin-induced demyelination; TMEV-IDD, Theiler&#x2019;s murine encephalomyelitis virus-induced demyelinating disease; UN, uncertain.</span></p>
<p style="top:267.2pt;left:51.0pt;line-height:9.5pt"><b><span style="font-family:MyriadPro,serif;font-size:9.5pt;color:#10137d">Table 6. </span></b><span style="font-family:MyriadPro,serif;font-size:9.5pt">Bradford Hill criteria (BHC) warranting most attention </span></p>
<p style="top:278.2pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MyriadPro,serif;font-size:9.5pt">for future probiotic and commensal therapy studies.</span></p>
<p style="top:291.9pt;left:90.0pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Probiotic Therapy</span></p>
<p style="top:291.9pt;left:190.9pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">Commensal Therapy</span></p>
<p style="top:303.8pt;left:55.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">BHC </span></b></p>
<p style="top:312.8pt;left:63.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">#</span></b></p>
<p style="top:303.8pt;left:79.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">1. Temporal relationship 2. Strength of relationship</span></p>
<p style="top:321.7pt;left:79.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">4. Replication of findings 3. Dose&#x2013;response relationship</span></p>
<p style="top:330.8pt;left:79.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6. Cessation of exposure 4. Replication of findings</span></p>
<p style="top:339.8pt;left:79.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">7. Specificity of </span></p>
<p style="top:348.8pt;left:87.4pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">association</span></p>
<p style="top:339.8pt;left:161.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">6. Cessation of exposure</span></p>
<p style="top:357.7pt;left:161.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">8. Coherence between multiple </span></p>
<p style="top:366.8pt;left:169.6pt;line-height:8.0pt"><span style="font-family:MyriadPro,serif;font-size:8.0pt">approaches</span></p>
<p style="top:379.1pt;left:51.0pt;line-height:8.0pt"><b><span style="font-family:MyriadPro,serif;font-size:8.0pt">Abbreviation</span></b><span style="font-family:MyriadPro,serif;font-size:8.0pt">: BHC, Bradford Hill criteria.</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-20</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">severity through EDSS and questionnaires, while </span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the pre-clinical studies were able to investigate </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">EAE and the other MS models more comprehen-</span></p>
<p style="top:92.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sively. MRI evaluation is a powerful, unbiased, and </span></p>
<p style="top:106.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quantitative surrogate for MS severity and progres-</span></p>
<p style="top:120.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sion, and this was conspicuously lacking in the </span></p>
<p style="top:134.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">human studies. Additionally, human studies were </span></p>
<p style="top:148.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">in all likelihood underpowered to detect potentially </span></p>
<p style="top:162.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">subtle effects of probiotic treatments, and con-</span></p>
<p style="top:176.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">founded by multiple environmental variables (e.g. </span></p>
<p style="top:190.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">diet, host baseline differences) that are impossible </span></p>
<p style="top:204.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to control in this setting.</span></p>
<p style="top:218.7pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Replication of findings (BHC #4) was one of </span></p>
<p style="top:232.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the most deficient Bradford Hill criteria across </span></p>
<p style="top:246.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">studies, with only 25% (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">n </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">= 28) of the formula-</span></p>
<p style="top:260.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tions receiving points and two of them (</span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. reuteri </span></i></p>
<p style="top:274.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. casei) </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">losing points. Another almost uni-</span></p>
<p style="top:288.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">formly unfulfilled criterion was cessation of expo-</span></p>
<p style="top:302.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sure, only addressed by six formulations. Both </span></p>
<p style="top:316.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic and commensal therapies would benefit </span></p>
<p style="top:330.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">from additional replication, testing more organ-</span></p>
<p style="top:344.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ism combinations, improved mechanistic evi-</span></p>
<p style="top:358.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">dence and comparison of live versus heat-killed </span></p>
<p style="top:372.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">organisms and their soluble products, and proto-</span></p>
<p style="top:386.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">col standardization to enable improved contextual </span></p>
<p style="top:400.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">comparison across studies.</span></p>
<p style="top:436.9pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Limitations</span></i></b></p>
<p style="top:457.9pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Study limitations</span></i></b></p>
<p style="top:471.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">There were several limitations to accurately asses-</span></p>
<p style="top:485.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sing the efficacies of both therapies. First, there was </span></p>
<p style="top:499.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">widespread study design variability in the species </span></p>
<p style="top:513.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and/or strain, dosage, duration of intervention, </span></p>
<p style="top:527.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">timeline, and sample characteristics. These varia-</span></p>
<p style="top:541.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tions would have been beneficial to external valida-</span></p>
<p style="top:555.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tion if the same strains were used across studies, but </span></p>
<p style="top:569.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">instead posed a challenge for assessing therapeutic </span></p>
<p style="top:583.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">utility. Standardized protocols outlining the opti-</span></p>
<p style="top:597.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">mal dosage, timeline, and duration for different </span></p>
<p style="top:611.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">organisms would be helpful for mitigating this </span></p>
<p style="top:625.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">issue, as was the focus of a review on probiotic </span></p>
<p style="top:639.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapy that concluded 10</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">9 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">CFU for 8&#x2013;12 weeks </span></p>
<p style="top:653.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">duration produced the most favorable results.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">31</span></sup></p>
<p style="top:667.1pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Another study design issue was exclusion criteria </span></p>
<p style="top:681.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and control of confounding variables, since some of </span></p>
<p style="top:695.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the human studies did not account for diet or stress, </span></p>
<p style="top:709.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">which can alter gut microbial composition and </span></p>
<p style="top:723.1pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">subsequently influence MGBA interactions and </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">concurrent DMT use, which could overshadow </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the true therapeutic efficacy if synergism exists </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">between the two.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">34 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Additionally, genetic variability </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">was also mostly unaccounted for in both human </span></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and animal studies (since the latter for the most </span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">part used a single strain of mouse). Furthermore, </span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">none of the human studies were conducted long </span></p>
<p style="top:148.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">enough to span the average remission period of 12&#x2013; </span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">18 months, so the true impact of each therapy on </span></p>
<p style="top:176.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reducing the severity of MS cannot be revealed with </span></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">certainty.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">1</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">85 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">As for animal studies, none of these </span></p>
<p style="top:204.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">can accurately capture the complexity of sponta-</span></p>
<p style="top:218.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">neous MS and its various forms in humans.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">86&#x2013;88</span></sup></p>
<p style="top:232.7pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Only five studies tested the effects of live versus </span></p>
<p style="top:246.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">heat-killed organisms or their products.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62 </span></sup></p>
<p style="top:260.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">This distinction is important, since equivalent effi-</span></p>
<p style="top:274.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cacy with heat-killed organisms would help to </span></p>
<p style="top:288.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">reduce any associated risks of therapy posed by </span></p>
<p style="top:302.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">live microbiota and likely improve treatment </span></p>
<p style="top:316.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">uptake and adherence in patients. Furthermore, </span></p>
<p style="top:330.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">this effect likely differs across organisms. For </span></p>
<p style="top:344.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">instance, </span></p>
<p style="top:344.7pt;left:358.9pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:344.7pt;left:379.7pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">paracasei</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">49 </span></sup></p>
<p style="top:344.7pt;left:445.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a </span></p>
<p style="top:344.7pt;left:462.5pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">combination </span></p>
<p style="top:344.7pt;left:533.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of </span></p>
<p style="top:358.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:358.7pt;left:331.4pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">crispatus </span></i></p>
<p style="top:358.7pt;left:388.4pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:358.7pt;left:422.5pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">L. </span></i></p>
<p style="top:358.7pt;left:447.9pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">rhamnosus</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">,</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53 </span></sup></p>
<p style="top:358.7pt;left:525.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:372.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a combination of two </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">subsp. lactis </span></p>
<p style="top:386.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">strains</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">53 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">did not need to be viable for EAE suppres-</span></p>
<p style="top:400.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sion, while </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola</span></i><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">56 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">and Lacto-mix</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">48 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">did. </span></p>
<p style="top:414.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Additionally, protection from EAE elicited by </span></p>
<p style="top:428.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">required the expression PSA by this bac-</span></p>
<p style="top:442.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">terium, indicating that this bacterial product alone </span></p>
<p style="top:456.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">can play an important role in EAE protection.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">62 </span></sup></p>
<p style="top:470.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Indeed, follow-up studies confirmed that live </span></p>
<p style="top:484.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">is not required, while PSA is sufficient </span></p>
<p style="top:498.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to elicit a therapeutic effects.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">81&#x2013;84 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Future studies </span></p>
<p style="top:512.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">should prioritize these distinctions to help optimize </span></p>
<p style="top:526.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">efficacy and therapeutic success.</span></p>
<p style="top:540.7pt;left:318.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Another limitation of this review was the quality </span></p>
<p style="top:554.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and risk of bias for the studies included. Most of the </span></p>
<p style="top:568.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">animal studies included were classified as &#x201c;medium </span></p>
<p style="top:582.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">quality&#x201d; with &#x201c;uncertain&#x201d; bias due to the lack of </span></p>
<p style="top:596.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">explicitly stated randomization and blinding mea-</span></p>
<p style="top:610.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">sures used. A lack of randomization can subject the </span></p>
<p style="top:624.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">results to inadvertent confounding and chance </span></p>
<p style="top:638.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">findings.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">39</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">40 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Animals that live together in the </span></p>
<p style="top:652.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">same cage or area of a room may have more similar </span></p>
<p style="top:666.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">characteristics to each other than compared to </span></p>
<p style="top:680.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a different cage or area importantly including the </span></p>
<p style="top:694.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">basal composition of their gut microbiomes. </span></p>
<p style="top:708.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Additionally, a lack of blinding can introduce </span></p>
<p style="top:722.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">both </span></p>
<p style="top:722.7pt;left:340.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">performance </span></p>
<p style="top:722.7pt;left:413.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:722.7pt;left:443.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">detection </span></p>
<p style="top:722.7pt;left:499.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bias, </span></p>
<p style="top:722.7pt;left:533.7pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">as </span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-21</span></p>


<p style="top:50.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">a researcher or caretaker&#x2019;s knowledge of the treat-</span></p>
<p style="top:64.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ment group can cause them to subconsciously act </span></p>
<p style="top:78.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">differently toward one group, such as providing </span></p>
<p style="top:92.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">extra care to sicker animals.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">39</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt">,</span></sup><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">40 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">It is entirely possi-</span></p>
<p style="top:106.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ble that these studies did in fact incorporate these </span></p>
<p style="top:120.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">measures into their protocol, but since it was not </span></p>
<p style="top:134.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">stated it was considered to be absent for this review. </span></p>
<p style="top:148.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Other issues regarding quality include the premise </span></p>
<p style="top:162.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">that the positive findings observed across studies </span></p>
<p style="top:176.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">may simply reflect consistency of confounding vari-</span></p>
<p style="top:190.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ables and/or publication bias, rather than the ther-</span></p>
<p style="top:204.7pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">apy itself.</span></p>
<p style="top:234.2pt;left:51.0pt;line-height:10.5pt"><b><i><span style="font-family:MyriadPro,serif;font-size:10.5pt;color:#10137d">Review limitations</span></i></b></p>
<p style="top:247.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">As for the risk of bias for this review, there were </span></p>
<p style="top:261.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">several methodological flaws in the assessment of </span></p>
<p style="top:275.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapeutic efficacy. Personal judgment was required </span></p>
<p style="top:289.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">for assessing each therapy&#x2019;s fulfillment of the </span></p>
<p style="top:303.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Bradford Hill criteria and there were no pre-defined </span></p>
<p style="top:317.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">guidelines as to what should be considered &#x201c;sufficient </span></p>
<p style="top:331.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">evidence.&#x201d; The scoring system was implemented as an </span></p>
<p style="top:345.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">arbitrary method to facilitate comparison of the effi-</span></p>
<p style="top:359.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cacies in the context of the recommendation criterion </span></p>
<p style="top:373.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and not intended to be a comprehensive assessment </span></p>
<p style="top:387.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of the therapies. Regardless, the aim of this review was </span></p>
<p style="top:401.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">to highlight areas within each therapy that should be </span></p>
<p style="top:415.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">strengthened in future studies, so the risk of bias in </span></p>
<p style="top:429.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">this sense seems low. Separately, a few of the Bradford </span></p>
<p style="top:443.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Hill criteria may be less important for establishing </span></p>
<p style="top:457.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">efficacy, causing the therapeutic to be penalized for </span></p>
<p style="top:471.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">lacking evidence in a non-applicable category. For </span></p>
<p style="top:485.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">example, a threshold effect rather than a dose&#x2013; </span></p>
<p style="top:499.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">response relationship might be necessary for obser-</span></p>
<p style="top:513.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ving beneficial effects. Cessation of exposure may also </span></p>
<p style="top:527.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">not be necessary to demonstrate, since these therapies </span></p>
<p style="top:541.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">would theoretically be lifelong as is the case for </span></p>
<p style="top:555.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">DMTs. Accordingly, another avenue for future </span></p>
<p style="top:569.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">research could be establishing a minimum set of </span></p>
<p style="top:583.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic specific criteria for comprehensively evalu-</span></p>
<p style="top:597.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">ating therapeutic strategies in both animal and </span></p>
<p style="top:611.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">human studies.</span></p>
<p style="top:625.4pt;left:63.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Other limitations of this review were related to </span></p>
<p style="top:639.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">the search and screening process for identifying </span></p>
<p style="top:653.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">relevant studies. First, the use of an English language </span></p>
<p style="top:667.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">filter in our search strategy imposed obvious restric-</span></p>
<p style="top:681.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tions on the number of studies included and extent </span></p>
<p style="top:695.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">of available evidence. Second, the operational defini-</span></p>
<p style="top:709.4pt;left:51.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tions we established limited the scope of probiotic </span></p>
<p style="top:50.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and commensal therapies to only live or heat-killed </span></p>
<p style="top:64.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">bacteria, excluding any mechanistic evidence that </span></p>
<p style="top:78.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">may have been generated in studies that used only </span></p>
<p style="top:92.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic/commensal strain-soluble products. The </span></p>
<p style="top:106.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">BH score for </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B fragilis</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, for example, could have </span></p>
<p style="top:120.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">been improved had the follow-up studies that </span></p>
<p style="top:134.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">focused on the </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">PSA symbiosis factor </span></p>
<p style="top:148.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">been eligible for inclusion.</span><sup><span style="font-family:MinionPro,serif;font-size:8.1pt;color:#00007f">81&#x2013;84 </span></sup><span style="font-family:MinionPro,serif;font-size:11.5pt">Lastly, we did not </span></p>
<p style="top:162.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">contact the authors of studies classified as medium </span></p>
<p style="top:176.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">or low quality for clarification of missing methodo-</span></p>
<p style="top:190.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">logical data (i.e. randomization, blinding). Attaining </span></p>
<p style="top:204.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">such information could have altered our quality </span></p>
<p style="top:218.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">assessments </span></p>
<p style="top:218.7pt;left:372.9pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span></p>
<p style="top:218.7pt;left:403.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">evaluations </span></p>
<p style="top:218.7pt;left:467.1pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">for </span></p>
<p style="top:218.7pt;left:493.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">BHC </span></p>
<p style="top:218.7pt;left:529.6pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">#2. </span></p>
<p style="top:232.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Regardless of these limitations, this review was </span></p>
<p style="top:246.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">intended as a resource to guide and optimize future </span></p>
<p style="top:260.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic and commensal therapy studies by high-</span></p>
<p style="top:274.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">lighting both emerging therapies and study short-</span></p>
<p style="top:288.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">comings, rather than to firmly conclude the </span></p>
<p style="top:302.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">therapeutic utility of specific formulations.</span></p>
<p style="top:338.1pt;left:306.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Conclusion</span></b></p>
<p style="top:358.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">In this comprehensive review, we used a Bradford </span></p>
<p style="top:372.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Hill criteria scoring approach to provide a multi- </span></p>
<p style="top:386.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">parameter assessment and ranking of evidence for </span></p>
<p style="top:400.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">specific gut microbial therapies, with the overall </span></p>
<p style="top:414.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">goal of identifying and highlighting areas of need </span></p>
<p style="top:428.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">for future research (see </span><span style="font-family:MinionPro,serif;font-size:11.5pt;color:#00007f">Tables 5 and 6</span><span style="font-family:MinionPro,serif;font-size:11.5pt">). Several </span></p>
<p style="top:442.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">formulations emerged as having the most promise, </span></p>
<p style="top:456.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">including VSL#3, </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. animalis, L. paracasei</span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">, and </span></p>
<p style="top:470.7pt;left:306.0pt;line-height:11.5pt"><i><span style="font-family:MinionPro,serif;font-size:11.5pt">E. coli </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">Nissle 1917 for probiotics; and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">P. histicola </span></i></p>
<p style="top:484.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:11.5pt">B. fragilis </span></i><span style="font-family:MinionPro,serif;font-size:11.5pt">for commensals. However, many </span></p>
<p style="top:498.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">other therapies fell short across a number of cri-</span></p>
<p style="top:512.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">teria, notably replication of findings. Other </span></p>
<p style="top:526.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">Bradford Hill criteria lacking evidence were tem-</span></p>
<p style="top:540.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">poral relationship and specificity of association for </span></p>
<p style="top:554.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">probiotic therapy, and strength of relationship, </span></p>
<p style="top:568.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">dose&#x2013;response relationship, and coherence for </span></p>
<p style="top:582.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">commensal therapy. Future studies should priori-</span></p>
<p style="top:596.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">tize addressing these shortcomings through better </span></p>
<p style="top:610.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">control of confounding, supporting immunological </span></p>
<p style="top:624.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">and microbiological findings with mechanistic </span></p>
<p style="top:638.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">experiments, improved standardization of proto-</span></p>
<p style="top:652.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">cols and therapeutic formutions, and the other </span></p>
<p style="top:666.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">suggestions discussed in this review. Focusing on </span></p>
<p style="top:680.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">these areas is necessary to make progress toward </span></p>
<p style="top:694.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">clinical implementation, since cheaper, safer, and </span></p>
<p style="top:708.7pt;left:306.0pt;line-height:11.5pt"><span style="font-family:MinionPro,serif;font-size:11.5pt">more durable treatments for MS are in demand.</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-22</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:50.0pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Disclosure Statement</span></b></p>
<p style="top:72.3pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">No potential conflict of interest was reported by the author(s).</span></p>
<p style="top:108.3pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">Funding</span></b></p>
<p style="top:130.5pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">This work was supported by NIH/NINDS to DNK [R01 </span></p>
<p style="top:142.5pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">NS097596]. TM was supported by Vermont Center for </span></p>
<p style="top:154.5pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Immunology / Infectious Diseases training grant, 5 T32 </span></p>
<p style="top:166.5pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">AI055402 from the National Institute of Allergy and </span></p>
<p style="top:178.5pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Infectious Diseases.</span></p>
<p style="top:214.5pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">ORCID</span></b></p>
<p style="top:236.7pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Theresa L. Montgomery </span></p>
<p style="top:236.7pt;left:160.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">http://orcid.org/0000-0003-3810- </span></p>
<p style="top:248.7pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">8511</span></p>
<p style="top:260.7pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Eyal Amiel </span></p>
<p style="top:260.7pt;left:108.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">http://orcid.org/0000-0002-1578-8705</span></p>
<p style="top:272.7pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Paula B. Deming </span></p>
<p style="top:272.7pt;left:131.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">http://orcid.org/0000-0003-3278-1705</span></p>
<p style="top:284.7pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Dimitry N. Krementsov </span></p>
<p style="top:284.7pt;left:160.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">http://orcid.org/0000-0003-2709- </span></p>
<p style="top:296.7pt;left:51.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">7466</span></p>
<p style="top:330.5pt;left:51.0pt;line-height:11.0pt"><b><span style="font-family:MyriadPro,serif;font-size:11.0pt;color:#10137d">References</span></b></p>
<p style="top:352.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">1. Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple </span></p>
<p style="top:364.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: mechanisms and immunotherapy. Neuron. </span></p>
<p style="top:376.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;97(4):742&#x2013;768. </span></p>
<p style="top:376.7pt;left:234.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:388.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">neuron.2018.01.021</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:400.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">2. Robertson D, Moreo N. Disease-modifying therapies in </span></p>
<p style="top:412.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple </span></p>
<p style="top:412.7pt;left:122.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: </span></p>
<p style="top:412.7pt;left:171.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">overview </span></p>
<p style="top:412.7pt;left:221.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span></p>
<p style="top:412.7pt;left:250.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">treatment </span></p>
<p style="top:424.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">considerations. Fed Pract. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;33:28&#x2013;34.</span></p>
<p style="top:436.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">3. Walton C, King R, Rechtman L, Kaye W, Leray E, </span></p>
<p style="top:448.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Marrie RA, Robertson N, La Rocca N, Uitdehaag B, </span></p>
<p style="top:460.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">van der Mei I, et al. Rising prevalence of multiple </span></p>
<p style="top:472.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis worldwide: insights from the Atlas of MS, </span></p>
<p style="top:484.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">third edition. Mult Scler. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;26(14):1816&#x2013;1821. </span></p>
<p style="top:496.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1177/1352458520970841</span></p>
<p style="top:508.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">4. F&#xf6;rster M, K&#xfc;ry P, Aktas O, Warnke C, Havla J, </span></p>
<p style="top:520.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Hohlfeld R, Mares J, Hartung H-P, Kremer D. </span></p>
<p style="top:532.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Managing risks with immune therapies in multiple </span></p>
<p style="top:544.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis. Drug Saf. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;42(5):633&#x2013;647. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1007/ </span></p>
<p style="top:556.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">s40264-018-0782-8</span></p>
<p style="top:568.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">5. Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, </span></p>
<p style="top:580.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Joseph F, Tomassini V, Wardle M, Pickersgill T, </span></p>
<p style="top:592.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Robertson N, Tallantyre E. Clinical outcomes of escala-</span></p>
<p style="top:604.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tion vs early intensive disease-modifying therapy in </span></p>
<p style="top:616.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">patients with multiple sclerosis. JAMA Neurol. </span></p>
<p style="top:628.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;76(5):536. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1001/jamaneurol.2018.4905</span></p>
<p style="top:640.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">6. Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, </span></p>
<p style="top:652.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Chitnis T. Discontinuation of disease-modifying ther-</span></p>
<p style="top:664.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">apy for patients with relapsing-remitting multiple </span></p>
<p style="top:676.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: effect on clinical and MRI outcomes. Mult </span></p>
<p style="top:688.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Scler Relat Disord. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;35:119&#x2013;127. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:700.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">msard.2019.07.021</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:712.7pt;left:63.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">7. Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, </span></p>
<p style="top:724.7pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Iaffaldano P, Simone M, Fanelli F, Patti F, D&#x2019;Amico E, et </span></p>
<p style="top:52.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">al. Long-term follow-up of pediatric MS patients starting </span></p>
<p style="top:64.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">treatment with injectable first-line agents: a multicentre, </span></p>
<p style="top:76.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Italian, retrospective, observational study. Mult Scler. </span></p>
<p style="top:88.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;25(3):399&#x2013;407. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1177/1352458518754364</span></p>
<p style="top:100.1pt;left:318.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">8. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. </span></p>
<p style="top:112.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Switching first-line disease-modifying therapy after fail-</span></p>
<p style="top:124.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ure: impact on the course of relapsing&#x2013;remitting multi-</span></p>
<p style="top:136.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ple sclerosis. Mult Scler. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2009</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;15(1):50&#x2013;58. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1177/ </span></p>
<p style="top:148.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1352458508096687</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:160.0pt;left:318.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">9. Hua LH, Harris H, Conway D, Thompson NR. Changes </span></p>
<p style="top:172.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in patient-reported outcomes between continuers and </span></p>
<p style="top:184.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">discontinuers of disease modifying therapy in patients </span></p>
<p style="top:196.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with multiple sclerosis over age 60. Mult Scler Relat </span></p>
<p style="top:208.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Disord. </span></p>
<p style="top:208.1pt;left:392.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;30:252&#x2013;256. </span></p>
<p style="top:208.1pt;left:491.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:220.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">msard.2019.02.028</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:232.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">10. Marrie RA. Environmental risk factors in multiple </span></p>
<p style="top:244.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis aetiology. Lancet Neurol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2004</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;3(12):709&#x2013;718. </span></p>
<p style="top:256.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/S1474-4422(04)00933-0</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:268.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">11. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. </span></p>
<p style="top:280.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Multiple sclerosis: risk factors, prodromes, and poten-</span></p>
<p style="top:292.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tial causal pathways. Lancet Neurol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2010</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;9(7):727&#x2013;739. </span></p>
<p style="top:304.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/S1474-4422(10)70094-6</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:316.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">12. Boziki MK, Kesidou E, Theotokis P, Mentis A-FA, </span></p>
<p style="top:328.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Karafoulidou E, Melnikov M, Sviridova A, Rogovski </span></p>
<p style="top:340.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">V, Boyko A, Grigoriadis N. Microbiome in multiple </span></p>
<p style="top:352.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: where are we, what we know and do not </span></p>
<p style="top:364.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">know. </span></p>
<p style="top:364.0pt;left:366.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Brain </span></p>
<p style="top:364.0pt;left:399.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Sci. </span></p>
<p style="top:364.0pt;left:424.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10(4):234. </span></p>
<p style="top:364.0pt;left:495.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3390/ </span></p>
<p style="top:376.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">brainsci10040234</span></p>
<p style="top:388.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">13. Galland L. The gut microbiome and the brain. J Med </span></p>
<p style="top:400.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Food. </span></p>
<p style="top:400.0pt;left:378.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;17(12):1261&#x2013;1272. </span></p>
<p style="top:400.0pt;left:495.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1089/ </span></p>
<p style="top:412.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">jmf.2014.7000</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:424.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">14. Camara-Lemarroy CR, Metz LM, Yong VW. Focus on </span></p>
<p style="top:436.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the gut-brain axis: multiple sclerosis, the intestinal bar-</span></p>
<p style="top:448.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">rier and the microbiome. WJG. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;24(37):4217&#x2013;4223. </span></p>
<p style="top:460.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3748/wjg.v24.i37.4217</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:472.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">15. Ochoa-Rep&#xe1;raz J, Mielcarz DW, Ditrio LE, Burroughs </span></p>
<p style="top:484.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">AR, Foureau DM, Haque-Begum S, Kasper LH. Role of </span></p>
<p style="top:496.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">gut commensal microflora in the development of </span></p>
<p style="top:508.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experimental </span></p>
<p style="top:508.0pt;left:393.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">autoimmune </span></p>
<p style="top:508.0pt;left:455.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">encephalomyelitis. </span></p>
<p style="top:508.0pt;left:539.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">J </span></p>
<p style="top:520.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Immunol. </span></p>
<p style="top:520.0pt;left:384.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2009</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;183(10):6041&#x2013;6050. </span></p>
<p style="top:520.0pt;left:495.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.4049/ </span></p>
<p style="top:532.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">jimmunol.0900747</span></p>
<p style="top:544.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">16. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, </span></p>
<p style="top:556.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Patel B, Mazzola MA, Liu S, Glanz BL, et al. Alterations </span></p>
<p style="top:568.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of the human gut microbiome in multiple sclerosis. Nat </span></p>
<p style="top:580.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Commun. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;7(1):12015. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/ncomms12015</span></p>
<p style="top:592.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">17. Camara-Lemarroy </span></p>
<p style="top:592.0pt;left:411.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">CR, </span></p>
<p style="top:592.0pt;left:436.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Metz </span></p>
<p style="top:592.0pt;left:466.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">L, </span></p>
<p style="top:592.0pt;left:483.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Meddings </span></p>
<p style="top:592.0pt;left:532.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">JB, </span></p>
<p style="top:604.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Sharkey KA, Wee Yong V. The intestinal barrier in </span></p>
<p style="top:616.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple sclerosis: implications for pathophysiology </span></p>
<p style="top:628.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span></p>
<p style="top:628.0pt;left:356.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">therapeutics. </span></p>
<p style="top:628.0pt;left:417.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Brain. </span></p>
<p style="top:628.0pt;left:452.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;141(7):1900&#x2013;1916. </span></p>
<p style="top:640.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1093/brain/awy131</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:652.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">18. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, </span></p>
<p style="top:664.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Matsuoka T, Chihara N, Tomita A, Sato W, Kim S-W, et </span></p>
<p style="top:676.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">al. Dysbiosis in the gut microbiota of patients with </span></p>
<p style="top:688.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple sclerosis, with a striking depletion of species </span></p>
<p style="top:700.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">belonging to Clostridia XIVa and IV clusters. Wilson </span></p>
<p style="top:712.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">BA, ed. PLoS ONE. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2015</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10(9):e0137429. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1371/ </span></p>
<p style="top:724.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">journal.pone.0137429</span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-23</span></p>


<p style="top:52.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">19. Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia </span></p>
<p style="top:64.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut </span></p>
<p style="top:76.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">microbiota from multiple sclerosis patients enables </span></p>
<p style="top:88.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">spontaneous autoimmune encephalomyelitis in mice. </span></p>
<p style="top:100.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Proc Natl Acad Sci USA. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;114(40):10719&#x2013;10724. </span></p>
<p style="top:112.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1073/pnas.1711233114</span></p>
<p style="top:124.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">20. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz </span></p>
<p style="top:136.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen </span></p>
<p style="top:148.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">X, et al. Multiple sclerosis patients have a distinct gut </span></p>
<p style="top:160.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">microbiota compared to healthy controls. Sci Rep. </span></p>
<p style="top:172.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;6(1):28484. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/srep28484</span></p>
<p style="top:184.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">21. Chang C-J, Lin T-L, Tsai Y-L, Wu T-R, Lai W-F, Lu C- </span></p>
<p style="top:196.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">C, Lai H-C. Next generation probiotics in disease ame-</span></p>
<p style="top:208.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lioration. J Food Drug Anal. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;27(3):615&#x2013;622. </span></p>
<p style="top:220.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.jfda.2018.12.011</span></p>
<p style="top:232.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">22. Xu H, Liu M, Cao J, Li X, Fan D, Xia Y, Lu X, Li J, Ju D, </span></p>
<p style="top:244.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Zhao H. The dynamic interplay between the gut micro-</span></p>
<p style="top:256.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">biota and autoimmune diseases. J Immunol Res. </span></p>
<p style="top:268.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">:1&#x2013;14. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1155/2019/7546047</span></p>
<p style="top:280.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">23. Smallwood TB, Giacomin PR, Loukas A, Mulvenna JP, </span></p>
<p style="top:292.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Clark RJ, Miles JJ. Helminth immunomodulation in </span></p>
<p style="top:304.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">autoimmune disease. Front Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;8:453. </span></p>
<p style="top:316.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/fimmu.2017.00453</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:328.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">24. Correale J. Helminth/parasite treatment of multiple </span></p>
<p style="top:340.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis. Curr Treat Options Neurol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;16(6):296. </span></p>
<p style="top:352.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1007/s11940-014-0296-3</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:364.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">25. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, </span></p>
<p style="top:376.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. </span></p>
<p style="top:388.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The International Scientific Association for Probiotics </span></p>
<p style="top:400.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and Prebiotics consensus statement on the scope and </span></p>
<p style="top:412.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">appropriate use of the term probiotic. Nat Rev </span></p>
<p style="top:424.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Gastroenterol </span></p>
<p style="top:424.1pt;left:153.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Hepatol. </span></p>
<p style="top:424.1pt;left:210.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;11(8):506&#x2013;514. </span></p>
<p style="top:436.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/nrgastro.2014.66</span></p>
<p style="top:448.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">26. Dargahi N, Johnson J, Donkor O, Vasiljevic T, </span></p>
<p style="top:460.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Apostolopoulos V. Immunomodulatory effects of pro-</span></p>
<p style="top:472.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">biotics: can they be used to treat allergies and autoim-</span></p>
<p style="top:484.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mune diseases? Maturitas. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;119:25&#x2013;38. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/ </span></p>
<p style="top:496.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">j.maturitas.2018.11.002</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:508.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">27. Bach J-F. The hygiene hypothesis in autoimmunity: </span></p>
<p style="top:520.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the role of pathogens and commensals. Nat Rev </span></p>
<p style="top:532.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Immunol. </span></p>
<p style="top:532.1pt;left:137.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;18(2):105&#x2013;120. </span></p>
<p style="top:532.1pt;left:239.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/ </span></p>
<p style="top:544.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">nri.2017.111</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:556.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">28. Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C. </span></p>
<p style="top:568.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Combined therapies to treat complex diseases: the role </span></p>
<p style="top:580.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of the gut microbiota in multiple sclerosis. Autoimmun </span></p>
<p style="top:592.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Rev. </span></p>
<p style="top:592.0pt;left:125.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;17(2):165&#x2013;174. </span></p>
<p style="top:592.0pt;left:236.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:604.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">autrev.2017.11.019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:616.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">29. Guarner F, Bourdet-Sicard R, Brandtzaeg P, Gill HS, </span></p>
<p style="top:628.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">McGuirk P, van Eden W, Versalovic J, Weinstock JV, </span></p>
<p style="top:640.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Rook GA. Mechanisms of Disease: the hygiene hypoth-</span></p>
<p style="top:652.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">esis revisited. Nat Rev Gastroenterol Hepatol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2006</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;3 </span></p>
<p style="top:664.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(5):275&#x2013;284. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/ncpgasthep0471</span></p>
<p style="top:676.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">30. Liu Y, Alookaran J, Rhoads J. Probiotics in autoimmune </span></p>
<p style="top:688.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span></p>
<p style="top:688.0pt;left:99.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inflammatory </span></p>
<p style="top:688.0pt;left:162.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disorders. </span></p>
<p style="top:688.0pt;left:209.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Nutrients. </span></p>
<p style="top:688.0pt;left:258.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10 </span></p>
<p style="top:700.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(10):1537. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3390/nu10101537</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:712.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">31. Morshedi M, Hashemi R, Moazzen S, Sahebkar A, </span></p>
<p style="top:724.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Hosseinifard </span></p>
<p style="top:724.0pt;left:142.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">E-S. </span></p>
<p style="top:724.0pt;left:176.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Immunomodulatory </span></p>
<p style="top:724.0pt;left:273.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span></p>
<p style="top:52.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">anti-inflammatory effects of probiotics in multiple </span></p>
<p style="top:64.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: a systematic review. J Neuroinflammation. </span></p>
<p style="top:76.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;16(1):231. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1186/s12974-019-1611-4</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:88.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">32. Zoledziewska M. The gut microbiota perspective for </span></p>
<p style="top:100.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">interventions in MS. Autoimmun Rev. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;18 </span></p>
<p style="top:112.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(8):814&#x2013;824. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.autrev.2019.03.016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:124.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">33. Jiang J, Chu C, Wu C, Wang C, Zhang C, Li T, Zhai Q, </span></p>
<p style="top:136.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Yu L, Tian F, Chen W. Efficacy of probiotics in multiple </span></p>
<p style="top:148.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: a systematic review of preclinical trials and </span></p>
<p style="top:160.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">meta-analysis of randomized controlled trials. Food </span></p>
<p style="top:172.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Funct. </span></p>
<p style="top:172.1pt;left:382.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2021</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;12(6):2354&#x2013;2377. </span></p>
<p style="top:172.1pt;left:495.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1039/ </span></p>
<p style="top:184.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">D0FO03203D</span></p>
<p style="top:196.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">34. Kohl HM, Castillo AR, Ochoa-Rep&#xe1;raz J. The micro-</span></p>
<p style="top:208.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">biome as a therapeutic target for multiple sclerosis: </span></p>
<p style="top:220.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">can genetically engineered probiotics treat the </span></p>
<p style="top:232.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">disease? </span></p>
<p style="top:232.0pt;left:377.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Diseases. </span></p>
<p style="top:232.0pt;left:428.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;8(3):33. </span></p>
<p style="top:232.0pt;left:494.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3390/ </span></p>
<p style="top:244.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">diseases8030033</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:256.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">35. Liu S, Rezende RM, Moreira TG, Tankou SK, Cox LM, </span></p>
<p style="top:268.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Wu M, Song A, Dhang FH, Wei Z, Costamagna G, </span></p>
<p style="top:280.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Weiner HL. Oral administration of mir-30d from feces </span></p>
<p style="top:292.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of MS patients suppresses MS-like symptoms in mice by </span></p>
<p style="top:304.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">expanding </span></p>
<p style="top:304.0pt;left:380.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Akkermansia </span></p>
<p style="top:304.0pt;left:441.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">muciniphila. </span></p>
<p style="top:304.0pt;left:499.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Cell </span></p>
<p style="top:304.0pt;left:524.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Host </span></p>
<p style="top:316.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Microbe. </span></p>
<p style="top:316.1pt;left:384.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;26(6):779&#x2013;794.e8. </span></p>
<p style="top:316.1pt;left:491.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:328.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">chom.2019.10.008</span></p>
<p style="top:340.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">36. Guarner F, Sanders ME, Eliakim R, Fedorak R, Gangl A, </span></p>
<p style="top:352.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Garisch J, Kaufmann P, Karakan T, Khan AG, Kim N, et </span></p>
<p style="top:364.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">al. World Gastroenterology Organisation Global </span></p>
<p style="top:376.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Guidelines: </span></p>
<p style="top:376.0pt;left:386.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">probiotics </span></p>
<p style="top:376.0pt;left:438.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span></p>
<p style="top:376.0pt;left:465.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">prebiotics. </span></p>
<p style="top:376.0pt;left:518.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">World </span></p>
<p style="top:388.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Gastroenterology Organisation. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">. [accessed </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2021 </span></p>
<p style="top:400.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Feb 1] </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">https://www.worldgastroenterology.org/ </span></p>
<p style="top:412.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">UserFiles/file/guidelines/probiotics-and-prebiotics-eng </span></p>
<p style="top:424.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">lish-2017.pdf </span></p>
<p style="top:436.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">37. Montgomery TL, K&#xfc;nstner A, Kennedy JJ, Fang Q, </span></p>
<p style="top:448.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Asarian L, Culp-Hill R, D&#x2019;Alessandro A, Teuscher C, </span></p>
<p style="top:460.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Busch H, Krementsov DN. Interactions between host </span></p>
<p style="top:472.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">genetics and gut microbiota determine susceptibility to </span></p>
<p style="top:484.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">CNS autoimmunity. Proc Natl Acad Sci USA. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;117 </span></p>
<p style="top:496.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(44):27516&#x2013;27527. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1073/pnas.2002817117</span></p>
<p style="top:508.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">38. Miyauchi E, Kim S-W, Suda W, Kawasumi M, Onawa S, </span></p>
<p style="top:520.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Taguchi-Atarashi N, Morita H, Taylor TD, Hattori M, </span></p>
<p style="top:532.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ohno H. Gut microorganisms act together to exacer-</span></p>
<p style="top:544.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">bate inflammation in spinal cords. Nature. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;585 </span></p>
<p style="top:556.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(7823):102&#x2013;106. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/s41586-020-2634-9</span></p>
<p style="top:568.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">39. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher </span></p>
<p style="top:580.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne </span></p>
<p style="top:592.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">JAC, et al. The Cochrane Collaboration&#x2019;s tool for asses-</span></p>
<p style="top:604.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sing risk of bias in randomised trials. BMJ. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2011</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;343 </span></p>
<p style="top:616.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(oct182):d5928&#x2013;d5928. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1136/bmj.d5928</span></p>
<p style="top:628.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">40. Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, </span></p>
<p style="top:640.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ritskes-Hoitinga M, Langendam MW. SYRCLE&#x2019;s risk of </span></p>
<p style="top:652.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">bias tool for animal studies. BMC Med Res Methodol. </span></p>
<p style="top:664.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;14(1):43. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1186/1471-2288-14-43</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:676.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">41. Hill AB. The environment and disease: association or </span></p>
<p style="top:688.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">causation? Proc R Soc Med. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1965</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;58(5):295&#x2013;300. </span></p>
<p style="top:700.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1177/003591576505800503</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:712.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">42. Gordis L. Epidemiology.5th ed.Philadelphia (PA): </span></p>
<p style="top:724.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Elsevier/Saunders;</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-24</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:52.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">43. Mestre L, Carrillo-Salinas FJ, Feli&#xfa; A, Mecha M, Alonso </span></p>
<p style="top:64.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">G, Espejo C, Calvo-Barreiro L, Luque-Garc&#xed;a JL, Estevez </span></p>
<p style="top:76.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">H, Villar LM, Guaza C. How oral probiotics affect the </span></p>
<p style="top:88.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">severity of an experimental model of progressive multi-</span></p>
<p style="top:100.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ple sclerosis? Bringing commensal bacteria into the </span></p>
<p style="top:112.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">neurodegenerative process. Gut Microbes. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;12 </span></p>
<p style="top:124.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(1):1813532. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1080/19490976.2020.1813532</span></p>
<p style="top:136.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">44. Calvo-Barreiro L, Eixarch H, Ponce-Alonso M, Castillo </span></p>
<p style="top:148.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">M, Lebr&#xf3;n-Gal&#xe1;n R, Mestre L, Guaza C, Clemente D, </span></p>
<p style="top:160.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">del Campo R, Montalban X, Espejo C. A commercial </span></p>
<p style="top:172.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">probiotic induces tolerogenic and reduces pathogenic </span></p>
<p style="top:184.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">responses in experimental autoimmune encephalomye-</span></p>
<p style="top:196.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">litis. Cells. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;9(4):906. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3390/cells9040906</span></p>
<p style="top:208.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">45. McMurran CE, Guzman de la Fuente A, Penalva R, Ben </span></p>
<p style="top:220.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Menachem-Zidon O, Dombrowski Y, Falconer J, </span></p>
<p style="top:232.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Gonzalez GA, Zhao C, Krause FN, Young AMH, et al. </span></p>
<p style="top:244.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">The </span></p>
<p style="top:244.1pt;left:100.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">microbiota </span></p>
<p style="top:244.1pt;left:152.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">regulates </span></p>
<p style="top:244.1pt;left:197.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">murine </span></p>
<p style="top:244.1pt;left:235.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inflammatory </span></p>
<p style="top:256.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">responses to toxin-induced CNS demyelination but </span></p>
<p style="top:268.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">has minimal impact on remyelination. Proc Natl Acad </span></p>
<p style="top:280.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Sci </span></p>
<p style="top:280.1pt;left:96.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">USA. </span></p>
<p style="top:280.1pt;left:126.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;116(50):25311&#x2013;25321. </span></p>
<p style="top:280.1pt;left:240.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1073/ </span></p>
<p style="top:292.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">pnas.1905787116</span></p>
<p style="top:304.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">46. Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox </span></p>
<p style="top:316.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">LM, Kivis&#xe4;kk P, Pierre IV, Hrishikesh L, Gandhi R, et al. </span></p>
<p style="top:328.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">A probiotic modulates the microbiome and immunity </span></p>
<p style="top:340.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in multiple sclerosis. Ann Neurol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;83(6):1147&#x2013; </span></p>
<p style="top:352.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">1161. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1002/ana.25244</span></p>
<p style="top:364.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">47. Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, </span></p>
<p style="top:376.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Kivisakk P, Vanande IP, Cook S, Gandhi R, Glanz B, </span></p>
<p style="top:388.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">et al. Investigation of probiotics in multiple sclerosis. </span></p>
<p style="top:400.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Mult </span></p>
<p style="top:400.0pt;left:113.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Scler. </span></p>
<p style="top:400.0pt;left:153.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;24(1):58&#x2013;63. </span></p>
<p style="top:400.0pt;left:240.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1177/ </span></p>
<p style="top:412.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1352458517737390</span></p>
<p style="top:424.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">48. Lavasani S, Dzhambazov B, Nouri M, F&#xe5;k F, Buske S, </span></p>
<p style="top:436.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Molin G, Thorlacius H, Alenfall J, Jeppsson B, Westr&#xf6;m </span></p>
<p style="top:448.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">B. A novel probiotic mixture exerts a therapeutic effect </span></p>
<p style="top:460.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">on </span></p>
<p style="top:460.1pt;left:96.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experimental </span></p>
<p style="top:460.1pt;left:158.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">autoimmune </span></p>
<p style="top:460.1pt;left:219.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">encephalomyelitis </span></p>
<p style="top:472.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mediated by IL-10 producing regulatory T cells. </span></p>
<p style="top:484.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Unutmaz </span></p>
<p style="top:484.0pt;left:121.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">D, </span></p>
<p style="top:484.0pt;left:141.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ed. </span></p>
<p style="top:484.0pt;left:163.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">PLoS </span></p>
<p style="top:484.0pt;left:193.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ONE. </span></p>
<p style="top:484.0pt;left:225.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2010</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;5(2):e9009. </span></p>
<p style="top:496.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1371/journal.pone.0009009</span></p>
<p style="top:508.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">49. Sanchez JMS, Doty DJ, DePaula-Silva AB, Brown DG, </span></p>
<p style="top:520.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Bell R, Klag KA, Truong A, Libbey JE, Round JL, </span></p>
<p style="top:532.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Fujinami RS. Molecular patterns from a human gut- </span></p>
<p style="top:544.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">derived Lactobacillus strain suppress pathogenic infil-</span></p>
<p style="top:556.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tration of leukocytes into the central nervous system. J </span></p>
<p style="top:568.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Neuroinflammation. </span></p>
<p style="top:568.1pt;left:168.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;17(1):291. </span></p>
<p style="top:568.1pt;left:240.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1186/ </span></p>
<p style="top:580.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">s12974-020-01959-2</span></p>
<p style="top:592.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">50. Salehipour Z, Haghmorad D, Sankian M, Rastin M, </span></p>
<p style="top:604.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Nosratabadi R, Soltan Dallal MM, Tabasi N, Khazaee </span></p>
<p style="top:616.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">M, Nasiraii LR, Mahmoudi M. Bifidobacterium ani-</span></p>
<p style="top:628.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">malis </span></p>
<p style="top:628.0pt;left:105.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in </span></p>
<p style="top:628.0pt;left:123.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">combination </span></p>
<p style="top:628.0pt;left:182.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with </span></p>
<p style="top:628.0pt;left:209.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">human </span></p>
<p style="top:628.0pt;left:247.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">origin </span></p>
<p style="top:628.0pt;left:280.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of </span></p>
<p style="top:640.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Lactobacillus plantarum ameliorate neuroinflammation </span></p>
<p style="top:652.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in experimental model of multiple sclerosis by altering </span></p>
<p style="top:664.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">CD4+ </span></p>
<p style="top:664.0pt;left:112.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">T </span></p>
<p style="top:664.0pt;left:131.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cell </span></p>
<p style="top:664.0pt;left:158.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">subset </span></p>
<p style="top:664.0pt;left:195.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">balance. </span></p>
<p style="top:664.0pt;left:239.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Biomedicine </span></p>
<p style="top:676.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Pharmacother. </span></p>
<p style="top:676.1pt;left:146.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;95:1535&#x2013;1548. </span></p>
<p style="top:676.1pt;left:236.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:688.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">biopha.2017.08.117</span></p>
<p style="top:700.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">51. Ezendam J, De Klerk A, Gremmer ER, Van Loveren H. </span></p>
<p style="top:712.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Effects of </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">Bifidobacterium animalis </span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">administered during </span></p>
<p style="top:724.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">lactation on allergic and autoimmune responses in </span></p>
<p style="top:52.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">rodents: immune effects of probiotics. Clin Exp </span></p>
<p style="top:64.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2008</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;154(3):424&#x2013;431. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1111/j.1365- </span></p>
<p style="top:76.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2249.2008.03788.x</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:88.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">52. Goudarzvand M, Rasouli Koohi S, Khodaii Z, </span></p>
<p style="top:100.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Soleymanzadeh Moghadam S. Probiotics </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">Lactobacillus </span></i></p>
<p style="top:112.1pt;left:330.4pt;line-height:9.5pt"><i><span style="font-family:MinionPro,serif;font-size:9.5pt">plantarum </span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">and </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">Bifidobacterium </span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">B94: cognitive function </span></p>
<p style="top:124.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in demyelinated model. Med J Islam Repub Iran. </span></p>
<p style="top:136.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;30:391.</span></p>
<p style="top:148.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">53. Consonni A, Cordiglieri C, Rinaldi E, Marolda R, </span></p>
<p style="top:160.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ravanelli I, Guidesi E, Elli M, Mantegazza R, Baggi F. </span></p>
<p style="top:172.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Administration of Bifidobacterium and Lactobacillus </span></p>
<p style="top:184.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">strains modulates experimental myasthenia gravis and </span></p>
<p style="top:196.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experimental </span></p>
<p style="top:196.0pt;left:392.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">encephalomyelitis </span></p>
<p style="top:196.0pt;left:473.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in </span></p>
<p style="top:196.0pt;left:493.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Lewis </span></p>
<p style="top:196.0pt;left:526.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">rats. </span></p>
<p style="top:208.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Oncotarget. </span></p>
<p style="top:208.1pt;left:385.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;9(32):22269&#x2013;22287. </span></p>
<p style="top:208.1pt;left:491.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.18632/ </span></p>
<p style="top:220.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">oncotarget.25170</span></p>
<p style="top:232.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">54. Libbey JE, Sanchez JMS, Fleming BA, Doty DJ, </span></p>
<p style="top:244.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">DePaula-Silva </span></p>
<p style="top:244.1pt;left:394.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">AB, </span></p>
<p style="top:244.1pt;left:418.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Mulvey </span></p>
<p style="top:244.1pt;left:457.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">MA, </span></p>
<p style="top:244.1pt;left:485.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Fujinami </span></p>
<p style="top:244.1pt;left:530.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">RS. </span></p>
<p style="top:256.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Modulation of experimental autoimmune encephalo-</span></p>
<p style="top:268.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">myelitis through colonisation of the gut with </span></p>
<p style="top:280.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Escherichia coli. Benef Microbes. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;11(7):669&#x2013;684. </span></p>
<p style="top:292.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3920/BM2020.0012</span></p>
<p style="top:304.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">55. Secher T, Kassem S, Benamar M, Bernard I, Boury M, </span></p>
<p style="top:316.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Barreau F, Oswald E, Saoudi A. Oral administration of </span></p>
<p style="top:328.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the probiotic strain Escherichia coli Nissle </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1917 </span><span style="font-family:MinionPro,serif;font-size:9.5pt">reduces </span></p>
<p style="top:340.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">susceptibility to neuroinflammation and repairs experi-</span></p>
<p style="top:352.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mental autoimmune encephalomyelitis-induced intest-</span></p>
<p style="top:364.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">inal barrier dysfunction. Front Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;8:1096. </span></p>
<p style="top:376.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/fimmu.2017.01096</span></p>
<p style="top:388.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">56. Mangalam A, Shahi SK, Luckey D, Karau M, Marietta E, </span></p>
<p style="top:400.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Luo N, Choung RS, Ju J, Sompallae R, Gibson-Corley K, </span></p>
<p style="top:412.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">et al. Human gut-derived commensal bacteria suppress </span></p>
<p style="top:424.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">CNS inflammatory and demyelinating disease. Cell Rep. </span></p>
<p style="top:436.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;20(6):1269&#x2013;1277. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.celrep.2017.07.031</span></p>
<p style="top:448.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">57. Shahi SK, Freedman SN, Murra AC, Zarei K, Sompallae </span></p>
<p style="top:460.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">R, Gibson-Corley KN, Karandikar NJ, Murray JA, </span></p>
<p style="top:472.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Mangalam AK. Prevotella histicola, a human gut com-</span></p>
<p style="top:484.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mensal, is as potent as Copaxone&#xae; in an animal model of </span></p>
<p style="top:496.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple sclerosis. </span></p>
<p style="top:496.1pt;left:416.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Front Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10:462. </span></p>
<p style="top:508.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/fimmu.2019.00462</span></p>
<p style="top:520.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">58. Shahi SK, Jensen SN, Murra AC, Tang N, Guo H, </span></p>
<p style="top:532.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Gibson-Corley KN, Zhang J, Karandikar NJ, Murray </span></p>
<p style="top:544.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">JA, Mangalam AK. Human commensal Prevotella his-</span></p>
<p style="top:556.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ticola ameliorates disease as effectively as interferon- </span></p>
<p style="top:568.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">beta in the experimental autoimmune encephalomyeli-</span></p>
<p style="top:580.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tis. Front Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;11:578648. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/ </span></p>
<p style="top:592.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">fimmu.2020.578648</span></p>
<p style="top:604.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">59. Maassen CBM, van Holten JCAM, Balk F, den Bak- </span></p>
<p style="top:616.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Glashouwer MJH, Leer R, Laman JD, Boersma WJA, </span></p>
<p style="top:628.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Claassen E. Orally administered Lactobacillus strains </span></p>
<p style="top:640.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">differentially affect the direction and efficacy of the </span></p>
<p style="top:652.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">immune response. Veterinary Quarterly. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1998</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;20 </span></p>
<p style="top:664.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(sup3):81&#x2013;83. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1080/01652176.1998.9694976</span></p>
<p style="top:676.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">60. Kouchaki E, Tamtaji OR, Salami M, Bahmani F, </span></p>
<p style="top:688.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi </span></p>
<p style="top:700.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">M, Jafari P, Asemi Z. Clinical and metabolic response </span></p>
<p style="top:712.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">to probiotic supplementation in patients with multiple </span></p>
<p style="top:724.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis: </span></p>
<p style="top:724.0pt;left:374.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">a </span></p>
<p style="top:724.0pt;left:389.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">randomized, </span></p>
<p style="top:724.0pt;left:448.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">double-blind, </span></p>
<p style="top:724.0pt;left:510.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">placebo- </span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-25</span></p>


<p style="top:52.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">controlled trial. Clin Nutrition. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;36(5):1245&#x2013;1249. </span></p>
<p style="top:64.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.clnu.2016.08.015</span></p>
<p style="top:76.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">61. Tamtaji OR, Kouchaki E, Salami M, Aghadavod E, </span></p>
<p style="top:88.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Akbari E, Tajabadi-Ebrahimi M, Asemi Z. The effects </span></p>
<p style="top:100.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of probiotic supplementation on gene expression </span></p>
<p style="top:112.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">related to inflammation, insulin, and lipids in patients </span></p>
<p style="top:124.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with multiple sclerosis: a randomized, double-blind, </span></p>
<p style="top:136.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">placebo-controlled trial. J Am Coll Nutr. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;36 </span></p>
<p style="top:148.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(8):660&#x2013;665. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1080/07315724.2017.1347074</span></p>
<p style="top:160.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">62. Ochoa-Rep&#xe1;raz J, Mielcarz DW, Ditrio LE, Burroughs </span></p>
<p style="top:172.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">AR, Begum-Haque S, Dasgupta S, Kasper DL, Kasper </span></p>
<p style="top:184.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">LH. Central nervous system demyelinating disease pro-</span></p>
<p style="top:196.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tection by the human commensal Bacteroides fragilis </span></p>
<p style="top:208.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">depends on polysaccharide a expression. JI. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2010</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;185 </span></p>
<p style="top:220.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(7):4101&#x2013;4108. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.4049/jimmunol.1001443</span></p>
<p style="top:232.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">63. Rahimlou </span></p>
<p style="top:232.0pt;left:125.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">M, </span></p>
<p style="top:232.0pt;left:149.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Hosseini </span></p>
<p style="top:232.0pt;left:195.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">SA, </span></p>
<p style="top:232.0pt;left:221.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Majdinasab </span></p>
<p style="top:232.0pt;left:278.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">N, </span></p>
<p style="top:244.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Haghighizadeh MH, Husain D. Effects of long-term </span></p>
<p style="top:256.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">administration of Multi-Strain Probiotic on circulating </span></p>
<p style="top:268.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">levels of BDNF, NGF, IL-6 and mental health in patients </span></p>
<p style="top:280.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">with multiple sclerosis: a randomized, double-blind, </span></p>
<p style="top:292.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">placebo-controlled trial. Nutr Neurosci. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;1&#x2013;12. </span></p>
<p style="top:304.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Published </span></p>
<p style="top:304.0pt;left:133.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">online </span></p>
<p style="top:304.0pt;left:177.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">June </span></p>
<p style="top:304.0pt;left:214.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">5. </span></p>
<p style="top:304.0pt;left:240.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1080/ </span></p>
<p style="top:316.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1028415X.2020.1758887</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:328.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">64. Salami M, Kouchaki E, Asemi Z, Tamtaji OR. How </span></p>
<p style="top:340.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">probiotic bacteria influence the motor and mental beha-</span></p>
<p style="top:352.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">viors as well as immunological and oxidative biomar-</span></p>
<p style="top:376.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">J </span><sup><span style="font-family:MinionPro,serif;font-size:9.5pt">kers in multiple sclerosis? A double blind clinical trial. </span></sup></p>
<p style="top:376.0pt;left:92.9pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Funct </span></p>
<p style="top:376.0pt;left:129.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Foods. </span></p>
<p style="top:376.0pt;left:169.3pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;52:8&#x2013;13. </span></p>
<p style="top:376.0pt;left:236.1pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j. </span></p>
<p style="top:388.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">jff.2018.10.023</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:400.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">65. Chen H, Ma X, Liu Y, Ma L, Chen Z, Lin X, Si L, Ma </span></p>
<p style="top:412.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Xueying, Chen X. Gut microbiota interventions with </span></p>
<p style="top:424.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Clostridium butyricum and norfloxacin modulate </span></p>
<p style="top:436.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">immune response in experimental autoimmune ence-</span></p>
<p style="top:448.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">phalomyelitis mice. Front Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10:1662. </span></p>
<p style="top:460.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/fimmu.2019.01662</span></p>
<p style="top:472.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">66. Abdurasulova IN, Matsulevich AV, Tarasova EA, </span></p>
<p style="top:484.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Kudryavtsev IV, Serebrjakova MK, Ermolenko EI, </span></p>
<p style="top:496.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Bisaga GN, Klimenko VM, Suvorov AN. Enterococcus </span></p>
<p style="top:508.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">faecium strain L-3 and glatiramer acetate ameliorate </span></p>
<p style="top:520.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experimental allergic encephalomyelitis in rats by </span></p>
<p style="top:532.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">affecting different populations of immune cells. Benef </span></p>
<p style="top:544.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Microbes. </span></p>
<p style="top:544.0pt;left:140.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;7(5):719&#x2013;729. </span></p>
<p style="top:544.0pt;left:240.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3920/ </span></p>
<p style="top:556.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">BM2016.0018</span></p>
<p style="top:568.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">67. Yamashita M, Ukibe K, Matsubara Y, Hosoya T, Sakai </span></p>
<p style="top:580.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">F, Kon S, Arima Y, Murakami M, Nakagawa H, </span></p>
<p style="top:592.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Miyazaki T. Lactobacillus helveticus SBT2171 attenu-</span></p>
<p style="top:604.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ates experimental autoimmune encephalomyelitis in </span></p>
<p style="top:616.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mice. Front Microbiol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2018</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;8:2596. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/ </span></p>
<p style="top:628.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">fmicb.2017.02596</span></p>
<p style="top:640.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">68. Kobayashi T, Kato I, Nanno M, Shida K, Shibuya K, </span></p>
<p style="top:652.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Matsuoka Y, Onoue M. Oral administration of probio-</span></p>
<p style="top:664.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">tic bacteria, Lactobacillus casei and Bifidobacterium </span></p>
<p style="top:676.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">breve, does not exacerbate neurological symptoms in </span></p>
<p style="top:688.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">experimental </span></p>
<p style="top:688.0pt;left:146.6pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">autoimmune </span></p>
<p style="top:688.0pt;left:217.0pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">encephalomyelitis. </span></p>
<p style="top:700.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Immunopharmacol Immunotoxicol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2010</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;32(1):116&#x2013; </span></p>
<p style="top:712.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">124. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3109/08923970903200716</span></p>
<p style="top:52.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">69. Kwon H-K, Kim G-C, Kim Y, Hwang W, Jash A, Sahoo </span></p>
<p style="top:64.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">A, Kim J-E, Nam JH, Im S-H. Amelioration of experi-</span></p>
<p style="top:76.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mental autoimmune encephalomyelitis by probiotic </span></p>
<p style="top:88.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mixture is mediated by a shift in T helper cell immune </span></p>
<p style="top:100.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">response. Clinical Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2013</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;146(3):217&#x2013;227. </span></p>
<p style="top:112.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.clim.2013.01.001</span></p>
<p style="top:124.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">70. Takata K, Kinoshita M, Okuno T, Moriya M, Kohda T, </span></p>
<p style="top:136.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Honorat JA, Sugimoto T, Kumanogoh A, Kayama H, </span></p>
<p style="top:148.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Takeda K, et al. The lactic acid bacterium Pediococcus </span></p>
<p style="top:160.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">acidilactici suppresses autoimmune encephalomyelitis </span></p>
<p style="top:172.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">by inducing IL-10-producing regulatory T cells. </span></p>
<p style="top:184.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ashour HM, ed. PLoS ONE. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2011</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;6(11):e27644. </span></p>
<p style="top:196.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1371/journal.pone.0027644</span></p>
<p style="top:208.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">71. Gharehkhani Digehsara S, Name N, Esfandiari B, Karim </span></p>
<p style="top:220.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">E, Taheri S, Tajabadi-Ebrahimi M, Arasteh J. Effects of </span></p>
<p style="top:232.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Lactobacillus casei strain T2 (LBRC-M10783) on the </span></p>
<p style="top:244.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">modulation of Th17/Treg and evaluation of miR-155, </span></p>
<p style="top:256.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">miR-25, and IDO-1 expression in a cuprizone-induced </span></p>
<p style="top:268.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">C57BL/6 mouse model of demyelination. Inflammation. </span></p>
<p style="top:280.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2021</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;44(1):334&#x2013;343. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1007/s10753-020-01339-1</span></p>
<p style="top:292.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">72. Ezendam J, Van Loveren H. </span><i><span style="font-family:MinionPro,serif;font-size:9.5pt">Lactobacillus casei </span></i><span style="font-family:MinionPro,serif;font-size:9.5pt">Shirota </span></p>
<p style="top:304.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">administered during lactation increases the duration of </span></p>
<p style="top:316.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">autoimmunity in rats and enhances lung inflammation </span></p>
<p style="top:328.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in mice. Br J Nutr. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2008</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;99(1):83&#x2013;90. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1017/ </span></p>
<p style="top:340.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">S0007114507803412</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:352.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">73. Baken KA, Ezendam J, Gremmer ER, de Klerk A, </span></p>
<p style="top:364.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Pennings JLA, Matthee B, Peijnenburg AACM, van </span></p>
<p style="top:376.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Loveren H. Evaluation of immunomodulation by </span></p>
<p style="top:388.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Lactobacillus casei Shirota: immune function, autoim-</span></p>
<p style="top:400.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">munity and gene expression. Int J Food Microbiol. </span></p>
<p style="top:412.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2006</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;112(1):8&#x2013;18. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.ijfoodmicro.2006.06.009</span></p>
<p style="top:424.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">74. Kobayashi T, Suzuki T, Kaji R, Serata M, Nagata T, </span></p>
<p style="top:436.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Ando M, Iizuka R, Tsujibe S, Murakami J, Kiyoshima- </span></p>
<p style="top:448.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Shibata J, et al. Probiotic upregulation of peripheral IL- </span></p>
<p style="top:460.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">17 responses does not exacerbate neurological symp-</span></p>
<p style="top:472.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">toms in experimental autoimmune encephalomyelitis </span></p>
<p style="top:484.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mouse models. Immunopharmacol Immunotoxicol. </span></p>
<p style="top:496.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2012</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;34(3):423&#x2013;433. </span></p>
<p style="top:496.1pt;left:495.7pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3109/ </span></p>
<p style="top:508.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">08923973.2010.617755</span></p>
<p style="top:520.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">75. He B, Hoang TK, Tian X, Taylor CM, Blanchard E, Luo </span></p>
<p style="top:532.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">M, Bhattacharjee MB, Freeborn J, Park S, Couturier J, et </span></p>
<p style="top:544.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">al. Lactobacillus reuteri reduces the severity of experi-</span></p>
<p style="top:556.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mental autoimmune encephalomyelitis in mice by mod-</span></p>
<p style="top:568.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">ulating gut microbiota. Front Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2019</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10:385. </span></p>
<p style="top:580.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3389/fimmu.2019.00385</span></p>
<p style="top:592.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">76. Johanson DM, Goertz JE, Marin IA, Costello J, </span></p>
<p style="top:604.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Overall CC, Gaultier A. Experimental autoimmune ence-</span></p>
<p style="top:616.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">phalomyelitis is associated with changes of the micro-</span></p>
<p style="top:628.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">biota composition in the gastrointestinal tract. Sci Rep. </span></p>
<p style="top:640.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10(1):15183. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/s41598-020-72197-y</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:652.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">77. Zheng J, Wittouck S, Salvetti E, Franz CMAP, Harris </span></p>
<p style="top:664.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">HMB, Mattarelli P, O&#x2019;Toole PW, Pot B, Vandamme P, </span></p>
<p style="top:676.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Walter J, et al. A taxonomic note on the genus </span></p>
<p style="top:688.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Lactobacillus: description of 23 novel genera, emended </span></p>
<p style="top:700.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">description of the genus Lactobacillus Beijerinck </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1901</span><span style="font-family:MinionPro,serif;font-size:9.5pt">, </span></p>
<p style="top:712.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">and union of Lactobacillaceae and Leuconostocaceae. </span></p>
<p style="top:27.2pt;left:51.0pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-26</span></p>
<p style="top:27.2pt;left:117.6pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">L. BLAIS ET AL.</span></p>


<p style="top:52.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Int J Syst Evol Microbiol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2020</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;70(4):2782&#x2013;2858. </span></p>
<p style="top:64.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1099/ijsem.0.004107</span></p>
<p style="top:76.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">78. Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, </span></p>
<p style="top:88.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Auer M, Deisenhammer F, Reindl M, Berger T. Long </span></p>
<p style="top:100.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">term clinical prognostic factors in relapsing-remitting </span></p>
<p style="top:112.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple sclerosis: insights from a 10-year observational </span></p>
<p style="top:124.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">study. Meuth SG, ed. PLoS ONE. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2016</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;11(7):e0158978. </span></p>
<p style="top:136.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1371/journal.pone.0158978</span></p>
<p style="top:148.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">79. McIvor GP, Riklan M, Reznikoff M. Depression in </span></p>
<p style="top:160.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple sclerosis as a function of length and severity </span></p>
<p style="top:172.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">of illness, age, remissions, and perceived social support. </span></p>
<p style="top:184.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">J Clin Psychol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1984</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;40(4):1028&#x2013;1033. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1002/ </span></p>
<p style="top:196.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1097-4679(198407)40:4&lt;1028::AID- </span></p>
<p style="top:208.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">JCLP2270400427&gt;3.0.CO;2-1</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:220.1pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">80. Moore P, Hirsta C, Harding KE, Clarkson H, </span></p>
<p style="top:232.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Pickersgilla TP, Robertson NP. Multiple sclerosis </span></p>
<p style="top:244.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">relapses and depression. J Psychosom Res. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2012</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;73 </span></p>
<p style="top:256.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">(4):272&#x2013;276. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1016/j.jpsychores.2012.08.004</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:268.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">81. Ochoa-Rep&#xe1;raz J, Mielcarz DW, Wang Y, Begum- </span></p>
<p style="top:280.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Haque S, Dasgupta S, Kasper DL, Kasper LH. A poly-</span></p>
<p style="top:292.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">saccharide from the human commensal Bacteroides </span></p>
<p style="top:304.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">fragilis protects against CNS demyelinating disease. </span></p>
<p style="top:316.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Mucosal Immunol. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2010</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;3(5):487&#x2013;495. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/ </span></p>
<p style="top:328.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">mi.2010.29</span></p>
<p style="top:340.0pt;left:59.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">82. Telesford KM, Yan W, Ochoa-Reparaz J, Pant A, </span></p>
<p style="top:352.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Kircher C, Christy MA, Begum-Haque S, Kasper DL, </span></p>
<p style="top:364.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Kasper LH. A commensal symbiotic factor derived from </span></p>
<p style="top:376.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Bacteroides fragilis promotes human CD39 + Foxp3 + T </span></p>
<p style="top:388.1pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cells and T reg function. Gut Microbes. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2015</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;6(4):234&#x2013; </span></p>
<p style="top:400.0pt;left:75.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">242. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1080/19490976.2015.1056973</span></p>
<p style="top:52.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">83. Wang Y, Begum-Haque S, Telesford KM, Ochoa-Rep&#xe1;raz </span></p>
<p style="top:64.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">J, Christy M, Kasper EJ, Kasper DL, Robson SC, Kasper </span></p>
<p style="top:76.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">LH. A commensal bacterial product elicits and modulates </span></p>
<p style="top:88.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">migratory capacity of CD39 + CD4 T regulatory subsets in </span></p>
<p style="top:100.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">the suppression of neuroinflammation. Gut Microbes. </span></p>
<p style="top:112.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;5(4):552&#x2013;561. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.4161/gmic.29797</span></p>
<p style="top:124.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">84. Wang Y, Telesford KM, Ochoa-Rep&#xe1;raz J, Haque- </span></p>
<p style="top:136.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Begum S, Christy M, Kasper EJ, Wang L, Wu Y, </span></p>
<p style="top:148.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Robson SC, Kasper DL, Kasper LH. An intestinal com-</span></p>
<p style="top:160.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">mensal symbiosis factor controls neuroinflammation </span></p>
<p style="top:172.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">via TLR2-mediated CD39 signalling. Nat Commun. </span></p>
<p style="top:184.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2014</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;5(1):4432. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1038/ncomms5432</span></p>
<p style="top:196.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">85. Rolak LA. Multiple sclerosis: it&#x2019;s not the disease you </span></p>
<p style="top:208.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">thought it was. Clin Med Res. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2003</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;1(1):57&#x2013;60. </span></p>
<p style="top:220.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.3121/cmr.1.1.57</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:232.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">86. Palumbo S, Pellegrini S. Experimental in vivo models of </span></p>
<p style="top:244.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">multiple sclerosis: state of the art. In: Zagon IS, </span></p>
<p style="top:256.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">McLaughlin PJ, editors. Multiple Sclerosis: perspectives </span></p>
<p style="top:268.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">in Treatment and Pathogenesis. Brisbane (AU): Codon </span></p>
<p style="top:280.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Publications; </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2017</span><span style="font-family:MinionPro,serif;font-size:9.5pt">. p. 173&#x2013;183. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">http://www.ncbi.nlm. </span></p>
<p style="top:292.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">nih.gov/books/NBK</span><span style="font-family:MinionPro,serif;font-size:9.5pt">470145</span></p>
<p style="top:304.0pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">87. Torkildsen &#xd8;, Brunborg LA, Myhr K-M, B&#xf8; L. The </span></p>
<p style="top:316.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">cuprizone model for demyelination. Acta Neurol </span></p>
<p style="top:328.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Scand. </span></p>
<p style="top:328.0pt;left:369.8pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">2008</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;117(s188):72&#x2013;76. </span></p>
<p style="top:328.0pt;left:469.5pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1111/j.1600- </span></p>
<p style="top:340.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">0404.2008.01036.x</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:352.1pt;left:314.2pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">88. Dal Canto MC, Kim BS, Miller SD, Melvold RW. </span></p>
<p style="top:364.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">Theiler&#x2019;s murine encephalomyelitis virus (TMEV)- </span></p>
<p style="top:376.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">induced demyelination: a model for human multiple </span></p>
<p style="top:388.1pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt">sclerosis. Methods. </span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">1996</span><span style="font-family:MinionPro,serif;font-size:9.5pt">;10(3):453&#x2013;461. doi:</span><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">10.1006/ </span></p>
<p style="top:400.0pt;left:330.4pt;line-height:9.5pt"><span style="font-family:MinionPro,serif;font-size:9.5pt;color:#00007f">meth.1996.0123</span><span style="font-family:MinionPro,serif;font-size:9.5pt">.</span></p>
<p style="top:27.2pt;left:425.8pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">GUT MICROBES</span></p>
<p style="top:27.2pt;left:502.3pt;line-height:7.5pt"><span style="font-family:MyriadPro,serif;font-size:7.5pt">e1943289-27</span></p>

</div>
